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Abstract 
 
Human serum albumin (HSA) is a plasma protein that fulfils a wide range 
of biological functions and is thought to be the major Zn2+ transporter in 
blood plasma. The high affinity Zn2+ binding site (Site A) has recently 
been characterised and is located at an interdomain site. In addition to 
metal binding, HSA is also important in the transport of fatty acids. 
Previous work has shown that the binding of Zn2+ at Site A and the 
binding of myristate at fatty acid site 2 are mutually exclusive.  It has been 
predicted that upon fatty acid binding, a conformational change occurs 
that can disrupt the residues that form Site A. This allosteric interaction 
could have an impact on the Zn2+ dependent activities of histidine-rich 
glycoprotein (HRG), a plasma protein involved in blood coagulation. The 
purpose of this work was to investigate the metal-binding properties of 
HSA and a peptide derived from HRG using a native MS approach. 
Furthermore, the possible Zn2+ transfer between the proteins was 
explored and also whether fatty acids influenced the Zn2+ distribution. 
 
Native ESI-MS was able to detect Zn2+ ions associating with HSA 
although the interactions with fatty acids appeared to be broken upon 
entering the gas phase. No apparent loss of Zn2+ from HSA was observed 
by ESI-MS following incubation with myristate which was confirmed by 
elemental analysis in solution. Travelling wave ion mobility-MS showed 
no significant conformational changes between apo-HSA and holo-HSA 
although Zn2+ appears to have a role in stabilising the domain I/II 
interface. HSA incubated with myristate showed a larger collisional cross 
section that is in agreement with the X-ray crystal structures.  
 
A peptide mimicking the His-rich region of HRG, HRGP330, was found to 
bind up to 5 Zn2+ ions by ESI-MS and evidence from a combination of  
circular dichroism spectroscopy, ion mobility and top-down MS/MS 
indicated that a conformational change occurs upon Zn2+ binding. During 
CID and ETD, Zn2+-binding fragments were able to be detected in order 
 xv 
 
to map which residues Zn2+ was bound to. However, numerous fragments 
were detected and so it would appear that several possible binding sites 
in HRGP330 have a similar binding affinity for Zn2+. Complementary ESI-
MS and elemental analysis showed that up to 90% of Zn2+ was 
transferred from HSA to HRGP330 even in the absence of fatty acid. Cu2+ 
also preferentially bound to HRGP330 over the N-terminal peptide mimic 
of HSA. Overall this could have implications for how these metal ions are 
transported in blood plasma as it would appear from this evidence that 
HRG is a significant competitor for metal ions bound to HSA.  
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 Chapter 1 
Introduction 
 
1.1 Metal ions in biological systems 
Many transition metals play crucial roles in biology where they can 
enhance or even determine the activities of biomolecules. Approximately 
50% of all enzymes require interaction with a metal ion to fulfil their 
biological function (Waldron et al., 2009). A delicate balance of these 
elements needs to be maintained as high concentrations can be toxic but 
too little can be equally damaging and have a detrimental effect on cells.  
 
Metal ions can be classed as “essential” to the development of an 
organism or “non-essential”. One hundred years ago, Bertrand derived a 
mathematical relationship between the concentration of the nutrient and 
the effect on health as shown in Figure 1.1 (Bertrand, 1912). For those 
that are essential (e.g. Zn2+) an optimal balance is needed and a 
deficiency can be detrimental to health. Essential metal ions can also 
become toxic when the concentration becomes excessive. Non-essential 
metal ions (e.g. Cd2+) can only be tolerated at a low concentration, which 
is demonstrated by the sharp drop in beneficial effects as the 
concentration increases. This model highlights that every trace metal ion 
can be potentially toxic and it is the concentration that determines this 
toxicity (Mertz, 1981).   
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Figure 1.1 Essential vs. non-essential metal ions. The diagram illustrates that the 
effect of a metal ion on an organism is concentration dependent. Biologically essential 
metal ions can become toxic at high concentrations and non-essential metal ions can 
only be tolerated at low concentrations. Adapted from Bertrand (1912).  
 
1.2 The importance of Zn2+ 
Zn2+ is the second most abundant trace metal ion present in man after 
iron, with 2-3 g in adult humans (Haase and Rink, 2009). It is considered 
to be relatively non-toxic to humans (Fosmire, 1990) and studies 
administering the radioisotope 65Zn to patients showed that 90% of the 
metal ion is stored in the bones and muscle (Wastney et al., 1986). In 
biology, Zn2+ exists only in a 2+ oxidation state and does not undergo 
redox reactions, a consequence of its filled d orbital. Furthermore, it is a 
borderline Lewis acid which allows it to interact with a variety of ligand 
donors including nitrogen, sulfur and oxygen. A study of 57 organisms in 
2006 indicated that Zn2+-binding proteins are extremely abundant, 
comprising 4-10% of proteomes (Andreini et al., 2006). 
 
Zn2+ is vital for many cellular processes, and its roles in nature can be 
broadly placed into three categories: structural, catalytic and regulatory.  
It is involved in the transmission of genetic information, the development 
Concentration
Optimal concentrationGood effects 
(health)
Bad effects
(death) Essential metal ions
Non-essential metal ions
Key
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of the immune system and as a signalling substance (Cousins et al., 
2006). On a cellular level it has critical roles in proliferation and apoptosis 
and therefore is essential for growth (Maret and Sandstead, 2006). Many 
enzymes require Zn2+ in order to be catalytically active, for example, 
carbonic anhydrase which allows the interconversion of carbon dioxide 
and water to bicarbonate and protons to proceed rapidly (Keilin and Mann, 
1940). In addition, Zn2+ is required in so-called “Zn2+ finger proteins” 
where the protein chain arranges itself around the metal ion to form a 
stable fold. An example of this was first discovered in a transcription 
factor from Xenopus Laevis, TFIIIA, which contained a series of these 
small domains which were ordered in the presence of Zn2+ (Miller et al., 
1985). 
 
1.3 Blood plasma proteins 
Blood plasma contains many different types of components including 
cells, low molecular weight compounds and proteins (Schaller et al., 
2008).  The concentrations of plasma proteins span a wide concentration 
range over 10 orders of magnitude (Anderson and Anderson, 2002). 
Lesser abundant proteins are often difficult to isolate and characterise 
due to the high content of albumin (55%) in blood which can cause 
interference. Globulins form the second most abundant fraction (38%) 
followed by fibrinogen which makes up around 7% of the total protein in 
plasma (Porth, 2002). Those proteins that are of much lower abundance 
include tissue leakage proteins and interleukins with concentrations as 
low as a few pg/ml (Anderson and Anderson, 2002). Proteins that are not 
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normally present in healthy plasma may accumulate as a biomarker for a 
particular disease which further complicates the system (Schaller et al., 
2008). This study will focus on two particular plasma proteins: human 
serum albumin (HSA) and histidine-rich glycoprotein (HRG) with a focus 
on their metal-binding properties.  
 
1.4 Human serum albumin (HSA) 
1.4.1 Structure and function 
 HSA is the most abundant protein in blood plasma and is synthesised in 
the liver (Peters, 1995). It belongs to the albuminoid protein family along 
with α-fetoprotein and vitamin D-binding protein. Expression of HSA 
begins during foetal development and is at normal levels at birth. The 
protein is continuously turned over and typically found at concentrations 
of ~0.6 mM in plasma (Peters, 1995).  It has the extraordinary ability to 
bind multiple types of ligand including metal ions, fatty acids, hormones 
and drug molecules (Kragh-Hansen et al., 2002; Fasano et al., 2005). 
HSA has an isoelectric point (pI) of 5.67 which indicates it is negatively 
charged at physiological pH. This negative charge is important for its 
biological roles, which are summarised in Figure 1.2. For example, HSA 
maintains colloid osmotic pressure by preventing water from escaping 
from the intravascular compartment. The protein does this by attracting 
positively charged sodium ions across the capillary membrane which 
causes water to follow. Ultimately, this distribution of fluids is important for 
regulating body temperature. 
 
 
Chapter One 
5 
 
 
Figure 1.2 Summary of the biological functions of HSA.  
 
The 66 kDa protein forms a heart-shaped structure with the dimensions 
80 x 30 Å (He and Carter, 1992). The structure consists of three 
homologous domains as highlighted in Figure 1.3: domain I from residues 
1-181 (blue), domain II from 188-373 (red) and domain III (green) from 
380-571. Each of the domains is separated into two sub-domains that are 
given the notation “A” and “B” (He and Carter, 1992; Curry et al., 1998; 
Sugio et al., 1999). It is a largely helical protein (67%) with each of these 
three domains containing 10 principal helices as highlighted in Figure 1.3 
(He and Carter, 1992; Peters, 1995).  A common characteristic within the 
albumin family is the formation of 17 disulfide bridges which stabilise its 
folded structure and allow it to have a lengthy in vivo circulating half-life of 
approximately 19 days (Peters, 1995). Six of these bridges are formed in 
domains II and III, with domain I only having five disulfide bonds and a 
free thiol at Cys34. This residue is susceptible to oxidation and it can form 
disulfide bonds with other free thiols in plasma such as circulating 
glutathione. 
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Figure 1.3 X-ray crystal structure of HSA. The three homologous domains are 
highlighted as follows: blue = domain I, red = domain II and green = domain III. The 
figure was created using PyMOL v1.3 and based on PDB 1AO6. 
 
 
1.4.2 HSA-dimer formation 
It has been well documented in the literature that HSA can form a dimer 
that is suggested to form through a covalent disulfide bond between 
Cys34 of two HSA molecules. Evidence against this, however, is that this 
residue is buried in a hydrophobic cavity 9.4 Å deep but it has been 
proposed that the pocket could flatten out to bring the residues closer 
together in space (Peters, 1995). A synthetic mercury bridged dimer was 
first produced by Straessle and co-workers in 1954 by linking the Cys34 
residue of two HSA molecules, although it showed low stability (Edsall et 
al., 1954; Straessle, 1954). Other efforts with longer linker molecules to 
avoid strain on the protein molecules achieved high yields and a dimer 
that was stable for over a year at room temperature (Komatsu et al., 
1999). It is not known in great detail what biological significance a HSA 
dimer may have, although the possible clinical applications have recently 
Domain I
Domain II
Domain III
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been reviewed (Taguchi et al., 2012).  These include its use as a plasma 
volume expander to treat conditions such as inflammation and as a drug 
carrier because it shows prolonged blood retention compared to the 
monomer.  
 
1.4.3 HSA as a Zn2+ transporter 
The concentration of Zn2+ in plasma is estimated to be ca. 15-20 µM 
(Kiilerich et al., 1980). It is thought that HSA is the major transporter of 
Zn2+ in blood plasma (Cousins, 1986) and binds approximately 80% of 
the metal ion present (Foote and Delves, 1984). The remainder is bound 
by α2-macroglobulin and low molecular weight compounds such as Cys 
and His which are able to compete for protein-bound Zn2+ (Giroux and 
Henkin, 1972). Although early studies implicated transferrin in Zn2+ 
transport this was found to be an insignificant amount (Chesters et al., 
1981).  
 
HSA has an important role in reducing the toxicity of Zn2+ to cells and it 
also influences the delivery of Zn2+. At physiological concentrations HSA 
was capable of protecting human WRL-68 cells from toxic concentrations 
of Zn2+ as high as 600 µM (Blindauer et al., 2009). The presence of 
albumin reduced the amount of Zn2+ uptake into erythrocytes suggesting 
that it is involved in a regulation mechanism (Gálvez et al., 2001). The 
Zn2+-albumin complex has also been shown to be important for Zn2+ 
acquisition by endothelial cells (Rowe and Bobilya, 2000; Tibaduiza and 
Bobilya, 1996). Cases of familial hyperzincemia, an excess Zn2+ disorder, 
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appear to be due to enhanced occupancy of the metal ion to HSA (Failla 
et al., 1982). 
 
1.5 Ligand binding to HSA 
1.5.1 Metal binding sites  
HSA has the capacity to bind various metal ions, both essential and toxic, 
with different specificities at each binding site (Martins and Drakenberg, 
1982; Bal et al., 1998). Although there is a lack of detailed structural 
information, four metal binding sites have been described in the literature:  
a) Amino-Terminal Cu2+ and Ni2+ binding motif (ATCUN) 
b) Site A 
c) Site B 
d) Free thiol on Cys34 
 
Each of these binding sites is described below in further detail including 
their structural elements and metal specificity. The binding constants that 
have been determined for Zn2+ Cd2+, Cu2+, Co2+ and Ni2+ ions by various 
methods are summarised in Table 1.1. Overall, this demonstrates that 
Cu2+ and Ni2+ ions show stronger binding to HSA than Zn2+ Cd2+ or Co2+ 
ions. HSA has a moderate affinity for Zn2+ with affinity in the high 
nanomolar range. The differences in the binding affinities obtained from 
different research groups can be attributed to important factors such as 
ionic strength, temperature and pH.    
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Table 1.1 Stability constants for metal ion- HSA complexes. 
Metal 
ion 
pH of 
study 
n
c
  logK1 Reference 
Zn N/A 3 7.53
b
  Masuoka and Saltman, 1994 
Zn N/A 1 7.10
b
 Ohyoshi et al., 1999 
Zn 7.4 1 6.98
a
 Giroux and Henkin, 1972 
Cd 7.4 2 5.30
a
 Goumakos et al., 1991 
Cu 7.5 1 16.18
a
 Lau and Sarkar, 1971 
Cu N/A 3 11.18
b
 Masuoka and Saltman, 1994 
Cu 7.4 1 12.00
a
 Rózga et al., 2007 
Ni 7.5 1 9.57
a
 Glennon and Sarkar, 1982 
Co 7.4 3 4.90
a
 Sokolowska et al., 2009 
 
a. K1 = apparent binding constant of the highest affinity binding site 
b. K1 = intrinsic binding constant of the highest affinity binding site. These are not 
dependent on pH.  
c. Number of binding sites 
 
Amino-Terminal Cu2+ and Ni2+ binding motif (ATCUN) 
The first metal site to be identified was the N-terminus which is the 
primary binding site for Cu2+ and Ni2+ and is known as an ATCUN motif. 
(Glennon and Sarkar, 1982; Harford and Sarkar, 1997). The motif can 
also be found in other proteins such as histatins (Harford and Sarkar, 
1997). This site at the N-terminus of HSA has been well characterised 
and four nitrogen ligands from Asp1, Ala2 and His3 coordinate to the 
central metal ion to form a square-planar structure as illustrated in Figure 
1.4. There is also evidence to suggest that in intact HSA Lys4 may be 
involved in this site (Sadler et al, 1994).  Although only 5-10% of Cu2+ in 
the blood is bound to HSA, it was suggested early on that a ternary 
albumin-Cu2+-histidine complex was important for Cu2+ transport (Lau and 
Sarkar, 1971). The majority of Cu2+ in plasma is tightly-bound to 
ceruloplasmin, which is a non-exchangeable fraction, and the remainder 
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associated with circulating amino acids (Neumann and Sass-Kortsak, 
1967).  
 
In contrast, HSA is the major transporter of Ni2+ with 95% estimated to be 
bound to the protein in vivo (Lucassen and Sarkar, 1979) although Ni2+ is 
generally thought to be non-essential for human health. Intriguingly, this 
ATCUN motif does not occur in some albumins from mammalian species 
such as dog serum albumin (DSA) and as a result this protein does not 
show a specific binding site for the first equivalent of Cu2+. This suggests 
that the mechanism of Cu2+ metabolism could differ across mammalian 
species (Appleton and Sarkar, 1971).  
 
Figure 1.4 Structure of the ATCUN motif at the N-terminus of HSA. Asp1, Ala2 and 
His3 are involved in binding and M represents a Cu
2+
 or Ni
2+
 ion. Lys4 may also have a 
role in metal binding as proposed by Sadler et al. (1994) 
 
 
Co2+ binding to HSA has attracted attention due to the albumin-cobalt 
binding assay (ACB assay), an FDA-approved test for myocardial 
ischemia (Bar-Or et al., 2000). In patients with acute coronary syndrome 
the binding of Co2+ in serum is significantly reduced (Bar-Or et al., 2001) 
M
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and this can be detected colorimetrically by measuring complex formation 
between Co2+ and dithiothreitol (DTT) which has absorbance at 470 nm. 
Early studies suggested that the N-terminal site was the primary binding 
site for Co2+ due to the fact that it was shown by potentiometry to interact 
with peptide mimics of the N-terminus (Lakusta and Sarkar, 1979). Sadler 
and co-workers (1994) provided further evidence for this by showing that 
addition of Co2+ to HSA reduced the intensity of the 1H-NMR resonances 
observed for the N-terminal residues (Asp1, Ala2, His3 and also Lys4). 
However, it was not clear if the binding mode was the same as the 
square-planar arrangement formed with Cu2+ and Ni2+. More recent 
studies have demonstrated that Co2+ actually competes with Zn2+ and 
Cd2+ for the occupation of Sites A and B and that only the third equivalent 
will be bound to the N-terminus (Mothes and Faller, 2007; Sokolowska et 
al., 2009). ITC and 111Cd-NMR experiments have also confirmed that the 
primary binding site is not the N-terminus as the addition of Co2+ to 
111Cd2+ loaded HSA caused suppression of the peaks for Sites A and B 
as seen by NMR spectroscopy. This could have implications for the 
molecular mechanism of the ACB assay as the reduced Co2+ binding of 
plasma from ischemic patients may be due to elevated fatty acids (Lu et 
al., 2012a). 
 
Site A 
The location of the high affinity Zn2+ binding site has previously been 
reported (Stewart et al., 2003), with increasing knowledge about the site 
being discovered over the past decade. The site is essentially pre-formed 
in HSA with little movement of the residues needed to accommodate the 
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metal ion. 111Cd-NMR experiments of HSA yield two signals at ~ 25-30 
ppm and another at 110-150 ppm, designated Site B and Site A 
respectively.  Site A has been identified as the high affinity Zn2+ binding 
site on HSA and an interdomain location was proposed based on analysis 
of the albumin crystal structures available. The amino acids involved are 
from two domains: His67 and Asn99 from domain I and His247 and 
Asp249 from domain II. It is important to note that this ligand set has also 
been identified in other Zn2+-binding enzymes such as human calcineurin, 
E. coli 5-endonucleotidase and kidney bean purple acid phosphatase 
(Stewart et al., 2003). Compared to Asp, Cys and His, Asn is a relatively 
weak and uncommon ligand for metal ions in proteins. Further evidence 
for the residues involved in the Zn2+ binding site was obtained using X-ray 
absorption fine structure (EXAFS) spectroscopy (Blindauer et al., 2009) 
which characterised it as a 5-coordinate site with oxygen and nitrogen 
ligands (Figure 1.5). In addition, mutations at His67 and Asn99 clearly 
affected the Zn2+ binding affinity, further confirming that these residues 
participate in metal binding (Stewart et al., 2003).  
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Figure 1.5 Zn
2+
 binding site located at the interface between domain I and domain 
II of HSA. Domain I is shown in blue and domain II is shown in red with the Zn
2+
 ion 
highlighted in magenta. The close-up image shows the 5-coordinate site composed of 
His67, Asn99, His247, Asp249 and a coordinating water molecule. The model was 
created using PyMOL v1.3 and based on the model published by Blindauer et al. (2009). 
 
Cd2+ can also bind to Site A but is readily displaced by Zn2+ as shown by 
113Cd-NMR spectroscopy (Martins and Drakenberg, 1982; Goumakos et 
al., 1991). Circular dichroism (CD) studies also indicated that it is a 
weaker binding site for Cu2+ and Ni2+ once the N-terminus has become 
saturated (Sadler and Viles, 1996) which was also confirmed by the work 
of Bal et al. (1998).  This is consistent with the findings of Masuoka and 
Saltman (1994) who demonstrated by equilibrium dialysis that the first 
equivalents of Zn2+ and Cu2+ do not bind to the same site. 
 
Site B 
 A high affinity Cd2+ site has been identified, Site B, but its location is yet 
to be fully characterised (Goumakos et al., 1991). The binding of Cu2+ or 
His67
Asp249
His247
Asn99
H2O
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Zn2+ to HSA did not reduce its affinity towards Cd2+ which supported the 
idea of a site that preferentially bound Cd2+ (Goumakos et al., 1991). This 
was later confirmed by 113Cd-NMR data which showed that the peak for 
Site B was not supressed by the addition of 0.5-1.5 mol. equiv. of Zn2+ 
(Sadler and Viles, 1996). It has been proposed that the site consists of all 
oxygen ligands plus one or no nitrogen ligands, based on the fact that its 
111Cd chemical shift is 30 ppm (Öz et al., 1998; Stewart et al., 2003). A 
13C-NMR study with tripeptides suggested residues Asp35, Glu36 and 
His37 as good candidates for this binding site (Lakusta et al., 1980).  
 
Free thiol located on Cys34 
The final metal binding site that can be discussed is the only free thiol on 
the protein located at Cys34. The remaining 34 Cys residues are involved 
in the formation of disulfide bonds which are a characteristic trait of the 
albumin family.  The sulfur has a high affinity for ‘soft’ acids for example 
Au+, Ag+ and Hg2+. Previous workers have reported that metallodrugs can 
bind at this site, for example Pt2+ anticancer drugs (Pizzo et al., 1988; 
Esposito and Najjar, 2002) and also Au+ antiarthritic drugs (Christodoulou 
et al., 1994). Although Sadler and co-workers later showed that it was 
predominantly Met residues that were involved in cisplatin binding and 
only a minor amount of the drug was bound to Cys34 (Ivanov et al., 1998). 
A more recent study found that cisplatin is able to form a cross-link 
between His67 and His247 and that there is competitive binding between 
Zn2+ and Pt2+ at this site (Hu et al., 2011).  
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1.5.2 Fatty acid transport by HSA 
It was recognised as early as the 1940’s that HSA extracted from serum 
contained fatty acids (Kendall, 1941) but it was not until over a decade 
later that researchers began to understand the physiological significance 
of this (Gordon and Cherkes, 1956). These acids are endogenous 
molecules which are insoluble in aqueous environments (Vorum et al., 
1992) and therefore need to be transported around the blood by HSA. 
These molecules are the building blocks of fat in the body and a source of 
energy as their metabolism yields large quantities of adenine triphosphate 
(ATP). Few proteins are able to bind fatty acids and HSA has the ability to 
bind large amounts and with high affinity (Spector, 1975). Depending on 
the carbon chain length, they can be categorised as short-chain fatty 
acids (SCFA) with aliphatic tails of fewer than 8 carbon atoms, medium-
chain fatty acids (MCFA) with 8-14 carbons atoms and long-chain fatty 
acids (LCFA) with greater than or equal to 16 carbon atoms (Beerman et 
al., 2003). The total concentration of fatty acids in blood plasma is 
approximately 300 µM (Van der Vusse, 2009) although only 5-10 nM are 
unbound (Richieri and Kleinfield, 1995). Typically the most common fatty 
acids found in the blood under normal conditions are oleic acid (18:1), 
palmitic acid (16:0) and linoleic acid (18:2) with 66% comprising of 
unsaturated acids (Saifer and Goldman, 1961). Importantly, fatty acids 
can dissociate from HSA very rapidly during circulation (Demant et al., 
2002) which allows HSA to work as an effective buffer against 
fluctuations in concentration. This also ensures that fatty acids bound to 
HSA are readily available to cells (Spector and Soboroff, 1971).  
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1.5.3 Fatty acid binding sites 
Experimental evidence has indicated that fatty acid binding stabilises 
HSA against denaturation (Kragh-Hansen, 1981). Under normal 
physiological conditions, 0.1-2 moles of fatty acids are complexed to HSA, 
but seven sites have been identified by X-ray crystallography (Curry et al., 
1998). Five of these sites are proposed to be of high to moderate affinity 
where the molecules are anchored into the protein by polar interactions 
(Bhattacharya et al, 2000). There is no evidence of such interactions at 
the other two sites and therefore these are thought to be weaker binding 
sites. Figure 1.6 shows the distribution of the high affinity binding sites 
occupied by myristate molecules. FA1 is located in subdomain IB and 
FA2 is at the interface between IA and IIA. FA3 and FA4 are both located 
in subdomain IIIA and FA5 is in subdomain IIIB. Sites FA6 and FA7 are 
not shown in Figure 1.6, but  FA6 lies at the interface between IIA and IIB 
and FA7 in subdomain IIA (Curry, 2004).  
 
Figure 1.6 X-ray crystal structure of myristate-bound HSA. The protein structure is 
shown in the same colour scheme as previous figures. Myristate molecules are shown to 
occupy FA sites 1-5 (orange). The figure was created using PyMOL v1.3 and based on 
PDB 1BJ5 (Curry et al., 1998). 
FA1
FA2
FA3
FA4
FA5
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For many years, efforts have been directed towards quantifying the 
affinity of various fatty acids for HSA, even though difficulties occur as 
they are not readily soluble in aqueous media. Simard and co-workers 
carried out an NMR titration of HSA with 13C-labelled palmitate, which 
revealed that FA sites 2, 4 and 5 are the high affinity binding sites 
whereas 1, 3, 6 and 7 are the low affinity binding sites (Simnard et al., 
2006). This is most likely because sites 2, 4 and 5 provide the most 
enclosed environment and the aliphatic chain can sit in the pocket in 
almost a linear conformation (Van der Vusse, 2009).  
 
1.6 Conformational changes of HSA 
1.6.1 pH-induced conformational changes 
HSA is a flexible molecule and can undergo several conformational 
changes. One trigger for this change is the pH of the environment (Carter 
and Ho, 1994; Peters, 1995) and this has an impact upon both the 
secondary and tertiary structure of HSA. The five structures described in 
the literature are summarised in Table 1.2. The N-(neutral) form is 
dominant at physiological relevant pH of 7.0-7.5. As the pH drops to 4.0, 
it is converted into the F-form which was shown by CD spectroscopy to 
involve a decrease in helical content (Era and Sogami, 1998). As the pH 
becomes more acidic further unfolding occurs to produce the E-form, until 
the molecule appears to have expanded to its full extent at pH 2.5. At 
alkaline pH, an N-to-B transition occurs which is thought to involve a loss 
of rigidity in the protein structure. 
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Table 1.2 Albumin conformations that are dependent on pH 
Abbreviation Name pH of transition Characteristics 
E Extended 2.7 Fully expanded form with 
disulfide bonds intact 
F Fast 4.3 Fast migrating form 
observed on gels 
N Neutral/Normal 7.0 Normal heart-shaped 
conformation observed at 
physiological pH. 
B Basic 8.0 Subtle change in molecule 
as it loses rigidity; 
physiologically  relevant 
A Aged 10.0 Slower migrating form 
observed on gels 
 
Dockal and co-workers demonstrated by CD spectroscopy and 
fluorescence measurements that during the N to B transition, domains I 
and II experienced an isomerisation in tertiary structure whereas domain 
III was unaffected (Dockal et al., 2000). The biological relevance of these 
isoforms has yet to be fully determined, although they are thought to be 
important for ligand binding and release. 
 
1.6.2 Fatty acid-induced conformational changes 
It has been shown that fatty acid binding is another trigger for a 
conformational change. Curry and co-workers compared myristate-bound 
HSA to unliganded HSA and found that substantial domain rotations 
occurred within the protein. Both domains I and III were moved 
considerably relative to domain II and a helix connecting domains I and II 
showed substantial bending (Curry et al., 1998). Later this conformational 
change was also found to occur with fatty acids of varying chain lengths 
from C10.0 to C18:0 (Bhattacharya et al., 2000). A combination of 
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chemical cross-linking and mass spectrometry has also been used to 
probe the effect of unsaturated fatty acid binding to HSA and the results 
correlated well with the changes observed in the crystal structures 
(Huang et al., 2005). 
 
It is unclear whether these conformational changes have physiological 
significance, but one theory is that it could allow HSA receptors to 
differentiate between HSA molecules loaded with fatty acid and those that 
are fatty acid-free. This could have important implications for the delivery 
of fatty acids to cells (Curry et al., 1999). Overall, it is debatable whether 
HSA protein receptors on cells exist but there has been some evidence 
put forward (Schnitzer and Oh, 1994; de Château et al., 1996; Tiruppathi 
et al., 1996; Luiken et al., 1997). The conformational change could also 
be biologically important in that it may mediate the interactions with other 
molecules. An example that supports this is the case of thyroxine where 4 
molecules of the hormone bind to fatty acid-free HSA, but upon myristate  
association, a fifth binding site for the hormone was identified in a new 
cleft created by movement of the domains (Petitpas et al., 2003). 
Interestingly, it appears that it is binding to fatty acid site 2 (FA2) that is 
mainly responsible for the conformational changes observed. This is 
discussed further with respect to implications for Zn2+ binding to Site A in 
section 1.7.2.  
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1.7 Interactive binding of metal ions and fatty acids 
1.7.1 Evidence that fatty acid binding influences Zn2+ binding 
Evidence to date that fatty acids influence the occupation of Site A has 
been obtained from combinations of 111Cd-NMR spectroscopy, 1H-NMR 
spectroscopy, isothermal titration calorimetry (ITC) and molecular 
modelling. Zn2+ is spectroscopically inactive, therefore it can usefully be 
replaced with isostructural Cd2+ in order to gain information about metal 
binding.   
 
During early studies of 113Cd binding to various mammalian albumins it 
was noted that there were differences in the appearance of the NMR 
peak corresponding to the major Zn2+ binding site (Sadler and Viles, 
1996). It was realised that these differences could be attributed to the 
heterogeneity of the samples and that the relative affinity of Cd2+ for Site 
A was reduced in the presence of fatty acid. In light of this, Stewart and 
co-workers (2003) compared samples with high and low concentrations of 
octanoate by 111Cd-NMR spectroscopy and found that the peak for Site A 
was supressed by fatty acid loading whereas Site B was not affected. 
Later experiments with myristate loading showed that both peaks 
observed in the 111Cd-NMR spectrum of BSA were supressed indicating 
myristate binding had an impact upon metal binding to both Sites A and B 
(Figure 1.7,  Lu et al., 2012b).  
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Figure 1.7 Influence of myristate loading on metal binding to BSA by 
111
Cd-NMR 
spectroscopy. For dialysed BSA two peaks are observed: one for Site A and one for 
Site B. In the presence of myristate these peaks are significantly affected. (Lu et al., 
2012b). 
 
Further evidence for a relationship between fatty acids and Zn2+ was 
gained from ITC. Titrations with Zn2+ in the presence of 5 mol. equiv. 
octanoate gave similar data as titrations carried out in the absence of 
fatty acid. This was consistent with 1H-NMR data showing simultaneous 
binding of Zn2+ and octanoate as although the H1 resonances for His67 
and His247 were affected it was concluded that octanoate binding to FA2 
does not abolish Zn2+ binding to BSA (Lu et al., 2012b). In contrast, 
analysis of BSA-Zn2+ in the presence of myristate by ITC revealed that 
Zn2+ binding is dramatically decreased. This suggested that the chain 
length of the fatty acid is an important factor. One of the most important 
outcomes of ITC was the observation that Zn2+ binding was affected by 
the addition 1-2 molar equivalents of myristate which are physiologically 
relevant levels in plasma (Lu et al., 2012b).  
 
 
 
 111Cd
A
B
BSA + 5 Myr
Dialysed BSA
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1.7.2 Disruption of Site A due to occupation of FA2 
X-ray crystallography of fatty acid-bound albumin showed that the 
occupation of site FA2 was mainly responsible for the conformational 
change observed. Crucially, this is the only fatty acid site that is located 
between two domains (Curry et al., 1998) and is also next to Site A, the 
major Zn2+ binding site. At this site, the carboxylate end of the molecule 
interacts with Arg257 and Ser287 in subdomain IIA and the aliphatic tail 
interacts with Tyr150 in subdomain IB.  In order to accommodate the fatty 
acid anion, domains I and II have to move by 10 Å to form a cavity that is 
large enough.  This causes significant disruption of the Zn2+ binding site 
as the His247/Asp249 pair from domain II and the His67/Asn99 pair from 
domain I are moved apart  by 4-6 Å (Stewart et al., 2003). 
 
Molecular modelling has given an insight into how fatty acids with 
different chain lengths could have an impact on the Zn2+ binding site. A 
model with octanoate bound shows that both the short-chain fatty acid 
and Zn2+ could be accommodated in their binding sites without the need 
for any conformational changes (Figure 1.8 B). As a result Site A is still 
observed to be intact as the C8 chain is too short to act as a pin between 
the two half sites. In contrast, when myristate is bound, a conformational 
change has to occur to accommodate the longer fatty acid chain and Zn2+ 
binding is lost (Figure 1.8 A, Lu et al., 2012b). 
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Figure 1.8 Molecular modelling shows binding modes of fatty acids with different 
chain lengths to FA2. When myristate is bound in FA2, Site A is disrupted (A) due to a 
significant conformational change whereas when octanoate occupies the site, the Zn
2+
-
binding site is still observed to be intact (B). Adapted from (Lu et al., 2012b). 
 
1.7.3 Biological significance  
The experimental observations indicate that fatty acids could be a way of 
regulating Zn2+ speciation in blood plasma. HSA in healthy plasma carries 
0.1-2 fatty acid molecules per protein, but some disease states including 
obesity, diabetes, cancer or cardiovascular disease are characterised by 
elevated fatty acid levels (Richieri et al., 1993). This is also a symptom of 
analbuminemia, which is a deficiency of HSA. Therefore this allosteric 
fatty acid “switch” mechanism may be a reason for shifts in Zn2+ 
distribution in plasma. The consequences of Zn2+ displacement from HSA 
are currently unknown, but predictions can be made. Zn2+ is potentially 
toxic to cells, so therefore an elevated fatty acid concentration could 
cause an increase in the unbound Zn2+ concentration in plasma which 
could be detrimental. A so-far unexplored link is the possibility that an 
increase in “free” Zn2+ concentration could have an impact on the 
A B
Myristate bound = Site A disrupted Octanoate bound = Site A intact
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activities of other proteins that are Zn2+-dependent such as histidine-rich 
glycoprotein (Stewart et al., 2009). This is the basis for this project and 
the hypothesis will be discussed later in this Chapter.  
 
1.8 Histidine rich glycoprotein (HRG) 
1.8.1 Structure and function 
HRG is a 75 kDa plasma protein that was first isolated from human serum 
in 1972 (Heimburger et al., 1972) and belongs to the cystatin superfamily 
(Koide and Odani, 1987). It is synthesised in the liver and is present in 
blood at relatively abundant concentrations of 1.5-2 µM. The local 
concentration, however, could increase when it is released from activated 
platelets or close to thrombocytes activated during coagulation (Leung et 
al., 1983). During pregnancy HRG levels fall to half their normal 
concentration and then gradually return to normal after birth (Morgan et 
al., 1978a). It has been suggested that this may be related to delivering 
essential metal ions to the foetus during development (Morgan, 1981). At 
birth, the HRG concentration is 20% of that in adults and then increases 
with age (Corrigan et al., 1990). Thrombophilia (or hypercoagulability), a 
condition that increases the risk of blood clots, has been shown to be a 
consequence of a HRG deficiency (Shigekiyo et al., 1998). 
 
HRG is involved in the formation of multi-protein complexes that regulate 
numerous biological processes, which has earned it the title the “Swiss 
Army Knife” of mammalian plasma (Poon et al., 2011). Its multidomain 
structure lends itself to being able to interact with many ligands including 
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heme (Morgan, 1978b; Katagiri et al., 1987), Zn2+ (Morgan, 1978b), 
plasminogen (Lijnen et al., 1980), fibrinogen (Leung, 1986),  
thrombospondin (Leung et al., 1984), vasculostatin (Klenotic et al., 2010) 
immunoglobulin (Gorgani et al., 1997) and heparin (Lijnen et al., 1983).  
Table 1.3 summarises the roles of HRG including comments on the 
supporting experimental evidence. With regards to the immune system, 
HRG is involved in the clearance of circulating immune complexes (ICs) 
whereby antibodies form complexes with target antigen and facilitate the 
clearance of invading microorganisms (Poon et al., 2010). If ICs are not 
cleared, deposition at tissues can occur, a consequence of which are 
diseases such as arthritis and vasculitis (Poon et al., 2011). 
 
In vascular biology, HRG regulates angiogenesis, the formation of new 
blood vessels from ones that already exist (Olsson et al., 2004). The 
process has to be tightly controlled in order to maintain the correct 
balance of oxygen and nutrients being delivered to cells in the organism. 
Unregulated angiogenesis can be extremely detrimental and is 
associated with a number of pathological conditions including ischemia, 
rheumatoid arthritis, thyroiditis and cancer (Folkman, 1995; Carmeliet and 
Jain, 2000). An additional function that has been found is that HRG 
shows antibacterial activity and that the His-rich region (HRR) is a 
requirement for this function (Rydengård et al., 2007). 
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Table 1.3 Biological functions of HRG. 
Function Comments Reference(s) 
Angiogenesis  
inhibitor 
Tumour angiogenesis was reduced in 
mice in the presence of HRG and 
tumour growth was reduced by >60 %. 
 
A peptide derived from the HRR 
showed antiangiogenic activity 
Olsson et al., 2004 
 
 
 
 
Dixelius et al., 2006 
 
Anticoagulant 
 
Mice that were HRG-deficient showed 
increased blood coagulation and 
clotting 
 
 
Tsuchida-Straeten  
et al., 2005 
Antifibrinolytic 
effect 
HRG deficient mice showed greater 
spontaneous fibrinolytic activity in 
clotted blood 
 
Tsuchida-Straeten  
et al., 2005 
 
Antibacterial  
A peptide derived from the HRR, 
(GHHPH)4, had antibacterial effect 
against E. faecalis in the presence of 
Zn
2+
 
 
HRG-deficient mice were more 
susceptible to S. pyogenes bacteria. 
 
Rydengård et al., 2006 
 
 
 
 
Shannon et al., 2010 
Antifungal HRG has significant antifungal action 
against Candida 
 
Rydengård et al., 2008 
 
Apoptotic and 
necrotic cell 
clearance 
A complex consisting of both HRG 
and immunoglobulin G (IgG) was 
characterised and found necessary to 
aid necrotic cell uptake by monocytes 
 
HRG binds to cytoplasmic ligands 
exposed in necrotic cells – this 
interaction is mediated by the N-
terminal domain. 
Poon et al., 2010 
 
 
 
 
Jones et al., 2005a 
 
Endotoxin-
neutralising 
effects 
 
A 25-mer peptide from the HRR was 
shown to be an endotoxin 
lipopolysaccharide 
(LPS) antagonist 
 
 
Bosshart and 
Heinzelmann., 2003 
Formation of 
immune 
complexes 
HRG regulates the binding of 
monomeric IgG and IC to monocytes. 
 
HRG binds to IgG and C1q as shown 
by ELISA 
 
Gorgani et al., 1999 
 
 
Gorgani et al., 1997 
Regulates T-cell 
adhesion 
HRG binds strongly to human T-cells 
with the interaction enhanced by Zn
2+
 
Olsen et al., 1996 
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No structure exists for HRG, however, suggestions have been made as to 
its domain structure from experimental observations. The different 
domains are illustrated in Figure 1.9 which is based on the models 
proposed in previous studies (Borza et al., 1996; Poon et al., 2011).  The 
proposed structure contains 2 N-terminal regions which show homology 
to cystatin-like domains: N1 which consists of residues 1-112 and N2 
from residues 113-225. The HRR occurs from residues 330-389 in the 
centre and is flanked by Pro-rich regions (PRRs). Finally, there is a C-
terminal domain from residues 440-507. Four intradomain and two 
interdomain disulfide bonds are distributed across the protein as well as 
six predicted N-glycosylation sites at various Asn residues. Plasmin 
readily cleaves the multi-domain protein into various fragments ranging 
from 9-67 kDa and after 30 minutes none of the intact protein remained in 
patients undergoing thrombolytic therapy (Smith et al., 1985).  
 
 
 
Figure 1.9 Multi-domain structure proposed for HRG. There are two cystatin-like N-
terminal domains (pink) and a His-rich region (HRR) in the centre of the molecule 
(green). The HRR is flanked by Pro-rich regions (PRRs; blue) and finally a C-terminal 
domain with a disulfide bond linking it back to the N-terminus. Carbohydrate recognition 
sites and disulfide bonds are highlighted. This is based on models by Borza et al. (1996) 
and Poon et al. (2011). 
N1 N2
PRR1HRRPRR2C
1 112 113 225
238303330389398431440507
= carbohydrate attachment (Asn45, Asn69, Asn107, Asn184, Asn326, and Asn327)
= disulfide bonds (Cys6-Cys486, Cys60-Cys71, Cys87-Cys108, Cys185-Cys399, 
Cys200-Cys223 and Cys306-Cys339)
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A 30 kDa fragment containing the HRR is released upon cleavage while 
the N- and C-terminal domains remain linked by disulfide bond Cys6-
Cys486 (Borza et al., 1996).  Far UV CD spectroscopy revealed that the 
N-terminal regions are mainly comprised of β-sheet and some α-helices 
which are similar to the structure of cystatin. The C-terminal region and 
both the HRR and PRR regions show a lack of regular secondary 
structure which can be attributed to their high Pro content. In fact, the C-
terminal appears to be predominantly random coil while a polyproline II 
helix has been suggested for the HRR and PRR which will be discussed 
in more detail below (Borza et al., 1996). 
 
1.8.2 The His-rich region of HRG 
Analysis of the primary structure shows that a quarter of the sequence is 
composed of His and Pro residues: 12.6 % His and 12.4 % Pro. The 
majority of these are found in the so-called HRR and PRR regions. The 
primary sequences of the HRR from mammalian species show 
conservation of the GHHPH pentapeptide with 12 tandem repeat units. 
This unusual domain shows some similarity to high molecular weight 
kininogen (HMWK), a protein from the blood circulation system which has 
a HRR that participates in coagulation and also has the ability to disrupt 
endothelial cell function (Zhang et al., 2000). The PRR shows similarity to 
Pro-rich proteins from parotid saliva, which have a repeating unit of 
QGPPP, with the sequence similarity between the two proteins being as 
high as 49% (Koide et al., 1986) Analysis of repeat units in protein 
sequences has shown that these are more common in eukaryotic 
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proteins than prokaryotic proteins and a reason for these could be that 
these proteins evolve quicker than those with non-repetitive units 
(Marcotte et al., 1998). In order for HRG to exert its anti-angiogenic 
properties the HRR is proteolytically released from the protein (Olsson et 
al., 2004) and smaller protein fragments have been found in preparations 
of HRG and identified by SDS-PAGE, which supports this idea 
(Kluszynski et al., 1997).  
 
The HRR and PRR lack conventional secondary structure such as α-
helices or β-sheet, probably due to the high Pro content. Borza and co-
workers carried out CD-spectroscopy on the HRR region obtained from 
proteolytic cleavage, which indicated the formation of a polyproline II helix 
(Borza et al., 1996). This type of secondary structure is characterised by 
a large negative peak at 203 nm and a small positive peak at 226 nm. 
This structure formation is due to a lack of basic and hydrophobic amino 
acids which precludes more compact protein folding. 
 
1.8.3 Metal binding to HRG 
Contrary to earlier observations (Morgan, 1981; Guthans and Morgan, 
1982) HRG does not appear to be a transporter for metal ions but there is 
inconsistent evidence for this. Analysis of hyperzincemic plasma showed 
that HRG concentrations were similar to that of normal plasma which is 
not in line with it being a major Zn2+ binder (Failla et al., 1982).  
Importantly however, its interactions with other binding partners are 
enhanced by Zn2+ but it is unclear how much Zn2+ would normally be 
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bound to HRG in vivo. Metal ion titrations and equilibrium dialysis have 
indicated that as many as 10 Zn2+ ions can bind to rabbit HRG (Morgan, 
1981) and human HRG (Horne et al., 2001) with the His residues being 
involved in metal coordination (Morgan, 1981). Evidence for His 
involvement has been demonstrated by chemically modifying the His 
residues with diethyl pyrocarbonate (DEPC) which caused HRG to lose 
the ability to bind both Zn2+ (Morgan, 1981; Burch et al., 1987) and 
heparin (Borza and Morgan, 1998). At physiological pH the imidazole ring 
is partially deprotonated therefore it is readily available for metal binding.  
It is likely that Zn2+ binding modifies the protein structure of HRG in order 
to mediate interactions with other biomolecules (Jones et al., 2005b). The 
His residues provide a good “anchorage point” for metal ions, particularly 
in unstructured proteins where the residues are far more accessible 
(Rowinska-Zyrek et al., 2013). It is thought that the extended 
conformation of the HRR allows easier metal ion access to the imidazole 
rings of the His residues. It has also been demonstrated that the binding 
of Zn2+ to the HRR is cooperative, so that the binding of the first Zn2+ ion 
could make it more favourable for subsequent Zn2+ ions to bind (Morgan, 
1981).   
 
As shown in Figure 1.10 the HRR from different species are highly 
conserved. There are some slight differences, however, which could 
suggest that there are differences in Zn2+ binding affinity. For example, 
human HRG has 12 GHHPH repeats whereas rabbit HRG has 15, and 
overall a longer HRR, which indicates that the latter could have the 
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capacity to bind more metal ions. Moreover, the repeating unit GHHPH is 
predominant in bovine, human, mouse and rat HRG whereas GPPPH is 
more common in rabbit HRG.  
 
 
Figure 1.10 Sequence alignment of the HRR of HRG from various mammalian 
species. Amino acids are coloured according to their chemical properties: hydrophobic 
(red), acidic (blue), basic (magenta), hydroxyl/sulfhydryl/amines (green).  Symbols 
represent conservation of amino acids: fully conserved (*), conservation between groups 
with strongly similar properties (:) and conservation between groups of less similar 
properties (.).  
 
In contrast, there is very little homology between the linker regions 
connecting the HRR and PRR thus highlighting the importance of these 
unusual domains with regards to the functionality of HRG (Hulett and 
Parish, 2002).  
 
The binding affinity of HRG for metal ions has been addressed by a 
number of research groups as summarised in Table 1.4, These indicate 
that HRG binds Zn2+ with logK ~ 5-6 which suggests it is a weaker metal 
binder than HSA. Although the binding of Zn2+ and Cd2+ showed a similar 
binding affinity, Morgan (1981) demonstrated that Zn2+ is the strongest 
binder of the two as it was able to inhibit heme binding to a much greater 
extent than Cd2+. The general consensus is that affinity data are difficult 
to obtain for HRG and these values may be underestimated due to the 
HUMAN    PLLPMSCSSCQHATFGTNGAQRHSHNNNSS-----DLHPHKHHSHEQHPHGHHPHAHHPH 354 
BOVINE   LPFPPPGLRCPHPPFGTKGNHRP---------------PHDHSSDE-------------- 263 
RABBIT   PLSPPFRPRCRHRPFGTNETHRFPHHRISVNI-IHRPPPHGHHPHGPPPHGHHPHGPPPH 343 
RAT      PQLPPGYP----PHSGANRTHRPSYNHSCNEHPCHGHRPHGHHPHSHHPPGHHSHGHHPH 346 
MOUSE    PQMLPGHS----GPSGTNRSHRPPHNHSCNEHPCHGQHPHGHHPHGQHPHGHHPHGQHPH 346 
                        *::  :*                ** * ..                
 
HUMAN    -------------------EHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQD 395 
BOVINE   ------------------------------HHPHGHHPHGHHPHGHHPHGHHPPDNDFYD 293 
RABBIT   GHPPHGPPPRHPPHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGHGFHD 403 
RAT      G--------------HHPHSHHSHGHHPPGHHPHGHHPHGHHPHGHHPHGHHPHGHDFLD 392 
MOUSE    G--------------HHPHGQHPHGHHPHGQHPHGHHPHGHHPHGDHPHGHHPHGHDFLD 392 
                                       : ***  **** ***  **** *  :.* * 
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fact that binding of Zn2+ and Cd2+ to the protein show cooperativity. 
Additionally, most work has been carried out using rabbit HRG, as the 
protein is more abundant in rabbit serum, but this has a longer HRR 
region compared to the human form. 
 
Table 1.4 Stability constants for metal ion-HRG complexes 
Metal ion pH of study Species logK Reference 
Cu 7.4 Rabbit 6 Morgan, 1981 
Cd 7.4 Rabbit 6
a
 Morgan, 1981 
Zn 7.4 Rabbit 6
a
 Morgan, 1981 
Zn 7.1 Rabbit 5 Guthans and Morgan, 
1982 
Zn 7.4 Rabbit 6-6.6 Burch and Morgan, 1985 
Zn 7.4 Human 5.4 Horne et al., 2001 
 
a 
Values must be taken with caution as due to cooperative binding of these metal ions 
the apparent Kd was qualitatively determined from competition experiments. However, 
these are still in good agreement with other estimations.  
 
1.8.4 Zn2+ mediates HRG-ligand interactions 
It has been recognised for some time that metal ions have a strong 
influence on the interactions between HRG and its binding partners.  
Binding to heparin was studied by Borza and Morgan (1998) who 
demonstrated that both Zn2+ and Cu2+ were effective at promoting this 
interaction. Ni2+ and Co2+ had some influence on the interaction, but not 
to the same extent as Zn2+ and Cu2+. Other divalent metal ions including 
Mn2+, Ca2+ and Mg2+ had no effect on promoting the binding of heparin. 
Additionally, this could have clinical significance as a combination of HRG 
and Zn2+ was shown to neutralise heparin although no appreciable effect 
was observed at normal plasma levels (Fu and Horne, 2002). The 
presence of Zn2+ ions enhanced the binding of a His-rich peptide to 
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tropomyosin with a suggested mechanism involving HRG becoming 
positively charged upon Zn2+ binding which facilitates its interaction with 
negatively charged tropomyosin (Doñate et al., 2004). Furthermore, the 
more recently discovered antibacterial activity of HRG was facilitated by 
low pH and Zn2+ (Rydengård et al., 2007). It has also been revealed that 
Zn2+ greatly increased the binding of HRG to platelets. As high 
concentrations of Zn2+ have been detected in activated platelets 
(Gorodetsky et al., 1993) this is a physiologically relevant function that 
could occur at blood clotting sites (Horne et al., 2001).  
 
1.8.5 Could the fatty acid “switch” mechanism be involved in the 
regulation of HRG functions? 
Elevated fatty acid levels may well result in an increase in plasma Zn2+ 
concentration through the fatty acid “switch” mechanism described above. 
An increase in the plasma Zn2+ concentration could allow more of the 
metal ion to associate with HRG and consequently trigger its interactions 
with its functional partners (Stewart et al., 2009). The proposed interplay 
between these two proteins is summarised in Figure 1.11. Even though 
HSA binds to Zn2+ with a greater affinity than HRG, the binding constants 
are not completely dissimilar so even small alterations in fatty acid levels 
could influence whether Zn2+ is bound to HSA and HRG. This suggested 
mechanism is biologically relevant as free fatty acids have been shown to 
be elevated during diseases such as cancer, diabetes and obesity (Brown 
et al., 1983; Richieri et al., 1993; Boden and Shulman, 2002). 
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Figure 1.11 Mechanism of possible HRG regulation by the levels of plasma fatty 
acids. An increase in fatty acid levels could affect the Zn
2+
 distribution in blood plasma 
and cause more Zn
2+
 to associate with HRG (Stewart et al., 2009). 
 
Additionally, an increase in fatty acids is also observed with myocardial 
ischemia, a heart disorder where a decrease in blood flow to the heart 
reduces its oxygen supply and hence fatty acid consumption 
(Hendrickson et al., 1997). When this is taken together with the fact that 
the local pH also drops during ischemia (Xia et al., 1996), which could 
cause HRG to become more protonated, then a scenario where fatty 
acids may affect the activities of HRG is even more viable.    
 
This model is based on the assumption that HSA is the major Zn2+ carrier 
in plasma due to its abundance and HRG would only be Zn2+ bound if 
conditions in plasma became abnormal. However, there is conflicting 
evidence for this which needs to be taken into account.  Indeed, Guthans 
and Morgan (1982) showed by equilibrium dialysis that when HSA was in 
10-fold excess over HRG, 88 % of the Zn2+ present was found to be 
bound to rabbit HRG. Altering the HRG:HSA ratio to 1:100 still resulted in 
 
Zn
1-2 equiv  
fatty acid
HRG+
HSA
HSA
2-5 equiv  
fatty acid
HRG
Zn
Functional 
complex
+
Increased fatty acid levels 
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equal concentrations of Zn2+ (29 µM) associating with both HSA and HRG. 
This led to the suggestion that HRG could also been an important 
competitor for Zn2+ in plasma although that fatty acid content of HSA used 
in this study is unclear.   
 
1.9 Research motivation and aims 
The aim of this work is to study the interactive binding of metal ions and 
fatty acids to albumin and to explore its biological significance. In 
particular native mass spectrometry will be used as a new approach to 
investigate metal ion binding to HSA directly.  Overall, structural details 
on the biomolecular interactions of HRG are lacking although there have 
been numerous studies linking it to important physiological functions.  
The possible link between the fatty acid “switch” mechanism and the 
HRG-Zn2+ interaction could have implications for Zn2+ transport in blood 
plasma although there is no experimental evidence for this as yet. The 
reported binding constants for HSA and HRG give no clear answer as to 
whether Zn2+-dependent HRG-complex formation would only occur as a 
result of elevated fatty acids and therefore this issue needs to be 
addressed.  
 
Objectives: 
1. To optimise mass spectrometry methods to study non-covalent HSA 
complexes under native conditions. This has mainly been applied in 
previous studies to investigate the binding of molecules that form 
covalent bonds with albumin (Chapter 3). 
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Can Zn2+ binding to HSA be observed in the gas phase? Do fatty 
acids have any effect on this?  
 
2. To utilise travelling wave- ion mobility mass spectrometry as a novel 
technique to study HSA complexes (Chapter 4). 
Can any conformational changes be detected in the presence of metal 
ions or fatty acids? 
 
3. To identify a suitable peptide mimic of the HRR of HRG and study its 
metal binding properties. There is currently very little structural 
information on HRG and its biomolecular interactions therefore this 
work will attempt to address this (Chapter 5).  
What are the metal binding properties of the HRGP330 peptide and 
can these be related to its biological functions? Do any structural 
changes occur upon metal binding? 
 
4. To investigate the distribution of metal ions between the peptide mimic 
of HRG and HSA and explore if fatty acids have an effect on this 
(Chapter 6).  
Is the peptide mimic of HRG able to compete with HSA for metal ions? 
Do fatty acids have any effect on the distribution?   
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1. Chapter 2 
Experimental Methods 
 
2.1 Materials and chemicals 
Wherever possible, reagents of the highest quality were used. If not 
stated, chemicals were obtained from either Fisher Scientific (UK) or 
Sigma Aldrich (UK). 
 
 
2.2 Methods for defatting HSA 
2.2.1 Dialysis of HSA 
Recombinant HSA (Recombumin™) was a gift from Novozymes® (batch 
number PDP090078) containing 31.1 mM octanoic acid, 141 mM sodium 
chloride and 15 mg/L polysorbate 80. The dialysis tubing acquired from 
Medicell International Ltd was prepared by boiling in 10 mM 
ethylenediaminetetraacetic acid (EDTA) for 1 hour, followed by storage in 
a fresh EDTA solution. SnakeSkin™ dialysis tubing (Pierce Protein 
Biology Products, 10 KDa MWCO) was used without any further 
preparation. HSA stock solution (5 ml) was diluted to 20 ml in water and 
transferred to the tubing. Dialysis was carried out against 5 L of 100 mM 
ammonium bicarbonate for 24 hours at 4 °C with at least two buffer 
changes. Samples were frozen with liquid nitrogen, lyophilised by freeze-
drying and stored at -20 °C.  
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2.2.2 Charcoal treatment 
The method used was based on that described (Chen, 1967) with slight 
modifications. HSA in distilled water was acidified to pH 3.0 using 
microlitre aliquots 0.1 M HCl. An equal weight of activated charcoal was 
added and the mixture stirred on ice for 1 hour. Charcoal was removed 
from the solution by centrifugation (Sorvall RC6 floor standing centrifuge) 
at 30,000 x g for 20 minutes at 2 °C. The solution was filtered through a 
0.22 µm filter and neutralised by addition of 0.2 M NaOH. Desalting into 
the appropriate buffer was achieved using a PD-10 column. 
 
2.3 Characterisation of HSA 
2.3.1 SDS-PAGE 
Two kits were used: the NuPAGE® system from Invitrogen and Biorad. 
Pre-cast gels NuPAGE® gels (10 well, 4-12% gradient Bis-Tris gels) were 
assembled in the electrophoresis apparatus (OmniPAGE mini, Geneflow). 
Ten microlitres of SeeBlue2® pre-stained molecular weight marker was 
loaded into the first well. Samples were mixed 1:1 with NuPAGE 4 x LDS 
sample buffer and loaded onto additional sample wells. Gels were run at 
200 mV for 35 minutes and then stained overnight with Coomassie Blue 
solution (0.25 g/L Coomassie Blue R-250, 10% acetic acid and 50% 
methanol). Gels were destained in distilled water overnight with agitation.  
 
Mini-Protein TGX pre-cast gels were assembled in the Biorad apparatus. 
Ten microlitres of Precision Plus Protein™ Dual Colour Standard was 
used as a reference. Samples were mixed 1:1 with the Laemmli sample 
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buffer and loaded onto the gel. Gels were allowed to run for 35 minutes at 
200 mV. Staining was achieved as described previously.  
 
2.3.2 Determining HSA concentration 
Protein concentration was estimated by measuring the absorption at 279 
nm and using a value of A279 (1 mg/ml, 1 cm) = 0.556 for HSA (Sadler et 
al., 1994).  
 
2.3.3 Assay for free thiol content 
A modified colorimetric assay was used to determine the free thiol 
concentration (Ellman, 1958). HSA samples (100-200 µL) were diluted 
with 2.6 ml of 0.1 M Tris-Cl (pH 7.05 containing 1 mM EDTA) and 200 µL 
of 2.5 mM DTNB (dissolved in 50 mM ammonium acetate, pH 5.0, 1 mM 
EDTA) was added. Milli-Q water was used to make the total sample 
volume up to 3 ml. The solution was left to react for 10-15 minutes at 
room temperature before measuring the absorbance at 412 nm (Biomate 
3 spectrophotometer, Fischer Scientific).  An 800 µM cysteine stock, 
containing 1 mM EDTA, was used to prepare standards of known thiol 
concentration.  Thiol concentration was calculated through calibration 
using these standard solutions. This was then divided by the protein 
concentration to give the free thiol content of the HSA sample. 
 
2.3.4 Reaction with DTNB for ESI-MS analysis 
Lyophilised HSA was dissolved in 2.5 ml potassium dihydrogen 
phosphate (100 mM, pH 8.0). Forty mol. equiv. of DTNB (5,5'-Dithio-
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bis(2-nitrobenzoic acid) were added to a 30 µM solution of HSA and 
incubated at room temperature for an hour. Excess DTNB was removed 
using a PD-10 column. Confirmation that the free thiol of Cys-34 had 
been covalently modified was obtained using ESI-MS (theoretical mass of 
HSA-NTB = 66,635 Da).  
 
2.4 ESI-MS of HSA  
2.4.1 Desalting with PD-10 column 
Lyophilised samples were reconstituted in 10 mM ammonium acetate (pH 
7.4). The PD-10 column (Sephadex® G-25, Amersham Biosciences) was 
equilibrated with the appropriate buffer (25 ml) and loaded with 2.5 ml of 
protein sample. Elution was achieved with 3.5 ml of the buffer solution. 
The column was washed with a further 25 ml of buffer, and stored at 4 °C. 
If required, protein eluate fractions were concentrated using Amicon® 
Ultra-4 centrifugal filter units (Millipore) with a 30 kDa MWCO.  
 
2.4.2 Sample preparation  
Native HSA was prepared at a concentration of 2.5-5 µM in 10 mM 
ammonium acetate (~ pH 7.4) with 10% methanol (v/v). To denature the 
protein, 1 % formic acid and 50% organic solvent (methanol or 
acetonitrile) was used. All buffers used for sample preparation were 
filtered through a 0.22 µm sterile (Millipore) filter to prevent blocking of the 
electrospray needles. Prior to analysis, samples were centrifuged at 
13,200 rpm for 2 minutes to ensure any precipitate was removed from 
solution.  
Chapter Two 
41 
 
2.4.3 Acquiring data: microTOF 
Mass spectra were recorded on a microTOF instrument (Bruker Daltonics, 
Germany) operating in the positive mode. Samples were introduced into 
the syringe pump with injection into the instrument at a flow rate of 240 
µL/hour. The following parameters were used:  source temperature = 
195 °C; capillary exit = 150 V; skimmer 1 = 50 V; skimmer 2 = 23.5 V; 
hexapole RF = 450 V; hexapole 1 = 24 V; hexapole 2 = 20.9 V; transfer 
time = 88 µs. Data were acquired for 1.2-1.5 minutes over an m/z range 
of 1500-5000. Raw data were averaged and deconvoluted using Bruker 
Daltonics Data Analysis v3.3.  
 
2.4.4 Acquiring data: maXis-UHR-TOF 
Positive electrospray mass spectra were acquired on a maXis ultra-high 
resolution time-of-flight (UHR-TOF) instrument (Bruker Daltonics, 
Germany) calibrated with Tune Mix for positive mode ESI (Bruker 
Daltonics). A syringe pump injected the sample into the mass 
spectrometer at a rate of 120 µL/hour. Data were collected for 
approximately 2 minutes over an m/z range of 1500-5000. This was 
extended to 7000 m/z to observe the dimer charge states. The following 
conditions were used for the Q-TOF mass spectrometer: dry gas = 4.0 
L/min; source temperature = 200 °C; funnel RF = 400 Vpp; multipole RF = 
400 Vpp; ISCID = 100 eV; collision cell energy = 10 eV; collision RF = 
1800 Vpp; ion cooler = 650 Vpp; transfer time = 140.4 µs; pre pulse 
storage = 20 µs.  
 
Chapter Two 
42 
 
Online nanoESI was also used to record spectra using an TriVersa 
NanoMate® system (Advion Biosciences, Ithaca, NY, USA) coupled to 
the maXis  instrument.  Aliquots of 5 µM protein samples (20 µL) were 
pipetted into the wells on the sample-loading plate from which 5 µL was 
taken up by the tip, in an automated process, and infused at a flow rate of 
approximately 120 nL/min. Spraying voltages in the range of 1.65 – 1.75 
kV were used and a gas pressure of 0.65 psi applied which gave ~ 100 
nA current. Data were acquired in the positive mode over an m/z range of 
1500-5000 and processed using the maximum entropy deconvolution 
algorithm (MaxEnt) within Bruker Compass Data Analysis v4.0.  
 
2.4.5 Identifying fatty acids in the low mass range  
To optimise the conditions for identifying small molecules in HSA samples, 
the conditions were adjusted as follows: dry gas = 4.0 L/min; source 
temperature = 200 °C; funnel RF = 400 Vpp; multipole RF = 400 Vpp; 
ISCID = 0 eV; collision cell energy = 10 eV; collision RF = 400 Vpp; ion 
cooler = 125 Vpp; transfer time = 100 µs; pre pulse storage = 5 µs. 
 
2.5 Preparation of HSA complexes 
2.5.1 Metal ion-bound HSA 
HSA solutions were incubated with 1-2 molar equivalents of the 
appropriate metal ion from the following stock solutions: 
Zn(CH3COO)2.2H2O, Cd(CH3COO)2.2H2O, Cu(CH3COO)2.H2O. Stock 
solutions were filtered through 0.22 µm filters prior to use. Following 
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incubation for 2 hours at 37 °C, unbound metal ions were removed by 
passage through a PD-10 column.   
 
2.5.2 Fatty acid-bound HSA 
Stock solutions of octanoic acid and myristic acid were prepared in Milli-Q 
water and heated to 60 °C in a water bath. The solution was cooled to 
37 °C and 1-5 mol. equiv. of fatty acid were added to HSA and incubated 
at 37 °C in a water bath for 2-5 hours.  
 
2.5.3 pH titration with HSA 
A 5 µM sample of Zn-HSA was titrated with microlitre additions of 1 % 
acetic acid (v/v). An aliquot was taken in order to measure the pH 
(Hamilton Biotrode pH electrode) and the pH of the ESI-MS sample was 
measured directly following analysis.  
 
2.6 Determination of metal: protein stoichiometry by ICP-OES 
Following incubation with the appropriate ligands, HSA samples were 
buffer exchanged into 10 mM ammonium acetate (pH 7.4) using a PD-10 
desalting column. ICP-OES (Inductively coupled plasma-optical emission 
spectroscopy) analyses were performed using an Optima 5300DV (Perkin 
Elmer). Ultrapure 72% nitric acid was obtained from in-house acid 
distillation. Samples were diluted with ultrapure 0.1 M HNO3 and analysed 
for S, Zn, Cd and Cu. Standards of these elements were prepared 
gravimetrically from high grade 10,000 ppm stocks in the range of 0.2-5 
ppm. The samples were measured in triplicate and then averaged. The 
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raw data (presented in mg/L) was divided by the atomic mass of the 
element to obtain the concentration in mmol/L. Protein concentration was 
estimated by dividing the sulfur concentration by the number of sulfur-
containing residues (41 for HSA). Subsequently, the number of metal ions 
bound to the protein was calculated by dividing the metal concentration 
by the protein concentration. 
 
2.7 NMR experiments with HSA 
2.7.1 1-D 1H NMR spectroscopy 
Lyophilised samples of HSA were reconstituted in 100% D2O and 
incubated at 4 °C overnight to minimise amide resonances. The sample 
was lyophilised again and stored at -20 °C. NMR samples were prepared 
to a concentration of 1 mM in 50 mM [D11]Tris-Cl, 50 mM NaCl, 100% 
D2O (v/v), pH 7.2. The pH* was measured using a pH meter calibrated 
with H2O buffers and was not corrected for the effect of deuterium. The 
corresponding pD value can be calculated by adding 0.41 to the observed 
pH* (Glasoe and Long, 1960). Additions of ligands were made as stock 
solutions in the same buffer. The pH* values were monitored before and 
after addition of ligands. Spectra were obtained on a Bruker Avance 700 
UltrashieldTM spectrometer using 8k complex data points over 256 scans. 
The data was apodized, firstly with a squared-sinebell function followed 
by a Gaussian function for resolution enhancement and then Fourier-
transformed.  
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2.7.2 111Cd-NMR spectroscopy 
Dialysed HSA was solubilised into 50 mM Tris-Cl, 50 mM NaCl with 10% 
D2O (pH 7.2). Proton decoupled 1-D 
111Cd-NMR spectra were obtained 
using a Bruker DRX500 spectrometer fitted with a broadband observe 
(BBO) probe. The operating frequency for 111Cd is 106.037 MHz and the 
pulse sequence employed inverse gated decoupling. Data were acquired 
at 37 °C and a spectral width of 300 ppm was used with 8k complex data 
points and 98k scans. Spectra were referenced using an external 
standard of 0.1 M Cd(ClO4)2. The data was zero-filled to 32k data points 
and apodized using exponential multiplication with a line-broadening 
factor of 90 Hz. Spectra were processed using TOPSPIN 2.0 provided by 
Bruker. 
 
2.8  TWIM-MS of HSA complexes 
2.8.1 Experimental parameters 
Samples of metal- and fatty acid-bound HSA were prepared according to 
sections 2.5.1 and 2.5.2. For TWIM-MS, 30 µM HSA samples were buffer 
exchanged into 200 mM ammonium acetate (pH 7.4). Ten microlitres was 
injected via a nanoflow source into a Synapt HDMS G2 system (Waters, 
Corporation, Milford, MA, USA). The instrument was operated in the 
positive mode with a source temperature of 90 °C. The following 
instrumental conditions were used: backing pressure 5 mBar; capillary 
voltage 1.5 kV; cone voltage 80 V; helium cell gas flow 180 mL/min; IMS 
cell gas flow 90 mL/min; travelling-wave height 40 V and travelling wave 
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velocity 700 m/s. A mass acquisition range of 500-5000 m/z was used. 
Data were processed using MassLynx v4.1 provided by Waters. 
 
2.8.2 TWIM-MS calibration: sperm whale myoglobin 
Arrival time distributions (ATDs) were extracted for each ion of interest. 
Calibration was achieved using 10 µM sperm whale myoglobin in 50% 
acetonitrile with 0.2% formic acid which was measured under the same 
conditions as in section 2.8.1. The calibration procedure followed has 
been described previously (Thalassinos et al., 2009).  
 
2.8.3 Estimation of theoretical cross sections using MOBCAL 
Theoretical calculations for the rotationally-averaged collision cross-
section were carried out using MOBCAL, a program to calculate 
mobilities (Mesleh et al., 1996; Shvartsburg and Jarrold 1996). These 
were carried out by Matthew Edgeworth. PA and EHSS approximations 
were performed on published X-ray crystal structures 1AO6 (Sugio et al., 
1999) and 1BJ5 (Curry et al., 1998) from the RCSB Protein Data Bank 
(www.rcsb.org, Berman et al. 2000).  
 
2.9 Purification of the synthetic peptide HRGP330 
2.9.1 Reverse phase-high performance liquid chromatography  
A crude synthetic peptide from the His/Pro-rich region of HRG was 
synthesized at the Keck Biotechnology Research Facility (Yale University, 
USA). The sequence is shown below and included an acetylated N-
terminus and amidated C-terminus. 
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Ac-DLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPH-CONH2 
 
The crude peptide was purified using reverse phase high performance 
liquid chromatography (RP-HPLC) on an Agilent 1100 instrument with 
HPLC grade solvents. Crude peptide (5 mg) was solubilised in 20% 
acetonitrile with 0.1% TFA. Aliquots of 50 µL were injected onto a Jupiter 
Proteo 90 Å C12 column (250 x 4.6 mm, Phenomenex) equilibrated with 
95% of the aqueous mobile phase (H20 + 0.1% TFA) and 5% organic 
mobile phase (Acetonitrile + 0.1% TFA). The peptides were eluted at 1 
ml/min using the gradient in Table 2.1 and elution monitored at 220 nm. 
Fractions were analysed for HRGP330 using a microTOF instrument 
using the same parameters described in section 2.4.3 but over a mass 
range of 400-5000 m/z.  
 
Table 2.1 Gradient used for purification of HRGP330 by RP-HPLC 
Time (mins) % Organic Mobile Phase 
0 5 
20 55 
40 100 
45 100 
50 5 
 
2.9.2 Lyophilisation of peptides 
Fractions containing HRGP330 were combined in a round bottomed flask 
and the acetonitrile/TFA removed on a rotary evaporator for 10 minutes. 
The solution was aliquoted into acid-washed Eppendorfs and freeze-dried. 
The dried peptide was stored at -20 °C until required. 
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2.9.3 Estimating HRGP330 concentration 
HRGP330 has no absorbance at 280 nm due to the lack of Cys, Trp and 
Tyr residues. Scopes’ Equation (1) was used to estimate the 
concentration by measuring the absorbance at 205 nm (Scopes, 1974). 
The lyophilized peptide was reconstituted in the appropriate aqueous 
buffer before the absorbance was measured. 
 
       ⁄    
    
      
 
 
c = concentration; A = absorbance; b = optical path length (cm) 
Equation 1 
 
2.10 Metal ion-binding experiments with HRGP330 
2.10.1 Desalting HRGP330 samples  
Lyophilized HRGP330 was reconstituted in 10 mM ammonium acetate 
(pH 7.4). Desalting was achieved using 5 ml polyacrylamide desalting 
columns with a 1.8 kDa exclusion limit (Pierce Protein Biology Products). 
The columns were inverted several times to resuspend the resin and then 
left to settle for 10 minutes. The storage solution (0.02% sodium azide) 
was removed from the column and it was equilibrated with 50 ml 10 mM 
ammonium acetate (pH 7.4). HRGP330 (0.5 ml) was loaded onto the 
column and 0.5 ml fractions collected. Emergence of peptide from the 
column was monitored by measuring the absorbance at 220 nm. The 
columns were regenerated by washing with 50 ml of buffer and stored at 
4°C.  
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2.10.2 Metal ion titrations by ESI-MS 
Metal stocks of Zn(CH3COO)2.2H2O, Cd(CH3COO)2.2H2O and 
Cu(CH3COO)2.H2O were prepared in Milli-Q water at a concentration of 
20 mM.  Microlitre aliquots were added to HRGP330 samples to achieve 
varying metal:peptide ratios. Samples were incubated at room 
temperature for 2 hours. Spectra were acquired using a maXis-UHR-TOF, 
as outlined in section 2.4.4, with parameters adjusted to suit smaller 
proteins. A syringe pump injected the sample into the mass spectrometer 
at a rate of 90 µL/hour. Raw data were collected for approximately 1-1.5 
minutes over a m/z range of 500-1500. The following conditions were 
used for the Q-TOF mass spectrometer: Dry gas = 4.0 L/min; dry gas 
temperature = 180 °C; funnel RF = 400 Vpp; multipole RF = 400 Vpp; 
collision cell energy = 10 eV; collision RF = 1300 Vpp; ion cooler = 650 
Vpp; transfer time = 148.4 µs. The data were deconvoluted, smoothed 
and baseline subtracted using Bruker Compass Data Analysis v4.0. 
 
2.10.3 pH titration of Zn5-HRGP330 by ESI-MS 
HRGP330 (20 µM) was incubated with 5 mol. equiv. of 
Zn(CH3COO)2.2H2O and desalted as described in section 2.10.1. 
Microlitre additions of 1% acetic acid were added to reduce the pH and 
spectra acquired for 2 minutes at each point. The pH range investigated 
was 2-7 and was double-checked for each sample following ESI-MS 
analysis.  
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2.10.4 CD spectroscopy of HRGP330 
Lyophilized HRGP330 samples were reconstituted in 10 mM sodium 
phosphate buffer (pH 7.4) and diluted to a concentration of 11 µM. Far-
UV CD spectra were measured on a J-720 spectropolarimeter (Jasco Inc, 
Easton, MD, USA) using quartz cuvettes with a 1 mm pathlength and a 
temperature of 20 °C. Spectra were recorded over a range of 180-260 nm 
with a data pitch of 0.2 nm, bandwidth of 1 nm, a scanning speed of 100 
nm/min and a response time of 1 s. Sixteen scans were averaged and the 
spectrum of the buffer was subtracted to give the final corrected spectrum. 
Titrations were carried out by adding microlitre additions of ZnCl2.  
 
2.10.5 Comparison of apo- and holo-HRGP330 using TWIM-MS 
Samples of Zn2+-bound HRGP330 were prepared using the same 
procedure as described in section 2.10.2.  Ten microlitres of 10 µM 
HRGP330 in 10 mM ammonium acetate (pH 7.4) was injected via a 
nanoflow source into a Synapt HDMS G2 system (Waters Corporation, 
Milford, MA, USA). The instrument was operated in the positive mode 
with a source temperature of 90 °C. The following instrumental conditions 
were used: backing pressure 2 mBar; capillary voltage 1.2 kV; cone 
voltage 40 V; helium cell gas flow 180 mL/min; IMS cell gas flow 90 
mL/min; travelling-wave height 40 V and travelling wave velocity 700 m/s. 
A mass acquisition range of 200-1500 m/z was used. To calibrate the ion 
mobility data 10 µM polyalanine in 50% acetonitrile was used. Data were 
analysed and processed using MassLynx v4.1 provided by Waters. 
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2.11 Comparison of apo- and holo-HRGP330 by NMR spectroscopy 
2.11.1 NMR sample preparation 
Samples of HRGP330 (0.3-0.5 mM) were prepared in protein NMR buffer: 
50 mM [D11]Tris-Cl, 50 mM NaCl, 10% D2O, pH 7.4. The pH was adjusted 
if necessary using 1 M DCl or 1 M NaOD and the pH measured prior to 
experiments. Aliquots of ZnCl2 from a 55 mM stock solution were added 
to HRGP330 at varying metal ion:peptide ratio. The pH was adjusted with 
1M DCl or NaOD and samples were allowed to equilibrate for 20 min 
before being spun to remove any aggregated protein. 
 
2.11.2 1-D 1H NMR spectroscopy 
Spectra were recorded on a Bruker Avance 700 Ultrashield™ 
spectrometer which has an operating frequency of 700.13 MHz for 1H. 
Suppression of the water signal was achieved using excitation sculpting 
with gradients (Hwang et al., 1995).  1-D spectra were obtained over 
various temperatures (5-35 °C) using 65k complex data points, 128 scans 
and a spectral width of 15 ppm. Spectra were processed using TOPSPIN 
2.0 provided by Bruker.  
 
2.11.3 2-D homonuclear [1H, 1H]  NMR spectroscopy 
2-D [1H,1H] total correlation (TOCSY) and nuclear Overhauser (NOESY) 
spectra were acquired over 32 scans with 4k data points in the F2 
dimension and 512 increments in F1. The spectral width was 13 ppm in 
both directions. A spin lock of 60 ms for the TOCSY and mixing time of 
500 ms for the NOESY were used. The raw data were processed in 
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TOPSPIN 2.0 with apodization using a squared sine-bell function and 
Fourier-transformed with 2k x 2k data points in F2 and F1. Baseline 
correction was employed in both directions. Analysis was carried out 
using Sparky v3.114 (Goddard and Kneller, 2007).  
 
2.11.4 Chemical shift referencing using residual water  
The chemical shift of water is typically 4.766 at pH 7.0, 298 K and no salt 
(Wishart et al., 1995). This chemical shift is affected by temperature (-
11.9 +/- 0.3 ppb/K), pH (-2 ppb/pH unit in the range of 2-7) and salt 
concentration (-9 ppb/100 mM salt). Residual water can be used as an 
internal standard and the shift is calculated according to Equation 2 
(where pH = 6.20, temperature = 5 °C and salt concentration = 50 mM).  
 
                                                
                    
Equation 2 
 
2.12 Electrospray-tandem mass spectrometry (ESI-MS/MS) 
MS/MS experiments were carried out on a dual ion funnel amazon speed 
ETD instrument (Bruker, Coventry, UK) operating in positive mode. 
HRGP330 was infused at a rate of 6 µL/min and acquisitions were 
performed using a scan speed of 8,100 m/z/sec-1. The following 
parameters were used: trap drive = 71.8; capillary exit = 140 V; source 
temperature = 180 °C. An isolation width of 4 m/z was used to select the 
ion of interest and CID was performed by applying an amplitude of 1.0 V. 
Fluoranthene was used as the electron transfer dissociation (ETD) 
reagent with an ETD reaction time of 100-120 ms followed by a proton 
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transfer reaction (PTR) time of 75 ms. Monoisotopic peaks were assigned 
using the SNAP™ peak detection algorithm.  Spectra were analysed 
using BioTools v3.2 and Sequence Editor provided by Bruker.  
 
2.13 Interaction of HRGP330 with a heparin dodecasaccharide  
An ammonium salt of an unsaturated heparin dodecasaccharide was 
obtained from Dextra Laboratories (Reading, UK) which had been 
produced by enzyme cleavage (purity ≥ 95%). To observe the complex 
formation, the dodecasaccharide was reconstituted in 10 mM ammonium 
acetate (pH 7.4) and incubated with HRGP330 at a 1:1 ratio for 1 hour 
prior to mass spectrometry analysis. For the protein-heparin complex, 
spectra were obtained in the positive mode using the method previously 
described in section 2.10.2. 
 
2.14 Determination of an apparent binding constant for HRGP330  
5 µM ZnCl2 was added to 10 µM Zincon in 50 mM HEPES and 100 mM 
NaCl at pH 7.4. Aliquots of HRGP330 in the same buffer were titrated in 
and the absorbance measured at 620 nm until a plateau was reached. 
The apparent binding constant was determined using Equation 3.  
 
                                   
                    ⁄
                    ⁄
 
Equation 3 
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The absorbance values were converted to percentages with 100% 
relative absorbance corresponding to the maximum absorbance observed 
at 620 nm for the Zn2+-Zincon complex.  
 
2.15 Zn2+ binding to full length HRG 
Rabbit HRG was a gift from Dr Alan Stewart (University of St Andrews). 
HRG was incubated with 10 mol. equiv. of Zn(CH3COO)2.2H2O for 2 
hours at 37 °C. Samples were buffer exchanged into 10 mM ammonium 
acetate (pH 7.4) using a PD-10 column. The protein fraction that eluted 
was concentrated using Amicon-Ultra 4 centrifugal filters with a 30 kDa 
MWCO membrane. Samples were diluted with ultrapure 0.1 M HNO3 and 
analysed using ICP-OES as described in section 2.6. HRG concentration 
was estimated by dividing the sulfur concentration by 13.  
 
2.16 Metal binding to Gly-Gly-His peptide 
2.16.1 ESI-MS 
A peptide mimic for the N-terminus of HSA, Gly-Gly-His, was obtained 
from GenScript Corporation (USA) which had a purity of > 95%. The 
lyophilised peptide was reconstituted into sterile water, aliquoted and 
frozen at -20 °C. Aliquots were thawed on ice and 1 mol. equiv. of the 
appropriate metal ion added. The peptide was incubated for 2 hours 
followed by analysis on a maXis-UHR-TOF instrument in the positive 
mode over a mass range of 5-2000 m/z. The following parameters were 
used: dry gas = 4.0 L/min; source temperature = 200 °C; funnel RF = 100 
Vpp; multipole RF = 300 Vpp; collision cell energy = 5 eV; collision RF = 
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600 Vpp; ion cooler = 200 Vpp; transfer time = 131.4 µs; pre pulse 
storage = 1 µs. 
 
2.16.2 1-D 1H NMR spectroscopy  
2 mM peptide samples were prepared in 90% H2O/ 10% D2O at pH 7.35. 
1H-HMR was carried out on a Bruker-DRX550 instrument operating at a 
frequency of 500.13 MHz for 1H. Data were obtained over 256 scans at a 
temperature of 25 °C. ZnCl2 was titrated into the peptide from a 50 mM 
stock solution.  
 
2.17 Metal ion transfer experiments 
2.17.1 Zn2+ distribution between HSA and HRGP330  
15 µM Zn-HSA (with or without 5 mol. equiv. myristate) was prepared as 
described in section 2.5.1 in 10 mM ammonium acetate (pH 7.4). 
Lyophilised HRGP330 was reconstituted in the same buffer and added to 
HSA at a concentration of 15 µM. The protein samples were incubated at 
37 °C for 2 hours after which time they were diluted to 5 µM and analysed 
by ESI-MS as outlined in section 2.10.2.  
 
2.17.2 Separation of HSA and HRGP330 with a MWCO filter 
To investigate Zn2+ binding to HRGP330 in the presence of  600 µM HSA, 
a 30 kDa MWCO filter was used to retain the HSA on the membrane but 
allow any Zn2+-bound HRGP330 to pass through. Zn-HSA (with or without 
5 mol. equiv. myristate) was prepared as in section 2.5.1 in 10 mM 
ammonium acetate (pH 7.4) and concentrated to ~600 µM. 10-20 µM 
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HRGP330 was added followed by incubation at 37 °C for 2 hours.  The 
peptide was separated from HSA by washing through an Amicon® Ultra-
0.5 centrifugal filter unit (30 kDa MWCO) 3 times at 13,000 rpm for 10 
minutes. The HRGP330 fraction was analysed by ESI-MS as outlined in 
2.10.2 and the HSA fraction was prepared for ICP-OES analysis 
according to section 2.6.  
 
2.17.3 Size exclusion chromatography 
600 µM HSA, 20 µM HRGP330 and 25 µM ZnCl2 (± 5 mol. equiv. 
myristate) were separated on a BioSep™-SEC-S2000 column (300 x 7.8 
mm, Phenomenex) in 10 mM HEPES, 50 mM NaCl (pH 7.4) following 
incubation at 37 °C for 2 hours. Aliquots of the fractions where proteins 
eluted (200 µL) were diluted to 3 ml in 3% HNO3 in acid-washed tubes 
and analysed for Zn on an Agilent 7500 ICP-MS instrument by Dr James 
Barnett. Protein concentration of the fractions was assessed using a BCA 
Protein Assay kit according to the manufacturer’s instructions (Pierce 
Protein Biology Products).  
 
2.17.3 Cu2+ transfer between Gly-Gly-His and HRGP330 
The Cu2+-Gly-Gly-His complex was formed by addition of 1:1 mol. equiv. 
Cu(CH3COO)2.H2O to the peptide in 10 mM ammonium acetate (pH 7.4). 
Addition of 0.2-1 mol. equiv. of HRGP330 was made from a stock in the 
same buffer. Following an equilibration period, samples were analysed on 
a maXis-UHR-TOF according to the same method in section 2.16.1. 
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2.18 Bioinformatic analysis 
Primary sequences of HSA and HRG were obtained from the protein 
database, UniProtKB, accessed via ExPASy. Sequence alignments were 
carried out using ClusalW2 (Larkin et al., 2007). The Unimod database 
(Matrix Science Ltd, London) was used to identify protein modifications 
from mass spectrometry data. Structures from the protein databank (PDB) 
were manipulated using DeepView Swiss PDB-viewer v4.01 (Guex and 
Peitsch, 1997) and PyMOL Molecular Graphics System v1.3 (Schrödinger, 
LLC).  
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2. Chapter 3 
HSA-ligand complexes 
 
3.1 Introduction 
In this Chapter, a high resolution Q-TOF instrument was used to optimise 
methods to study large protein complexes. Once weakly bound buffer and 
salt adducts were removed efficiently, this enabled production of data on 
metal binding to HSA. It was found that the interactions with biologically 
relevant fatty acids are removed on transfer into the gas phase. 
Conversely, perfluorinated fatty acids (PFCAs) were observed to bind in 
the gas phase and the data showed that Zn2+ remained bound to HSA 
even in the presence of perfluorinated octanoic acid (PFOA). This is 
consistent with the hypothesis proposed by Lu et al. (2012b) that Zn2+ is 
able to still bind in Site A when a short-chain fatty acid molecule is bound 
to FA2.  
 
3.2 Electrospray-ionisation mass spectrometry (ESI-MS) 
3.2.1 An overview of mass spectrometry 
Mass spectrometry has been developed over the years to become an 
essential tool in the fields of both chemistry and biology. The mass of a 
molecule is an important characteristic and the ability to measure it 
precisely is necessary for a variety of scientific investigations. A mass 
spectrometer is an instrument that can measure the mass-to-charge ratio 
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(m/z) of ions in the gas phase. The instrument can be separated into five 
different components that are outlined in Figure 3.1. Firstly the sample of 
interest is injected into the mass spectrometer, followed by the formation 
of ions in the ion source. The ions are separated depending on their m/z 
by the mass analyser and the ion intensity at each different m/z value is 
registered by the detector. A digitizer allows this information to be 
converted into a user-friendly data format known as the mass spectrum. 
Typically, instruments have two mass analysers, for example the maXis-
UHR-TOF used in this work has a quadrupole coupled to a time-of-flight 
analyser. A collision cell located between these allows MS/MS data to be 
obtained. 
 
Figure 3.1 A general overview of a mass spectrometer. A schematic diagram of the 
components that make up a conventional mass spectrometer. 
 
 
3.2.2 Development of ESI-MS for biomolecules  
Until the late 1980’s, researchers in the field of mass spectrometry 
believed that it was impossible to transfer large biomolecules from 
solution to the gas phase without breaking any covalent bonds and 
ultimately destroying the molecule. With the introduction of two new 
methods of ionisation, electrospray ionisation (ESI) and matrix assisted 
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laser desorption ionisation (MALDI), came the realisation that 
biomolecules could be preserved in the gas phase by using these soft 
ionisation techniques.  ESI-MS is a technique that was first pioneered by 
John Fenn, who later received the Nobel Prize for the work. Firstly, the 
technique was employed for small molecules (Yamashita and Fenn, 
1984), but then later extended to larger biomolecules such as 
oligonucleotides and proteins (Fenn et al., 1989). It has become an 
indispensable tool for analysing biomolecules of varying sizes and also 
their complexes. Early examples of ESI-MS to study non-covalent 
interactions include Zn2+ and Ca2+ binding to the metalloproteinase 
matrilysin (Feng et al., 1995) and the observation of a heme-myoglobin 
complex (Katta and Chait, 1991).     
 
3.2.3 Mechanisms of ion formation 
The sample is typically dissolved in a volatile buffer and/or organic 
solvent and infused continuously into the ion source. The solution is 
sprayed through a capillary needle which has a high electrical potential 
with respect to the entrance of the mass spectrometer. This electric field 
induces a charge accumulation on the surface of the solution at the end 
of the capillary, known as a Taylor cone (Figure 3.2). At a critical point the 
solution breaks away from the Taylor cone to form multiply charge 
droplets.  A heated nebulising gas (typically nitrogen) flows around the 
outside of the capillary and directs the newly-released droplet towards the 
mass spectrometer in addition to aiding desolvation of the droplets.  
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Figure 3.2 Ion formation during ESI-MS. A schematic diagram showing the steps 
involved in the CRM mechanism of ion formation during ESI-MS. Adapted from (Kebarle, 
2000).  
 
Gas phase ions form as solvent evaporates from the droplets. The 
mechanism of ion formation can be described using the two proposed 
models:  the charge residue model (CRM) or the ion evaporation model 
(IEM). The CRM suggests that once the droplet is released from the 
Taylor cone, solvent evaporation occurs until the charge repulsion in the 
droplet exceeds the surface tension (or Rayleigh limit). The droplet can 
divide by means of a Coulombic explosion and this process is repeated 
until a single, multiply-charged, analyte ion is produced (Dole et al., 
1968). In contrast, the IEM proposed by Iribarne and Thomson (1976) 
suggests that as the droplet reaches a particular radius the field strength 
of the surface of the ion becomes sufficiently large enough to eject the 
analyte ion out of the droplet. The IEM is thought to be the mechanism 
through which ions with a low mass are formed while the CRM is 
dominant for multiply charged ions with a high mass such as proteins 
(Kebarle, 2000; Kebarle and Verkerk, 2009).  
 
3.3 Advantages of ESI-MS  
A main advantage of ESI is that for instruments of limited m/z range, the 
production of the multiply-charged ions allows the observation of 
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molecules of higher masses at lower m/z values.  It is also a particularly 
good technique for studying molecules that associate non-covalently 
because the gentle ionisation involved ensures that these complexes 
remain intact and can be detected. As proteins are proposed to form ions 
via the CRM model, non-covalent complexes are expected to survive in 
the gas phase due to a cooling effect as the solvent evaporates (Wilm, 
2011). It is also an extremely sensitive technique that can analyse 
samples in a short time, requiring only low micromolar concentrations of 
the analyte. In addition, ESI-MS can be advantageous over other 
techniques for studying large proteins. NMR spectroscopy can provide 
detailed structural information on biomolecules as large as ribosomes 
although this requires large quantities of sample and hours, or even days, 
of instrument time (Cabrita et al., 2009). Furthermore, the protein may 
need to be isotopically labelled. X-ray crystallography is also an important 
technique in structural biology, however, some proteins can be difficult to 
crystallise and various conditions have to be screened in a trial and error 
process (Drenth, 2007). 
 
3.4 Maintaining the native structure of proteins in the gas phase 
3.4.1 Sample preparation 
In the early days, mass spectrometry was mainly applied to proteomics, 
and routine analysis of intact proteins often used denaturing conditions 
(high concentrations of organic solvent or acidic solutions) in order to 
observe an accurate mass. With the development of instrumentation and 
methods for sample preparation it has become possible to study proteins 
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in their “native” state (Winston and Fitzgerald, 1997). This relies on 
proteins being prepared in volatile buffers at physiologically-relevant pH 
values. Purification of proteins by chromatography often utilises non-
volatile buffers including Tris and HEPES and salts such as sodium 
chloride which are incompatible with mass spectrometry. The presence of 
these ionic substances will supress the ionisation of the analyte of 
interest (van Duijn, 2010).  It is necessary for the protein samples to be 
buffer-exchanged into a volatile buffer and be as homogenous as 
possible. The sample concentration used for experiments is typically in 
the low micromolar range which prevents non-specific association of 
protein molecules, a common artefact at physiological pH.  
 
3.4.2 Instrumental conditions 
In addition to sample preparation, instrumental factors are also important. 
Time-of-flight mass analysers allow ions at a high m/z to be detected and 
the addition of a reflectron greatly increases the resolution (Mamyrin et al., 
1973). Ion cooling is important for protein complexes as this removes 
excess energy that the ions may have acquired in the collision cell from 
interactions with neutral gas molecules (Chernushevich and Thomson, 
2004). Lenses are then used to focus the ions into the mass analyser and 
the lower energy of the ions improves the resolution that is achieved. 
Transmission of the ions through the mass spectrometer under native 
conditions can also be problematic particularly for large protein 
complexes. One approach to improve this is to increase the backing 
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pressure because the low transmission is largely due to the high energy 
and energy-spread of high m/z ions (van den Heuvel and Heck, 2004). 
 
3.5 How has ESI-MS previously been applied to albumin? 
Although there are a variety of ligands that are transported around the 
blood by HSA, few of these interactions have been characterised using 
mass spectrometry. This is possibly because at the physiological 
conditions required to observe intact HSA complexes, the protein shows 
a weak spectrometric response (Henrotte et al., 2004) In particular, the 
binding of metal ions and fatty acids has not been investigated using this 
method although there has been success with drugs and other small 
molecules. Table 2 summarises the albumin-ligand interactions that have 
been investigated by ESI-MS to date, taking into account albumin 
proteins from various species. The majority of the ligands described here 
are exogenous. Combined with the extensive research on albumin, it 
would be interesting to apply mass spectrometry techniques to study 
endogenous molecules that bind to HSA. 
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Table 3.1. Non-covalent albumin complexes observed by ESI-MS. 
Ligand Albumin 
type 
Comments Reference 
Anti-hepatitis B 
immune RNA 
Human Stoichiometric ratios 
calculated 
Qi et al., 2007 
Berberine Human Plant extract; determined 
binding constant 
Cao et al., 2007a 
Digitoxin Human Cardiac glycoside; used 
nanoESI-MS 
Benkestock et al., 2005* 
DNA Bovine KD measured by ESI-MS Greig et al., 2002 
FK506 and 
FK520 
Human Immunosuppressant drugs Ray and Stearns, 1995 
Gd-DTPA 
Gd-C4Me-DTPA Gd-
EOB-DTPA 
MP-2269 
Human Gadolinium(III) chelates 
used as MRI contrast 
agents 
Henrotte et al., 2004 
Growth hormone 
releasing factor 
Bovine 44 amino acid peptide Baczynskyj et al., 1994 
Glyburide Human Anti-diabetic drugs; used 
nanoESI-MS 
Benkestock et al., 2005* 
Iopanoic acid Human Iodine containing contrast 
agent; used nanoESI-MS 
Benkestock et al., 2005* 
Ketoprofen Human NSAID drug; used 
nanoESI-MS 
Chen et al., 2006 
KP1019 and KP418 Human Ru(II) anticancer agents; 
negative electrospray 
Groessl et al., 2006 
Naproxen Human NSAID drug; used 
nanoESI-MS 
Benkestock et al., 2005* 
Oligonucleotide Bovine 20mer phosphorothioate 
oligonucleotide; 
determined KD 
Shaw et al., 1991 
Para-Sulfonato-
Calix[n]arene 
derivatives 
Bovine Molecules of biological 
interest; KA determined by 
ESI-MS 
Da Silva et al., 2006 
Puerarin Human Isoflavone of biological 
interest 
Qi et al., 2006 
Sodium aescinate Human Anti-inflammatory Qi et al., 2006 
Suramin Human Prostate cancer treatment 
undergoing clinical trials 
Roboz et al., 1998 
Tanshinone IIA Human Medicinal herb used in 
Chinese medicine 
Liu et al., 2008 
Tectoridin Human Isoflavone of biological 
interest; stoichiometric 
ratios calculated 
Cao et al., 2007b 
Tropane alkaloids Human Anticholinergic drugs; 
measured binding 
constant 
Ma et al., 2008 
Warfarin  Human Anti-coagulant Benkestock et al., 2005*; 
Liu et al., 2008 
 
*Indicates that although intact HSA was originally used, low mass resolution on the 
instrument mean published data were acquired using only Domain II. 
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3.6 Results and discussion 
3.6.1 Native ESI-MS of HSA 
A recombinant form of HSA was used in this work as this is typically more 
homogeneous with regards to the state of Cys34 and fatty acid content 
than HSA extracted from plasma. Furthermore, it is a safer alternative to 
handling plasma proteins extracted from human blood. The charge states 
that are observed under different conditions can be related to the protein 
conformation (Chowdhury et al., 1990). Denaturation unfolds the protein 
and allows basic sites to become more accessible to protons and 
therefore highly charged states are observed. Under native conditions the 
protein is folded and as a result can accept fewer charges. The mass 
spectrum of HSA acidified with formic acid is shown in Figure 3.3 A where 
at least 3 bell-shaped charge state distributions were observed to overlap.  
 
 
Figure 3.3 Comparison of the charge state distribution for denatured and native 
HSA. A) 5 µM HSA in 10 mM ammonium acetate with addition of 1% formic acid, pH 3.0 
B) 5 µM HSA in 10 mM ammonium acetate (pH 6.90).  
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In contrast, using native conditions, four peaks were observed 
corresponding to the charge states 19+ through to 16+. (Figure 3.3 B). 
Deconvolution of the raw spectrum in Figure 3.3 A gave a clear indication 
of the components of the recombinant albumin sample which is shown in 
Figure 3.4. The most abundant peak observed was 66,437.38, in 
excellent agreement with the theoretical mass of 66,438.41 Da. A small 
proportion of Asp1-Ala2 truncation product was also observed at 66,253 
Da (Chan et al., 1995). The second most abundant peak had a mass 
increase of 32 Da, possibly an oxidation product (+ 2O) of Cys34 or a Met 
residue. This has been observed before with recombinant HSA in borate 
buffer at pH 8.0 (Nicholls and Morton, 2010). Therefore it is possible that 
extensive dialysis in ammonium bicarbonate at pH 7.80-7.90 contributed 
to this oxidation. This was also not observed in early experiments, 
suggesting that storage time was a factor in the species occurring. The 
free thiol content of HSA was assessed using a cysteine assay with 
DTNB. The result indicated that there was 0.63 ± 0.04 mol SH mol-1 HSA 
in a fresh sample of HSA. The reported literature values for recombinant 
HSA are as high as 0.90 mol SH mol-1 HSA suggesting that the thiol had 
been partially oxidised (Ivanov et al., 1998). ESI-MS analysis following 
reaction of HSA with DTNB showed that 68% of the protein had been 
modified to produce a mass of 66,635 Da (Figure A2, Appendix). The 
only remaining species was that with +2O which suggests this is an 
oxidation occurring at Cys34 which subsequently blocks the residue from 
reaction with DTNB (Figure A2). 
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Figure 3.4 Deconvoluted spectrum of acid-denatured HSA. Two major species are 
observed with masses of 66,437.38 and 66,470.15 Da. A small proportion of HSA with 
Asp1 and Ala2 cleaved off is also present.  
 
The HSA-dimer was observed with charge states from 27+ to 24+. The 
presence of the dimer was consistent but always of insufficient intensity 
to be studied in great detail. This formation of the dimer has been related 
to factors including the age of the sample, storage temperature and 
moisture content (Peters, 1995). Intriguingly, a dimeric species was only 
observed under native conditions which contradicts the idea that it is 
formed through a disulfide bond between to HSA molecules. At low pH, 
the protein would be denatured but would still allow the observation of an 
-S-S- bonded species therefore, based on this evidence it is likely to be a 
non-covalent dimer.  
 
3.6.2 Incomplete desolvation of the analyte ions 
The charge states observed at physiological pH under mild conditions 
were extremely broad which complicated the analysis i.e. the mass 
observed was not comparable to that predicted from the primary 
sequence. Further research into the limitations of ESI gave an indication 
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that the reason could be the formation of buffer adducts from the aqueous 
conditions used to preserve native protein complexes. Broad peaks are 
observed because the ion current is distributed over a heterogeneously 
solvated species as a result of an insufficient desolvation process (McKay 
et al., 2006) although manipulation of instrumental parameters can 
overcome this to some extent (Sobott and Robinson, 2004). Suggested 
approaches to improving desolvation include increasing the temperature 
of the counter flow gas, increasing the vacuum pressure and optimising 
the collision energies (Loo, 2000).  
 
Collision induced dissociation (CID) is typically carried out in two areas of 
the instrument: the source region and the collision cell. Experiments were 
undertaken which involved varying the collision cell energy; it was 
typically set at 6-10 eV to give the large HSA ions enough energy for 
transmission. An increase to 20 eV reduced the peak broadness, 
however, at increased collision cell energy the intensity of peaks was 
considerably reduced and so the spectra were not improved. The other 
method to enhance the desolvation involves optimising the in-source 
collision induced dissociation (ISCID). Figure 3.5 shows spectra collected 
with various ISCID energies applied. An increase to 100 eV reduced the 
broadness of the peaks without changing the charge state distribution.  
This removed the unwanted buffer adducts and gave clear, well defined 
charge states with accurate masses without inducing fragmentation of the 
intact protein. In addition, the intensity of the signal was not compromised 
and enough data could be obtained for deconvolution. 
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Figure 3.5 Effect of in-source CID on desolvation of protein complex ions. ESI 
mass spectrum of HSA with increasing ISCID energies ranging from 0-140 eV. Samples 
were 2.5 µM in 10 mM ammonium acetate.  
 
Above 100 eV, the intensity for native HSA signals dropped and also the 
charge state distribution was shifted slightly to the right hand side of the 
spectrum. The charge state distribution for the dimer became 
considerably more abundant in relative intensity at 140 eV.  An 
explanation for this could be that increasing the activation energy of the 
ions focuses them and as a result higher m/z ions are favoured (Loo, 
1997). This could also support the idea that the dimeric form occurs 
through a covalent disulfide bond between Cys34 of two HSA molecules 
as a weaker interaction would be expected to break easily at the higher 
energy applied. These experiments highlighted the importance of finding 
a balance between removal of non-specific adducts and preserving the 
non-covalent complexes of interest.  
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3.6.3 NanoESI-MS of HSA 
NanoESI-MS using a TriVersa Nanomate® (Advion) was also used as in 
NanoESI, initial droplet size is smaller which can improve sensitivity 
(Wilm and Mann, 1996). Higher order aggregates of HSA were observed 
in the spectra with charge state distributions of a trimer and tetramer 
centred around 6500 and 7500 m/z respectively (Figure 3.6 A). It is 
unclear as to what extent these oligomer formations are an artefact 
formed during the gentle ionisation process or if they are always present 
in HSA solutions as weak bands were detected for these assemblies on 
SDS gels as in Figure 3.6 B.  
 
Observations of non-specific protein assemblies have been recently 
documented in the literature. Lane and co-workers attempted to improve 
the understanding of this phenomenon by modelling the number of 
molecules that would exist in a droplet, just before it is introduced into the 
mass spectrometer, using Monte Carlo methods (Lane et al., 2009). The 
model assumes that as the protein concentration increases, the 
probability of more than one biomolecule being contained within the 
droplet also increases. As it is most likely that desolvation of protein ions 
proceeds via the CRM model, non-specific association of the 
biomolecules may occur at the final stages of the ionisation process.  
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Figure 3.6 Observation of higher order oligomers of HSA during nano-ESI-MS and 
SDS-PAGE A) Samples (5 µL) were infused into a maXis-UHR-TOF mass spectrometer 
using a TriVersa Nanomate® (Advion) B) For SDS-PAGE samples were loaded onto a 4-
12% SDS PAGE pre-cast gel (Invitrogen). As more concentrated samples are loaded 
the dimer and higher oligomers become more visible but dimers are clearly present even 
at the lowest concentration. 
 
Although this model goes some way to explaining the observations of 
oligomers, at the experimental concentrations used (2.5-5 µM) the model 
predicts that the droplets should contain only one or even no molecules. 
This indicates that to a certain degree the assemblies are already formed 
in solution. 
 
3.6.4 Analysis of Zn2+-HSA  
A comparison of the charge states for apo-HSA and Zn2+-HSA is shown 
in Figure 3.7 A and B and there is no obvious difference between them. 
The close-up of the 18+ charge state shows two new peaks are observed 
in D compared to C: the first corresponds to the addition of a Zn2+ ion to 
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HSA (3695.11 m/z; theoretical = 3695.49 m/z) and a second which 
corresponds to the addition of Zn2+ to the oxidised species of HSA 
(3697.30 m/z). The difference compared to the theoretical values could 
be due to the broadness of the peaks. Only 1 Zn2+ ion was detected to be 
bound to HSA in the gas phase even when higher metal:protein ratios 
were used which suggests only binding to Site A is maintained during 
ESI-MS. 
 
Figure 3.7 Native ESI-MS of HSA shows 1 Zn
2+
 ion bound. Charge state distribution 
of A) apo-HSA and B) Zn
2+
-HSA. Close-up of the 18+ charge state of C) apo-HSA and D) 
Zn
2+
 HSA. Two new peaks are evident upon the addition of the metal ion. 
 
To confirm the observations of experiments in the gas phase, samples 
were analysed in solution for inorganic elements. ICP-OES analysis 
indicated that 1.06 Zn2+ ions were bound per HSA molecule in these 
preparations which fits with the mass shifts observed.  The data suggest 
that non-covalent metal complexes of HSA can be preserved in the gas 
phase even when less gentle conditions are used. This is consistent with 
the work of Gumerov et al. (2003) who found that studying Fe3+ binding to 
transferrin under extremely mild conditions was impractical. Interestingly, 
Chapter Three 
74 
 
a further peak centred around 3710 m/z is seen to be present for apo-
HSA but not Zn2+-HSA. It is possible that this is residual octanoic acid 
present in the sample as the mass is very close to the addition of two 
octanoate molecules. One line of evidence for this is that when a titration 
was carried out with increasing molar equivalents of octanoic acid, this 
peak increased in intensity. This will be discussed in more detail in 
section 3.6.6. 
 
3.6.5 pH-induced Zn2+ release and unfolding of HSA 
A sample of Zn2+-bound HSA (0.95 Zn2+ ions per molecule as determined 
by ICP-OES) was titrated with varying amounts of acetic acid to achieve 
samples at varying pH which were analysed under the same conditions. 
The same four peaks were observed as in the previous section, however, 
at pH 7.36 the mass shift was greater than the addition of 1 Zn2+ ion and 
so it is possible that salt adducts contributed to this. At pH 6.15 the 
complex is still observed and the peaks are more resolved.  As the pH 
was lowered to 5.46 there was little change to the Zn2+ binding although 
the protein began to partially unfold as higher charge states become 
visible. At pH 5.05 a clear bimodal distribution is observed as the charge 
states for partially unfolded HSA increase significantly in intensity. Below 
pH 5.0 Zn2+ has been released from the protein and only the peaks for 
HSA and HSA(oxidised) are visible. 
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The same observation is made at pH 3.96 although the charge states for 
native HSA are reduced in intensity. The increase in intensity of the 
higher charge states is concurrent with the loss of Zn2+ binding which 
indicates the metal ion could have a stabilising effect between domains I 
and II.  
 
3.6.6 Analysis of HSA in the presence of fatty acids 
To investigate the effect of fatty acids on HSA, titrations were carried out 
with both octanoate and myristate as shown in Figure 3.9 A and B. With 
increasing octanoate concentration, there was a substantial increase in 
the peak centred around 3710 m/z; the relative intensities at each point (1, 
3 and 5 mol. equiv. octanoate) were 29%, 37% and 40% respectively. 
This peak was also evident in samples that had been dialysed which 
indicates it could be bound octanoate still remaining from the protein 
stock which originally contained 31 mM octanoic acid as a stabiliser. The 
data suggested that this was a non-covalent species as it was not visible 
once the protein was denatured (cf. Figure 3.4). This larger adduct had a 
mass of ~ 300 Da larger than HSA although an accurate mass could not 
be established due to the broadness of the peak.  
 
In contrast, this peak was less apparent during the myristate titration and 
no change was visible. Clearly, this observation could be consistent with 
the interactions with myristate being broken in the gas phase although the 
larger adduct could be 2 molecules of octanoate-bound HSA (144.21 x 2 
= 288.42 Da).  
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Figure 3.9 HSA titrated with varying amounts of fatty acid followed by ESI-MS.  A) 
Aliquots of octanoate from a 0.5 mM stock solution were added to HSA and incubated at 
37 °C for 2 hours B) Aliquots of myristate from a 1 mM stock solution were added to 
HSA at 37 °C for 2 hours. Mass spectra were obtained on a maXis-UHR-TOF instrument. 
A peak ~300 Da larger than HSA (*) that was observed in native samples was observed 
to increase in intensity in the presence of increased octanoate.  
 
 
Although fatty acids bind to HSA with relatively high affinity (Kd = 0.05-1 
µM), it would appear that the interactions are too hydrophobic even 
though some polar side chains are thought to be involved at the high 
affinity binding sites. In the gas phase, hydrophobic binding partners are 
likely to dissociate as they are no longer being forced together as they 
would be in the presence of water molecules (Bich et al., 2010). 
Therefore, ESI-MS of HSA does not reflect the fatty acid binding that 
would occur in solution. More recently, Liu et al., (2009) have been able 
to characterise fatty acids binding to bovine β-lactoglobulin. However, it 
could be that the stabilisation of this hydrophobic protein-ligand 
interaction in the gas phase is due to the fatty acid being sterically 
trapped inside the cavity. The EF loops form a lid over the cavity, as can 
be observed in the crystal structure with myristate (3UEV), which may 
restrict movement of the ligand (Loch et al., 2012). The fatty acid binding 
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sites on HSA need to be less hindered in order to facilitate rapid 
dissociation of the molecules during transport.  
 
3.6.7 Binding of PFCAs to HSA in the gas phase: a fatty acid mimic 
 PFCAs were chosen as a fatty acid mimic as the fatty acids investigated 
were not observed to remain bound in the gas phase. Fluorination of the 
molecules means they cannot be metabolised in the same way as their 
biologically relevant counterparts (D’eon et al., 2010).  On a molecular 
level, HSA has been shown to be the most likely candidate for interaction 
of PFCAs that become present in blood serum at low levels (Han et al., 
2003). 
 
PFOA is an example of a C8 PFCA that is produced on an industrial 
scale and used in the production of Teflon® for cookware.  It has been 
demonstrated by 19F-NMR spectroscopy that PFOA, and other similar 
molecules, would bind in the same 7 hydrophobic cavities on HSA as 
fatty acids (D’eon et al., 2010) and it has been shown to bind to other 
fatty acid binding proteins. Han et al. (2003) reported the dissociation 
constant for PFOA binding to HSA as 0.38 mM, compared to 0.05-1 µM 
for fatty acids (Spector, 1975). Therefore, it is not thought that the PFOA 
molecule would be able to displace fatty acids once they are bound to 
HSA (Han et al., 2003). A native ESI-MS study identified the binding of up 
to 8 molecules (Henrotte et al, 2004) of PFOA to HSA in neutral 
ammonium acetate buffer. Following incubation with 5 mol. equiv. PFOA, 
and using the method developed on the maXis-UHR-TOF, 3 molecules of 
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PFOA were observed to be bound to HSA.  Due to its impact on Zn2+ 
binding, the fatty acid site of the highest interest is FA2, which is one of 
the three highest affinity binding sites, therefore under these conditions it 
is likely to be occupied by PFOA. Additionally it has been demonstrated 
that FA2 becomes populated at HSA:FA concentrations as low as 1:1 
(Simard et al., 2005). To obtain an optimum ISCID energy to observe 
non-covalent binding but remove buffer and salt adducts, mass spectra 
were obtained between 75 and 125 eV. The relative intensity for each 
complex was calculated and plotted to produce Figure 3.7. As the ISCID 
was increased the peak corresponding to HSA with no PFOA bound 
increased in a sigmoidal fashion. Non-covalent interactions with PFOA 
begin to significantly decrease at 105 eV, and a value of 100 eV 
appeared to be a good compromise between obtaining good spectra and 
preserving the complexes.  
 
To ascertain if PFOA was a reasonable mimic for fatty acid binding and 
its impact on metal binding to HSA, 111Cd NMR spectroscopy and 1H 
NMR spectroscopy were carried out to probe the effect on metal binding 
and the histidine residues. In the presence of 5 mol. equiv. PFOA the 
111Cd NMR peak for Site A was supressed and the peak for Site B was 
still prominent albeit slightly reduced in intensity (Figure A3, Appendix). 
This is the same effect that has been previously observed for octanoate 
(Stewart et al., 2003). Figure A3 B (Appendix) shows the effect of PFOA 
on the 1H-HMR spectrum of HSA where the His residues can clearly be 
seen.  
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Figure 3.10 Binding of PFOA to HSA by ESI-MS. A) Spectra of HSA obtained with 
varying concentrations of PFOA. The numbers above the peaks correspond to number 
of PFOA molecules bound. B) Spectra were obtained at varying ISCID energies from 75-
125 eV and the relative intensities plotted against the ISCID.  
 
 
Peak 5 was unaffected by the addition of PFOA and also there was only a 
slight impact on peak 10. Peaks 6 and 6b disappeared completely and 
the intensity of peak 9 was also reduced considerably. Peaks 1 and 4, 
B 
Chapter Three 
81 
 
which have been previously shown to correspond to His67 and His247, 
were no longer present once 5 mol. equiv. of PFOA were added. A 
previous titration with octanoate, showed that peak 4 became sharper 
which is different to that observed in the presence of PFOA, however, 
overall, the changes that occurred with both were largely similar 
indicating that the binding mode is the same. The fact that peaks 1 and 4 
are affected by PFOA and also that Site A is perturbed in 111Cd-NMR are 
both good indicators that PFOA binds in the vicinity of the Zn2+-binding 
site. The evidence indicates that PFCAs are able to bind in the gas phase 
because the C-F bond is polar compared to a C-H bond which is non-
polar. The hydrophilic fluorine atoms interact strongly with the lone pairs 
of polar amino acids and these associations are stabilised in the gas 
phase. However, fatty acid binding involves hydrophobic interactions 
which are not stabilised in the gas phase.  
 
3.6.8 Concurrent PFOA and Zn2+ binding 
As PFOA was shown to be a good model for octanoate, a sample 
incubated with both 5 mol. equiv. PFOA and Zn2+ was analysed by ESI-
MS. Figure 3.12 shows the spectra obtained with an expansion of the 
most abundant 18+ charge state (Figure 3.12B).  The two major peaks 
correspond to HSA-PFOA-Zn2+ (3718.44 m/z, theoretical mass = 3718.53 
m/z) and also a HSA(oxidised)-PFOA-Zn2+ complex (3720.16 m/z, 
theoretical mass = 3720.30 m/z). The same set of peaks was also 
observed for the complex with 2 PFOA molecules bound (3741.60 m/z, 
theoretical mass = 3741.52 m/z). This would suggest that PFOA and Zn2+ 
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can bind simultaneously to HSA which would fit the hypothesis put 
forward for octanoate binding, i.e. that it does not disrupt Zn2+ binding in 
the same way predicted for myristate.  ICP-OES evidence also suggested 
the ability of HSA to bind Zn2+ was not perturbed by the presence of 
PFOA. Zn-HSA was prepared in the absence and presence of PFOA in 
10 mM ammonium acetate and subjected to gel filtration. Analysis of the 
solution showed Zn2+-HSA had 1.48 Zn2+ per protein while following 
incubation with 5 mol. equiv. PFOA and gel filtration there was still 1.47 
Zn2+ per protein. Therefore, neither in solution nor in the gas phase does 
PFOA perturb Zn2+ binding. 
 
Figure 3.11 Simultaneous binding of PFOA and Zn
2+
 to HSA observed by ESI-MS. 
A) Charge states observed B) Expansion of the 18+ charge state showing peaks 
corresponding to the mass of Zn
2+
 bound to a PFOA complex. 
 
Interestingly, Wu et al. (2009) carried out CD and fluorescence 
spectroscopy of PFOA-bound HSA and this indicated a conformational 
change occurred as is also observed with normal fatty acids. Although as 
with octanoate the conformational change may not be significant enough 
to disrupt the interdomain Zn2+ binding site. 
Chapter Three 
83 
 
3.6.9 Analysis of Zn2+ binding in the presence of myristate 
Figure 3.8C shows the effect of myristate on the Zn2+-HSA complex. The 
peaks are much broader than those observed in the presence of Zn2+ only. 
The average mass of the peak hinted that Zn2+ binding had not been lost 
from HSA and ICP-OES analysis of the same sample in solution 
confirmed that 1.21 Zn2+ ions were still bound. This does not support the 
hypothesis that myristate would induce a conformational change that 
disrupts Zn2+ binding.  
 
Figure 3.12  Effect of myristate on Zn
2+
 binding to HSA. A) HSA with the addition of 
Zn
2+ 
B) HSA with the addition of Zn
2+
 and 5 mol. equiv. myristate. The spectra on the 
right hand side are zoomed in on the 18+ charge state.  
 
One explanation for this could be that myristate binding may displace the 
Zn2+ from Site A to another site on HSA as there are two further sites that 
can accommodate Zn2+. Evidence for this is that Goumakos et al. (1991) 
showed that HSA became saturated at 3.3 ± 0.2 Zn2+ ions which would 
indicate that there are two further binding sites in addition to Site A. 
Furthermore, ICP-OES analysis during this work showed > 2 mol. equiv. 
of Zn2+ remaining associated with HSA following passage through a gel 
filtration column. These other two binding sites are proposed to be Site B 
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and the N-terminus. Additionally, myristate has also been shown to 
displace metal ions from Site B (Lu et al., 2012b) which may result in 
increased binding at the N-terminus. This would rationalise why the ICP-
OES results show a similar Zn2+:HSA stoichiometry in the absence and 
presence of myristate as ICP-OES cannot provide information on to 
which of the three potential sites the Zn2+ is bound. Another explanation 
for there being no decrease in the Zn2+ binding ability of HSA in the 
presence of myristate could be that the buffer conditions are different as 
ESI-MS is not compatible with high concentrations of non-volatile buffers 
and salts. 
 
One important question to address is could Zn2+ bind to the N-terminus if 
fatty acids displaced it from Sites A and B? To investigate if Zn2+ binding 
to the N-terminus is possible, 1 mol. equiv. of Zn2+ was added to a 
peptide mimic of this site that has been well characterised (Lau et al., 
1974) which is shown in Figure 3.13 B. No evidence of an interaction was 
observed by ESI-MS while the control sample with 1 mol. equiv. of Cu2+ 
did show an intense peak corresponding to the Cu2+-Gly-Gly-His complex 
(Figure 3.13 A).  It was thought that perhaps the interaction with Zn2+ was 
simply too weak to be observed by ESI-MS and a  previous study using 
13C-NMR spectroscopy did suggest that Zn2+ can form a complex with the 
tripeptide (Lakusta et al.,1980). Therefore the Zn2+-Gly-Gly-His interaction 
was also studied by 1H NMR spectroscopy. 
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Figure 3.13 Comparison of Zn
2+ 
binding to Gly-Gy-His peptide by ESI-MS and 
1
H 
NMR spectroscopy. A) ESI-MS spectra of Gly-Gly-His in the presence of 1 mol. equiv. 
Cu
2+
 or B) 1 mol. equiv. Zn
2+
 C) 1-D 
1
H NMR spectra of Gly-Gly-His titrated with varying 
amounts of ZnCl2.  
 
Substantial changes to lineshapes were observed and Figure 3.13 C 
shows the broadening that occurs to the CH2 group of the His residue 
which suggests that there is an interaction with Zn2+ in solution. Overall, 
this indicates that Zn2+ may bind to the N-terminus of HSA if the other 
sites are saturated or no longer available due to the fatty acid-induced 
conformational change, even though this interaction may be too weak to 
be detected by ESI-MS.  
 
3.6.10 Identification of myristic acid in low mass range 
Additional evidence for fatty acid interactions being broken in the gas 
phase was obtained by scanning the low mass range while HSA samples 
were being injected. This has been shown with other molecules; for 
example Jones and co-workers detected perfluorooctane sulfonic acid 
(PFOS) at 499 m/z when BSA was subjected to high collision energy and 
the interaction between the protein and the compound was lost (Jones et 
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al., 2003). Once the conditions were optimised for smaller molecules, a 
peak at 229.21 m/z for protonated myristic acid was observed (Figure 
3.14 B). Using Smart Formula 3D a molecular formula and theoretical 
isotopic distribution was generated for the molecule which matched that 
of myristic acid (Figure 3.14 C). 
 
Figure 3.14 Detection of protonated myristic acid in the low m/z range of HSA.  A) 
Full spectrum showing small molecules and native HSA peaks B) Expansion of the low 
m/z range shows protonated myristic acid C) This is confirmed by the formula and 
theoretical isotopic distribution calculated from Smart Formula 3D. The isotopic 
distributions are in close agreement.  
 
Importantly, no extra collision energy was needed to observe this peak 
supporting the idea that the interaction of the fatty acid was broken during 
the transition to the gas phase. This experiment was repeated on two 
different maXis-UHR-TOF instruments (Instrument 2 at Bruker, Coventry, 
UK) to ensure the reproducibility of the data and the unbound myristic 
acid was detected on both indicating that it was present in the sample. 
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3.7 Conclusion 
Experimental conditions were optimised using the maXis-UHR-TOF to 
study large proteins. A balance between stripping the protein of weakly-
bound buffer molecules and being able to investigate ligand binding to 
HSA meant binding of 1 metal ion to HSA could be resolved. Evidence for 
only 1 Zn2+ ion being bound to HSA was observed by ESI-MS which is 
likely to be Site A. The interactions of HSA with myristate were disrupted 
in the gas phase resulting in no significant mass increase observed for 
these complexes, although, a larger HSA species was in agreement with 
the addition of 2 octanoate molecules. This could suggest that for two 
binding sites at least the interactions with octanoate are not completely 
abolished. For myristate bound samples, protonated myristic acid was 
detectable in the low mass range confirming that the ligands were too 
hydrophobic to remain bound in the gas phase. PFOA was used as a 
model compound to mimic a natural fatty acid as this interaction was 
preserved in the gas phase due to the more hydrophilic nature of fluorine. 
The ESI-MS data indicated that 1 Zn2+ ion can bind to HSA in the 
presence of PFOA which would fit with the hypothesis that this size 
molecule can fit in FA2 along with Zn2+ being bound in Site A. With 
addition of myristate to the Zn2+-complex it appeared from the mass 
observed that Zn2+ was still bound. This was also confirmed in solution 
which does not support the overall hypothesis that myristate binding to 
HSA at FA2 displaces Zn2+ from its major binding site.
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Chapter 4 
Travelling-wave ion mobility 
mass spectrometry of HSA  
 
4.1 Introduction 
In this chapter, travelling wave ion mobility mass spectrometry (TWIM-MS) 
was applied as a novel technique to study HSA complexes with metal 
ions and fatty acids. Instrumental conditions were optimised to prevent 
unfolding of the protein, although this gave an insight into how metal ions 
may influence the conformational flexibility of HSA. The data obtained 
were compared to theoretical cross sections obtained from published 
crystal structures.   
 
4.2 Ion mobility-mass spectrometry  
4.2.1 Development of IM-MS 
Ion-mobility-mass spectrometry (IM-MS) is an analytical technique 
whereby the conformation of molecules can be studied. It was first 
introduced in the 1970’s under the name plasma chromatography as a 
method to separate ions (Cohen and Karasek, 1970) and was soon 
recognised as a powerful tool that could be used to analyse a whole host 
of molecules (Collins and Lee, 2001). During the 1990’s the technique 
was applied to larger biomolecules with Clemmer demonstrating protein 
conformer separation using cytochrome c (Clemmer et al., 1995). The 
development of high resolution IM-MS over the past decade has further 
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enabled the separation of structural isomers that have an identical mass 
(Wu et al., 2000).   
 
As described previously conventional mass spectrometry involves four 
processes: sample introduction, sample ionisation, mass separation and 
detection. The addition of an IM cell to a mass spectrometer allows for an 
extra separation step which is dependent on the mobility of the ions 
(Kanu et al., 2008). The mobility of an ion is measured by the time it takes 
to pass through a buffer gas which is subjected to a weak electric field 
(drift time). The mobility can be dependent on many factors including 
molecular mass, charge on the ion, size of the ion and the polarizability of 
the drift gas used (Karasek, 1974). 
 
4.2.2 TWIM-MS 
Four types of IM-MS are available but only one will be discussed here: 
TWIM-MS (Pringle et al., 2007). Unlike other traditional IM-MS methods 
where the electric field is applied constantly, a high electric field is applied 
to one part of the cell and is swept sequentially through the cell in the 
direction that the ions are moving. This is achieved by using a stacked 
ring ion guide (SRIG) (Giles et al., 2004) which consists of a series of ring 
electrodes stacked orthogonally to the axis on which the ions travel. Ions 
are propelled down the SRIG in pulses or “waves” and it is therefore 
given the name “travelling wave”. The ions exit the IM cell at unequal 
times because the time it takes for the ion to exit the cell is dependent on 
its mobility through an inert gas as it travels along the travelling voltage 
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wave. Separation of ions is then achieved as ions that have a high 
mobility can keep up with the wave and exit the IM cell faster. Ions that 
have a lower mobility have more interactions with the buffer gas, roll over 
the top of the wave and have to wait for ensuing waves to propel them 
through the cell. As a consequence these ions exit the cell later (Giles et 
al., 2004). A longer drift time through the IM cell indicates that the ion has 
a larger collisional cross section (Jarrold, 1999). The quantity of ions 
exiting the cell is plotted as a function of time, known as the arrival time 
distribution (ATD).  
 
4.2.3 A commercially available TWIM-MS instrument: Synapt HDMS 
The travelling wave ion guide has been integrated into a conventional 
hybrid Q-TOF mass spectrometer to produce the Synapt HDMS 
instrument which is manufactured by Waters (Pringle et al., 2007). The IM 
cell is located between two mass analysers, namely a quadrupole and a 
TOF. A close-up view of the TriWave cell is shown in Figure 4.1. The IM 
cell contains three travelling wave-enabled SRIGs: trap, IM and transfer 
cell. Ions first accumulate in the trap, are released into the IM ion guide 
for the actual separation and then pass into the transfer region to allow 
them to travel to the TOF mass analyser (Pringle et al., 2007). Although 
suggested flow rates for the buffer gas in this region are indicated on the 
diagram, these can be optimised depending on the sample. The presence 
of a helium cell prior to the nitrogen region maximises the transmission of 
the ions into the IM cell. 
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Figure 4.1 An outline of the ion mobility cell in the Synapt G2 instrument. This is a 
schematic view of the TriWave cell where the separation of the ions according to their 
mobility takes place. The three main regions of the IM cell (trap, IM separation and 
transfer) and labelled on the diagram. The black lines represent the electrode pairs. 
Adapted from Pringle et al. (2007).  
 
In the transfer region a travelling wave voltage is continuously applied in 
order to maintain the mobility separation of the ions as they travel to the 
TOF and then the detector. A main advantage of this instrument is that it 
allows the simultaneous collection of both ATD data and mass spectra 
which is achieved by synchronising the TOF acquisition with the release 
of ions from the trap SRIG into the IM SRIG (Pringle et al., 2007). 
 
4.2.4 Calibration of TWIM-MS data 
In order to obtain a good estimate of the collisional cross section from 
ATD values for an unknown molecule, the ATD data must be calibrated 
using the mobilities of standards for which there are established cross 
sections. Different research groups have developed various approaches 
to calibrating ATD data. A calibration method has been previously 
published by the Scrivens group (Thalassinos et al., 2009) and was used 
throughout this work. The size of the unknown molecule dictates which 
standard will be used for calibration and for the experiments on HSA 
Trap
Ions from 
quadrupole
Gate IMS
Helium
180 ml/min
Nitrogen
90 ml/min
Transfer
Argon
3 ml/min
Ions to 
TOF
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reported here, sperm whale myoglobin was used as a calibration 
standard. Importantly the calibration standard must be analysed under 
the same conditions as the unknown sample (Leary et al., 2009) as the 
buffer gas, T-wave height and wave velocity can have an impact on the 
ATD of an ion. For the estimation of protein cross sections, a power fit 
series has been shown to be the most appropriate (Thalassinos et al., 
2009). 
 
4.3 Results and discussion 
4.3.1 TWIM-MS of recombinant HSA at physiological pH 
TWIM-MS was used as a novel technique to study the conformation of 
HSA and its binary and ternary complexes. Preliminary experiments with 
10 mM ammonium acetate as in Chapter 3 did not yield reliable data as 
the ion transmission through the IM cell was insufficient. To overcome 
this, the buffer concentration was increased to 200 mM ammonium 
acetate as higher concentrations have been shown to stabilise large 
proteins (Sterling et al., 2010). In addition a high backing pressure was 
used, as Ruotolo et al. (2008) suggested that for IM experiments of 
proteins between 50-200 kDa a backing pressure of 5.5 mbar was 
optimal. Using the Synapt G2, the charge states observed were 14+ to 
17+ for apo-HSA. These are slightly different charge states than observed 
from standard electrospray in Chapter 3 (16+ to 19+) because the Synapt 
G2 has a nanospray source.  As collisional activation had been shown to 
be beneficial on other instruments, cone voltages of 60, 80 and 100 V 
were investigated and the conformations of the protein compared. 
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Although all three conditions appeared to produce the same charge state 
distribution associated with the monomeric folded form of the protein, 
shown in Figure 4.2 A, the ATD suggested otherwise.  
 
At 60 and 80 V, one conformation was observed, but when the cone 
voltage was increased to 100 V, a significant change occurred and three 
different conformations were observed in the ATD plot. The single 
observed conformation in both the 60 V and 80 V spectra had an arrival 
time of 8.71 ms and 8.85 ms respectively for the 16+ charge state. It was 
established that this was the heart-shaped, folded form of HSA as the 
values were in close agreement with the theoretical collisional cross 
section, 3847 Å2, calculated from the PDB structure of HSA (see Figure 
4.8 B for details).  
 
As the cone voltage was increased, less of this species was observed 
and two more extended conformations were seen at 10.03 and 11.47 ms 
(16+ charge state, Figure 4.2 B). For the 15+ charge state, extended 
conformations were observed at 12.50 and also at 10.03 ms, which 
dominated at 100 V, while the native conformation had an arrival time of 
9.54 ms at both 60 and 80 V. The calculated cross sections for these, 
provided in Figure 4.2 C, indicated that the ions with longer arrival times 
were extended forms of the protein and their dominance at higher cone 
voltages is in line with expectations. 
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Figure 4.2 Comparison of ATD for the 16+ and 15+ charge states of apo-HSA at 
varying cone voltages of 60, 80 and 100 V. A) ATD at cone voltage = 60 V (red), 80 V 
(green) and 100 V (blue). Arrows highlight the new conformations observed as the cone 
voltage is increased. B) Table showing the estimated collisional cross sections of 
conformations observed for each cone voltage. Partially unfolded conformations are 
highlighted (blue).  
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A larger number of solvent clusters are stripped away from the protein at 
100 V compared to lower cone voltages which could explain these 
additional conformations. These unfolded conformations are novel 
observations and could reflect intermediates between the N and F-forms 
of HSA, which are described in detail in section 1.6.1. As a result of these 
findings, subsequent experiments were carried out with a cone voltage of 
80 V where only one conformation was observed.  
 
4.3.2 Comparison of N- and F-forms of HSA 
In order to see if altered conformations of HSA at different pH values 
could be identified by TWIM-MS, a sample of HSA at pH 4.0 was 
analysed. The N-form is thought to be a compact, heart shape structure 
whereas conversion to the F-form is characterised by elongation of the 
protein structure. It has previously been shown that at least two steps of 
isomerisation occur to the N form before full expansion of the protein 
occurs (Leonard and Foster, 1961). At pH 4.0 the charge states showed 
that HSA is denatured to some extent as more highly charged states are 
observed. In this experiment the charge states at pH 7.4 ranged from 15+ 
to 18+. Two particular charge states, 17+ and 18+, were present at both 
pH 7.4 and 4.0 which allowed a comparison of the ATDs (Figure 4.3). At 
pH 7.4 two peaks were observed in the ATD which represent the native-
like conformations that travel through the gas relatively quickly.  At pH 4.0 
the single peak observed for each charge state has a much longer arrival 
time (20.88 and 17.97 ms) indicating that it is a more extended 
conformation of HSA. 
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Figure 4.3 ATDs for the 17+ and 18+ charge states of HSA measured at pH 7.4 and 
pH 4.0.  The blue shaded region indicates the conformations at pH 7.4 and the grey 
shaded region indicates conformations at pH 4.0. The cone voltage was 100 V which 
explains why there are two conformations observed at pH 7.4. 
 
Therefore, it can be seen that at pH 4.0 there is a large amount of 
unfolding which could correspond to the F-form of the protein. Carter and 
Ho (1994) suggested that the F-form was a separation of two halves of 
the molecule from each other. Differences in the mobility of ions under 
native and denatured conditions have been previously recognised. An 
example is the case of cytochrome c where the 9+ ion observed from an 
aqueous solution was much smaller than that observed using a 
denaturing buffer (Hudgins et al., 1997). Furthermore, Faull et al. (2008) 
demonstrated that haemoglobin at pH 4.5 had a greater collisional cross 
section than those measured at neutral pH. Both of these studies are in 
pH 7.4 pH 4.0
17+
17+
18+
18+
(ms)
(ms)
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agreement with what is observed in this work and so it would appear that 
pH-dependent conformations of HSA can be observed even when the 
species have the same number of charges.  
 
4.3.3 Comparison of the conformations of apo- and holo-HSA 
The effect of Zn2+ and Cd2+ binding on protein conformation was 
investigated using TWIM-MS. The same charge state distribution (14+-
17+) was observed for the metal bound forms of HSA as for apo-HSA. 
The ATDs for the most abundant charge states showed no difference 
between apo-HSA, Zn2-HSA and Cd2-HSA as shown in Figure 4.4. The 
ATD for Cd2-HSA showed a very slight increase in drift time suggesting it 
had a less compact structure than apo-HSA and Zn2-HSA. It has not yet 
been determined where the other high affinity binding site for Cd2+, Site B, 
is located although 111Cd-NMR spectroscopy suggests a ligand set 
containing one or less nitrogen atoms, different to that for the high affinity 
Zn2+ site. This could account for the small differences in ATD for this 
particular complex. The 17+ charge state shows evidence of another 
conformation beginning to appear in both the apo- and holo- HSA 
complexes. As this charge state is the most highly charged out of those 
observed, this more elongated conformation could be due to partial 
unfolding of the protein. This observation could indicate that a partially 
unfolded conformation is present under mild conditions as well as when 
the collisional activation is higher. 
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Figure 4.4 Comparison of ATD for the 17+, 16+, 15+ and 14+ charge states of apo-
HSA, Zn2-HSA and Cd2-HSA. Green = apo-HSA, Purple = Zn2-HSA and Blue = Cd2-
HSA. The cone voltage was 80 V in all experiments.  
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Using these IM data, estimated collisional cross sections were obtained 
by calibration with sperm whale myoglobin. The experimentally- 
determined collisional cross sections were plotted against charge state 
(Figure 4.5) and show the expected trend of more highly charged ions 
having a less compact structure. For the apo- and metal forms, no 
significant differences are observed although Cd2-HSA showed a slightly 
larger collisional cross section for all of the charge states, consistent with 
the slightly longer arrival times. Site A only undergoes minor re-
arrangements to accommodate a Zn2+ ion therefore no great change in 
cross section is in agreement with the proposed model for the 
interdomain site.  In the case of Cd2-HSA, the protein structure may be 
slightly less compact. 
 
 
 
Figure 4.5 Dependence of the estimated collisional cross section on charge state 
for apo-HSA, Zn2-HSA and Cd2-HSA. There is no major difference in the cross 
sections calculated for the apo- or holo-HSA complexes. 
 
Although the collisional cross sections of apo- and holo-HSA were similar, 
the partially unfolded conformations of HSA observed in Figure 4.2 were 
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able to give an indication of how the metal ions influenced the 
conformational flexibility of HSA. The high affinity Zn2+ site, Site A, 
involves residues from both domains I and II, as illustrated previously 
(Chapter 1, Figure 1.5). Therefore metal ion binding at this site has been 
speculated to make the domain interface more rigid. Figure 4.6 shows the 
ATD for the 16+ and 15+ charge state of Zn2-HSA measured at 60, 80 
and 100 V. Comparison to the ATD to Figure 4.2 shows some interesting 
differences. 
.  
 
Figure 4.6 Comparison of ATD for the 16+ and 15+ charge states of Zn2-HSA at 
varying cone voltages of 60, 80 and 100 V. Cone voltage  = 60 V (red), 80 V (green) 
and 100 V (blue). Arrows highlight the new conformations observed as the cone voltage 
is increased.  
 
The two extended conformations of the protein are considerably less 
intense for the 16+ charge state and do not dominate the ATD as was 
16+16+
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observed for apo-HSA. In fact the native form of HSA is the most 
prominent peak in the ATD at 9.12 ms. For the 15+ charge state the 
difference is more subtle although the unfolded conformation observed at 
12.50 ms for apo-HSA is not visible in Figure 4.6. These observations are 
experimental evidence that occupation of Site A by Zn2+ has a stabilising 
effect on the domain I/domain II interface. This outcome can also be used 
to explain why in the 1H-NMR spectroscopy of HSA other His residues, 
apart from the Zn2+ ligands His67 and His247, broaden when 1 mol. 
equiv. of Zn2+ is added (Blindauer et al., 2009) as the stabilisation of the 
interface means the sidechains are less flexible. Other interdomain His 
residues appear to be affected by metal ion binding even though they are 
not directly involved in coordination which would support the idea that 
Zn2+ binding locks domain I and II in place. 
 
4.3.4 Conformational changes induced by fatty acids 
Previous studies indicate that a conformational change occurs when fatty 
acids bind to HSA (Curry et al., 1998; Bhattacharya et al., 2000). This 
causes the relative movement between domains I and II and results in 
disruption of the Zn2+ binding site as His67/Asn99 and His247/Asp249 are 
no longer in close proximity to each other (see Figure 1.5). Previously, 
conformational changes induced by fatty acid binding have been studied 
by other approaches including cross linking of Lys residues followed by 
tryptic digestion and analysis of the peptides produced (Huang et al., 
2005). TWIM-MS was used to compare the mobility of HSA samples that 
had been extensively dialysed to samples that had high concentrations of 
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myristate present. The HSA was studied in the presence of myristate and 
not myristate/Zn2+ so the experimental cross section could be directly 
compared to the theoretical value calculated from the structure deposited 
in the PDB. Although the Synapt used a much gentler nanospray source, 
a HSA-myristate complex could not be preserved as no significant 
increase in mass was observed (cf. Chapter 3). However, HSA in the 
presence myristate showed an increased collisional cross section 
compared to apo-HSA under the same conditions. The sample that had 
been incubated with myristate had a large increase in cross section which 
was estimated to be 87 Å2 for the 15+ charge state (Figure 4.7). 
 
 
Figure 4.7 Dependence of charge state for the estimated collisional cross sections 
of apo-HSA and HSA in the presence of 5 mol. equiv. myristate. There are large 
differences in cross sections observed for each protein sample.  
 
In order to validate these experimental data, theoretical cross sections 
were calculated using MOBCAL, an open source program (Mesleh et al., 
1996; Shvartsburg and Jarrold, 1996). X-ray crystal structures are 
available for apo-HSA and myristate bound HSA, files 1AO6 and 1BJ5 in 
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the Protein Data Bank, respectively. Theoretical cross sections are 
calculated based on projection approximation (PA) and exact hard sphere 
scattering (EHSS) approximation. The PA method can underestimate the 
cross sections of more complex molecules such as proteins as they 
undergo more interactions with the buffer gas. The EHSS method takes 
into account the scattering between the ion and the buffer gas correctly 
but can overestimate cross sections (Jarrold, 1999). However, these 
models are used because they take substantially less computational time 
than others such as the more accurate trajectory method (TJ) (Jarrold, 
1999).  
 
The PA and EHSS cross sections for 1AO6 and 1BJ5 are outlined in 
Figure 4.8 B. The experimentally-determined cross sections fall between 
the theoretical values for the PA and EHSS. There is good agreement 
between the experimental values and those calculated from the PA 
method but the EHSS method overestimates the cross section of HSA 
significantly.  Some examples of native gas phase conformations have 
smaller estimated cross sections than those obtained from the EHSS 
method, for example in the case of bovine pancreatic trypsin inhibitor 
(BPTI) (Shelimov et al., 1997). This could be due to a lack of water 
molecules which would otherwise occupy cavities in the protein structure 
and increase its size. Furthermore, polar side chains, which would usually 
extend out into the solvent, collapse onto the protein surface in the gas 
phase (Shelimov et al., 1997).   
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Complex HSA (1AO6) HSA-5Myr (1BJ5) 
Experimental 3920 Å² 4007 Å² 
PA 3847 Å² 3923 Å² 
EHSS 5054 Å² 5127 Å² 
 
Figure 4.8 Comparison of experimental and theoretical collisional cross sections 
for HSA complexes. A) Overlay of the protein structures from 1AO6 (red; FA free) and 
1BJ5 (green; 5 myristates) B) Table summarising the experimental cross sections and 
those obtained from the PA and EHSS methods.  
 
The theoretical difference between the cross sections calculated from the 
PA method is 76 Å2 which compares well with the experimental difference 
of 87 Å2.  An overlay of 1AO6 and 1BJ5 is also shown in Figure 4.8 A 
which indicates the structural changes induced by fatty acid binding. The 
crevice in the centre of the protein is considerably expanded and domains 
I and III are moved away from each other.  
 
Taking into account the experimental and theoretical results, it can be 
suggested that even though the interactions with fatty acids were broken 
on entering the gas phase, the expanded conformation induced by fatty-
acid binding in solution was apparently retained in the gas phase during 
the time in which the experiment was performed. This can be rationalised 
B 
A 
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as it has been shown that gas phase structures reflect the native 
structure of proteins in solution over short time scales (Hoaglund-Hyzer, 
1991; Breuker and McLafferty, 2008). A study of cytochrome c that 
involved trapping the ions for various periods of time prior to IM 
experiments showed that protein native structure was retained for 30-60 
ms. Trapping the ions for longer than this resulted in unfolded 
conformations being observed (Badman et al., 2005). Other reports have 
indicated that structural features can be retained for longer than 100 ms 
(Wyttenbach et al., 2009). The TWIM-MS experiments in this work were 
carried out on a shorter timescale of 10-20 ms therefore there is less 
chance for the solution structure to rearrange into the most  stable FA-
free conformation in the gas phase.  
 
4.4 Conclusion 
In summary, this chapter has described efforts to study HSA complexes 
using TWIM-MS. The estimated collisional cross section of HSA at 
physiologically relevant pH was in good agreement with theoretical values 
obtained from the crystal structures. At pH 4.0 a significantly elongated 
conformation was observed, providing evidence for a pH-induced 
conformational change. This could reflect two halves of the molecule 
becoming separated which results in a longer arrival time. No significant 
increase in the collisional cross sections for metal-bound forms of HSA 
was seen compared to the apo-form. However, the Cd2-HSA form had a 
consistently larger collisional cross section. In the presence of Zn2+ less 
unfolding to extended protein conformations was observed, compared to 
the apo-form, which could indicate Zn2+ having a stabilisation effect on 
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the domain I/domain II interface. Even though HSA-myristate interactions 
appeared to be broken in the gas phase, an increased collisional cross 
section was still detected for myristate-HSA compared to apo-HSA, which 
could mean on the timescale of the IM-MS experiment the protein had not 
returned to its most stable FA-free conformation in the gas phase. 
Overall, this evidence has indicated that TWIM-MS can be applied to 
study native HSA using a method that hasn’t been attempted previously 
and has given an important insight into how ligand binding can influence 
the conformation of HSA. 
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3.  Chapter 5 
Metal binding properties of a 
peptide mimic from HRG 
 
5.1 Introduction 
In this Chapter, the metal binding properties of a peptide mimic 
(HRGP330) from the HRR of HRG were explored by native ESI-MS, NMR 
spectroscopy and tandem MS/MS. Although some potential biological 
roles for HRG have been acknowledged, there is a shortfall on structural 
information as to how it might fulfil these. Additionally, many studies have 
utilised rabbit HRG, which may have different metal-binding properties, 
whereas the peptide sequence used here is derived from the human form.  
 
5.2 HRGP330: a peptide mimic of the His/Pro-rich region 
Histidine rich glycoprotein (HRG) contains a His/Pro-rich region which 
shows some similarities to high-molecular-weight kininogen (HMWK) 
(Nordahl et al., 2005), a 72 kDa protein from the blood coagulation 
system, with which it shows 17% sequence similarity.  HRGP330, a 35 
amino acid peptide derived from the HRR was selected to mimic the Zn2+ 
binding properties and Zn2+-mediated interactions of HRG. The primary 
sequence consists of amino acids 330-365 from the full length HRG 
sequence which is highlighted in Figure 5.1. The nomenclature used by 
Dixelius et al. (2006) does not count the signal peptide and only the main 
chain hence the position of HRGP330 in Figure 5.1 is shifted by 18 
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residues to 348-383 as highlighted in red. This peptide has been shown 
to be biologically active and has been used for in vivo experiments 
confirming that it is suitable for mimicking physiological conditions. It has 
been demonstrated that HRGP330 shows antiangiogenic properties both 
in vitro and in vivo (Dixelius et al., 2006). HRGP330 at a concentration of 
23 nM was able to inhibit chemotaxis of primary endothelial cells which 
had been induced by vascular endothelial growth factor. Also in 2006, 
Vanwildemeersch et al. (2006) showed that HRGP330 can bind to both 
heparin and heparan sulphate in a Zn2+-dependent manner.          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Location of HRGP330 in the full-length sequence of human HRG. The 
red residues indicate the sequence of HRGP330. The residues coloured in blue are the 
signal peptide.  
 
  
HRGP335, a related 26 amino acid peptide (residues 353-378; Arg378 is 
replaced by Gly), was shown to bind to defined heparin oligomers in the 
presence of Zn2+ with increased binding observed with increasing 
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       310        320        330        340        350        360 
PDERDHSHGP PLPQGPPPLL PMSCSSCQHA TFGTNGAQRH SHNNNSSDLH PHKHHSHEQH 
 
       370        380        390        400        410        420 
PHGHHPHAHH PHEHDTHRQH PHGHHPHGHH PHGHHPHGHH PHGHHPHCHD FQDYGPCDPP 
 
       430        440        450        460        470        480 
PHNQGHCCHG HGPPPGHLRR RGPGKGPRPF HCRQIGSVYR LPPLRKGEVL PLPEANFPSF 
 
       490        500        510        520 
PLPHHKHPLK PDNQPFPQSV SESCPGKFKS GFPQVSMFFT HTFPK 
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oligomer length. This reached maximum binding with the heparin 
dodecasaccharide and tetradecasaccharide (Vanwildemeersch et al., 
2006). Modifications to HRGP330 used in this work included C-terminal 
amidation and an N-terminal acetylation to avoid metal binding occurring 
at these sites. HRGP330 was selected as it has been previously shown to 
be a minimal active domain of HRG (Dixelius et al., 2006). Furthermore, 
its relatively small size (4.3 kDa) allows it to be studied by techniques 
such as MS, MS/MS and NMR spectroscopy. The peptide has no 
aromatic residues and furthermore Zn2+ is spectroscopically inactive 
therefore ESI-MS is an invaluable tool that can be used to study the 
peptide-metal ion interactions. 
 
5.3 Results and discussion 
5.3.1 Purification of HRGP330 by HPLC 
HRGP330 typically eluted from the HPLC column at 9.2 min (Figure 5.2). 
This corresponded to an acetonitrile concentration of 25% which shows 
that it was the least hydrophobic component of the sample. The peak that 
eluted slightly later at 9.6 min was shown by ESI-MS to correspond to 
HRGP330 with a mass increase of 56 Da (Figure A5, Appendix). This 
was attributed to a t-butyl protecting group still remaining from the 
synthesis. As a result, it was beneficial to use TFA in the separation as 
this cleaves protecting groups although ESI-MS data indicated that this 
modification did not appear to interfere with metal binding. The identity of 
the peptide was confirmed by ESI-MS as shown in Figure 5.3. The HPLC 
fractions were infused directly into the instrument and therefore the 
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samples had a low pH of 2.0. As a result a range of charge states were 
observed with 5+ being predominant. 
 
Figure 5.2 Purification of crude HRGP330 with RP-HPLC. Example of a 
chromatogram obtained from loading crude HRGP330 onto a Jupiter Proteo 90 Å 
column using an Agilent 1100 instrument. The blue line shows an increasing gradient of 
acetonitrile containing 0.1% TFA. 
 
 
 
 
Following deconvolution of the raw data, the experimental mass of 
4333.98 Da was observed (theoretical mass = 4334.58 Da) which was 
the most abundant peak. The mass of the peptide eluting at 9.6 min was 
4390.0 Da and this fraction contained more impurities (Figure A5). SDS-
PAGE was also used to check the purity and HRGP330 was observed 
just below the 10 kDa standard. This is at a higher position than expected 
indicating it migrates more slowly through the gel. One reason for this 
could be that the unusual composition of the peptide means it may not 
take up as many SDS molecules. After the peptide had been buffer-
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exchanged into a neutral buffer, the predominant charge states were +4 
and +5.  
 
 
 
 
 
Figure 5.3 Identification of purified HRGP330 by SDS-PAGE and ESI-MS. A) SDS 
PAGE of HRGP330 fractions. B) Charge state envelope C) Deconvoluted mass 
spectrum. The HPLC fraction that eluted at 9.2 minutes was injected directly into the 
mass spectrometer to produce the spectrum. 
 
 
At physiologically-relevant pH, a small amount of Zn2+ contamination was 
sometimes observed in the samples that had been purified. The peak 
corresponding to the Zn2+-bound species had a relative intensity of ~ 5% 
and so was not significant. This could be from contamination during the 
purification process. To avoid this contamination, once the peptide was 
brought up to neutral pH, the containers used for experiments were acid-
washed. It could also not be ruled out that that the source of 
contamination was the mass spectrometer. In order to test this, a sample 
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was tested on two different mass spectrometers (Figure 5.4). This 
confirmed that at least on one of these, the sample was binding metal 
ions upon injection into the instrument and not as a result of 
contamination in the laboratory. This phenomenon has previously been 
reported by Mattapalli et al. (2009) who found evidence that the apo-form 
of a model Zn2+ finger peptide became Zn2+-bound on infusion into the 
mass spectrometer even after rigorous cleaning.  
 
Figure 5.4 Comparison of apo-HRGP330 spectra from two different mass 
spectrometers. Two new peaks became apparent in the second spectrum which have a 
mass shift of 63 Da and 126 Da compared to HRGP330 i.e. addition of 1 or 2 Cu
2+
 or 
Zn
2+
 ions. The low resolution results in difficulty in assigning these unambiguously. 
 
They concluded that Zn2+ from previous experiments was being deposited 
in the stainless steel emitter of the instrument and then detected in other 
samples (Mattapalli et al., 2009). Although this example showed a 
particularly extreme amount of contamination, it highlighted how the 
peptide can readily bind trace metal ions from the environment. 
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5.3.2 Metal binding properties of HRGP330 investigated by ESI-MS 
Prior to the addition of metal ions, the peptide was desalted and buffer 
exchanged into 10 mM ammonium acetate (pH 7.4). The literature 
suggests that up to 10 Zn2+ ions could bind in the HRR (Morgan, 1981). 
The region characterised as the HRR is 59 amino acids in length and 
HRGP330 spans approximately half this region.  Therefore, 1, 2 and 5 
mol. equiv. of metal ion were titrated into the peptide. The spectra for 
three titrations with Zn(CH3COO)2.2H2O (A), Cd(CH3COO)2.2H2O (B) and 
Cu(CH3COO)2.H2O (C) are shown in Figure 5.5. The masses of Zn
2+ and 
Cu2+ are within 1 Da of each other and so high resolution MS allows the 
unambiguous assignment of which metal ion is present. The highlighted 
peak on the right hand side shows the experimental isotopic distribution 
of HRGP330 with 1 metal ion bound with a comparison to the theoretical 
model.  At a HRGP330:Zn2+ ratio of 1:1, Zn1-HRGP330 was observed at 
a low intensity but the most abundant peak was apo-HRGP330. Similarly, 
once 2 mol. equiv. of Zn2+ were added, a peak for Zn2-HRGP330 was 
observed but the apo-form was still present in substantial quantities. 
Once 5 mol. equiv. Zn2+ were present, the apo-form disappeared from the 
spectrum completely and a range of metallated species were observed. 
The most abundant metalloform was Zn4-HRGP330. Mangani et al., 
(2003) carried out EXAFS on a Zn2+-bound complex of HRG associated 
with rabbit skeletal muscle AMP deaminase, a protein that has similarities 
to HRG but has a unique extended N-terminal region (Ranieri-Raggi et 
al., 1997). The possible models of Zn2+ coordination proposed were 3 
coordinating His imidazole rings, with an additional sulfur from Cys or a 
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Cl- ligand, in a mononuclear or dinuclear site. There is only one Cys 
residue in the HRR not involved in disulfide bonds therefore a CysHis3 
site could potentially form. However, HRGP330 contains no Cys residues 
and still binds a number of metal ions. Assuming that 3 His residues 
coordinate to Zn2+ then 5 metal ions would be able to coordinate to 
HRGP330 which is in agreement with the ESI-MS data.  
 
The titration with Cd2+ also resulted in a range of metallated peptide 
species but notably the apo-HRGP330 was present throughout the 
experiment, even when 5 mol. equiv. Cd2+ were present. The most 
abundant species was the Cd2-HRGP330 form which could indicate that 
this metal ion has a lower affinity for HRGP330 than Zn2+ and this fits with 
previous observations made in the literature (Morgan, 1981).  
 
The titration with Cu2+ followed a similar course to the titration with Zn2+ 
with a Cu4-HRGP330 species being the most abundant. The only 
difference was that apo-HRGP330 was no longer observed once 1 mol. 
equiv. of Cu2+ was present which indicates that HRGP330 has a high 
affinity for this metal ion. It has been suggested that HRG could be 
involved in Cu2+ transport and indeed some studies have found the 
protein has a higher affinity for Cu2+ than Zn2+ (Morgan, 1981; Guthans 
and Morgan, 1982) .  Although it is mainly Zn2+ that is thought to mediate 
the interactions of HRG with heparin, Cu2+ could also have an influence 
(Borza and Morgan, 1998). 
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Figure 5.5 Metal binding properties of HRGP330. 15 µM HRGP330 was titrated with 1, 
2 and 5 mol. equiv. of A) Zn(CH3COO)2.2H2O B) Cd(CH3COO)2.2H2O and C) 
Cu(CH3COO)2.H2O. The buffer was 10 mM ammonium acetate at pH 7.4. The isotopic 
distribution for 1 mol. equiv. of the metal ion bound to HRGP330 is shown on the right 
hand side together with a comparison to the theoretical model.  
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Some groups have investigated small His-containing peptides and their 
interaction with Cu2+ including an MS study of the oligopeptide 
(GHHPG)5G which found that one Cu
2+ binds per GHHPH moiety 
(Hutchens et al., 1992). It is unsurprising that Cu2+ binds more strongly 
than other metal ions as it is able to deprotonate backbone amides to a 
much greater extent than Zn2+. La Mendola et al. (2012) suggested a 
model where only two His residues in the peptide Ac-HGHH-NH2 were 
involved in Cu2+ coordination.  
 
As shown in Figure 5.5, there was a preference for forming the [Metal 
ion]2-HRGP330 species before fully saturating the apo-HRGP330 with 
one metal ion. An explanation for this is that the binding of metal ions to 
HRG is cooperative and so the addition of the first Zn2+ ion could induce a 
conformational change that makes it easier for the second Zn2+ ion to 
bind. This was demonstrated previously using small peptides where two 
Zn2+ ions bound to the sequence Ac-(HHPHG)2-NH2 with higher stability 
compared to one Zn2+ binding to Ac-(HHPHG)-NH2 (Jancsó et al., 2009). 
Cooperativity has also been observed for Zn2+ and Cd2+ binding to full 
length HRG (Morgan, 1981). 
 
5.3.3 Comparison of Zn2+ binding to intact HRG  
Attempts were made to study rabbit HRG under native MS conditions 
however, the charge states were of too low intensity to interpret and small 
peptides were observed which could be the result of protein degradation 
(Figure A6, Appendix). To gain an understanding of the Zn2+ binding 
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properties, the sample was analysed by ICP-OES which indicated 8.4 
Zn2+ per HRG molecule. This is consistent with previous literature that 10 
metal ions can bind per protein (Morgan, 1981) and the slight discrepancy 
could be Zn2+ loss occurring during the gel filtration column. As yet it is 
unclear as to how many Zn2+ ions are required to be bound to HRG in 
order for the protein to have an anti-angiogenic effect but some authors 
have shown that only one Zn2+ may be bound per 10 HRG molecules 
endogenously (Horne et al., 2001; Fu and Horne, 2002).    
 
5.3.4 pH titration of Zn5-HRGP330 
In order to understand how metal binding to HRGP330 facilitates its 
biological function, it is necessary to study the Zn2+ binding and release 
properties of the His-rich domain. One way in which HRG could become 
positively charged is through acidic conditions and the protein has been 
proposed to be a plasma pH sensor (Borza and Morgan, 1998). The pH 
dependence of Zn2+ binding to HRGP330 was explored using a pH 
titration as shown in Figure 5.6. At a physiologically relevant pH (7.36), a 
range of metallated states were observed as described previously. As the 
pH was lowered to 6.33, a complete loss of Zn5-HRGP330 was observed 
indicating the loss of a Zn2+ ion from a low affinity binding site. A small 
peak for Zn4-HRGP330 was still present, however, this has drastically 
reduced in intensity. As the conditions became more acidic (pH 5.05) the 
most abundant species was Zn1-HRGP330 with a sharp increase in the 
apo form. The apo-form became most abundant at pH 4.66 but Zn1-
HRGP330 could still be observed at pH 3.31. Interestingly, from this data 
Chapter Five 
118 
 
there appears to be one metal binding site that is more stable at low pH 
whereas a significant drop in the intensity of Zn4- and Zn5-HRGP330 
occurs across a relatively small change in pH.  
 
Figure 5.6 pH titration of Zn5-HRGP330. Zn5-HRGP330 (20 µM) was titrated with 
microlitre additions of 1% acetic acid followed by analysis using ESI-MS 
 
 
 
5.3.5 CD spectroscopy of HRGP330 
CD spectroscopy can be used to study the conformation of proteins and 
any conformational changes that are induced by ligands. This technique 
was used to study samples of HRGP330 in the absence and presence of 
metal ions (Figure 5.7). It is useful to have complementary solution phase 
data to compare with mass spectrometry experiments where the protein 
is in the gas phase. In the HRR of HRG there is a lack of conventional 
secondary structure such as α-helices and β-sheets. The high His and 
Pro content in this region indicates that formation of a polyproline type II 
helix with numerous His residues could occur. Previously a limited 
proteolysis approach isolated a 30 kDa fragment containing the HRR and 
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this showed evidence for a polyproline II helix (Borza et al., 1996). The 
spectrum for apo-HRGP330 shows a negative band at 198 nm and a 
slight positive band with a maximum at 221 nm indicated by the black line 
in Figure 5.7. These bands are characteristic of a polyproline II helix 
(Ronish & Krimm, 1974). In the presence of 2 mol. equiv. Zn2+, an 
increase in the negative band was observed and also a slight increase in 
the positive band. The same observation was seen when the Zn2+ 
concentration was increased to 5 mol. equiv. with respect to HRGP330.  
 
Figure 5.7 Far-UV region CD spectrum of HRGP330 in the presence and absence 
of Zn
2+
. The black line represents the signal for HRGP330 (11 µM in 10 mM potassium 
phosphate, pH 7.4). The red line was observed after addition of 2 mol. equiv. ZnCl2 and 
the grey line after addition of 5 mol. equiv. ZnCl2. 
 
 
An increase in the negative band upon metal ion binding has been 
reported for His-rich antimicrobial peptides from histatin which could 
indicate similarity between the structural features occurring in both 
peptides (Brewer and Lajoie, 2000). The interpretation of CD spectra in 
terms of polyproline II helical content can be difficult because its CD 
spectrum can be similar to that of a random coil and also there is not yet 
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an established way to quantify the amount of polyproline II helix structure 
within the peptide. Nevertheless, the substantial change in band 
intensities suggests that a conformational change occurs upon Zn2+ 
binding. 
 
5.3.6 TWIM-MS of HRGP330 
As described in Chapter 4, TWIM-MS is an invaluable technique for 
studying the conformation of biomolecules. The distinctive negative band 
in the CD spectrum (Figure 5.7) indicated a lack of traditional secondary 
structure elements and this could be due to the abundance of Pro 
residues. This makes HRGP330 an interesting candidate for IM-MS 
studies as the effect of coordinating metal ions on the peptide structure 
can be probed in more detail. 
 
Firstly, apo-HRGP330 was analysed in 10 mM ammonium acetate (pH 
7.4) on a Synapt HDMS G2 instrument. The ATDs observed for charge 
states ranging from 6+ to 3+ are shown in Figure 5.8 A. The ATDs are 
used to estimate the collisional cross section of the peptide for each 
charge state in Figure 5.8 B. The charge states 6+, 5+ and 4+ appear to 
show one conformation, however, the 4+ charge state has an unusually 
small collisional cross section and does not fit the linear trend where 
increasing charge leads to increasing collisional cross section.  
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Figure 5.8 ATDs and estimated collisional cross sections of the charge states 
observed for apo-HRGP330. A) ATDs for the charge states observed which are given 
in ms B) Estimated collisional cross sections calculated from the ATDs. The samples 
were 10 µM HRGP330 in 10 mM ammonium acetate (pH 7.4). There are 3 points for the 
3+ charge state representing the 3 different conformations observed. The estimated 
cross sections were the same across two datasets.  
 
Furthermore, the 3+ charge state shows the presence of at least 3 
different conformers, two of which have a more compact structure, as 
each peak in the ATD represents at least one gas phase conformation of 
the ion. A possible explanation for this could be the difference in the 
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conformation of HRGP330 as it reaches a more native (more folded) 
charge state. 
 
5.3.7 Comparison of apo- and Zn2+ bound HRGP330 by TWIM-MS 
The ATDs for the 5+ charge state of Zn2+-HRGP330 are compared in 
Figure 5.9 A and the width of the ATD can be related to the number of 
different conformations that contribute to the area under the peak. A 
relatively sharp ATD is observed in the plot for apo-HRG330, compared 
to the Zn2+-bound forms, suggesting one defined conformation dominates 
in this case. In contrast the ATDs for Zn2-HRGP330, Zn3-HRGP330, Zn4-
HRGP330 and Zn5-HRGP330 are broader indicating multiple 
conformations. The peak for Zn1-HRGP330 was of too low intensity to 
produce reliable data. Furthermore as the number of Zn2+ ions interacting 
with HRGP330 increases, the ATD moves to a shorter arrival time 
indicating that the peptide structure becomes more compact.  
 
Calculation of the estimated cross sections for the 5+ charge state is 
shown in  in Figure 5.9 B. Apo-HRGP330 has a larger estimated cross 
section than the holo-forms and a decrease in estimated cross section is 
observed for all the Zn2+-bound forms. The 5+ charge state shows a clear 
trend of the decrease in the collisional cross section as more Zn2+ 
becomes bound. This suggests that the Zn2+ bound forms have a more 
compact structure. This correlates well with the hypothesis that Zn2+ 
alters the conformation of the HRR of HRG to mediate interactions with 
ligands.  
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Figure 5.9 Effect of Zn
2+
 binding on the ATD and collisional cross section of the 5+ 
charge state of HRGP330. A) ATDs of Zn
2+
 bound species which are given in ms B) 
Estimated collisional cross sections calculated. The sample was 10 µM HRGP330 in 10 
mM ammonium acetate (pH 7.4). The error bars represent the standard error in the two 
datasets obtained in the presence of Zn
2+
 ions. 
 
5.4 NMR spectroscopy of HRGP330 
5.4.1 1-D and 2-D NMR spectroscopy of apo-HRGP330 
1-D 1H NMR spectroscopy of apo-HRGP330 at 25 °C showed a mixture 
of sharp and broad peaks, suggesting an unfolded structure. Various 
temperatures from 5-35 °C were investigated in order to gain more 
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information from the spectra and improve the resolution. Figure 5.10 
shows that as the temperature is decreased, a greater dispersion of the 
peaks in the fingerprint region is observed, indicating that at 5 °C the 
peptide appears to have a more ordered structure. Consequently, all 
subsequent experiments were performed at 5 °C. 
 
 
 
Figure 5.10 Stacked plot of 700 MHz 1-D 
1
H-NMR spectra showing fingerprint 
region of HRGP330 obtained at varying temperatures from 5-35 °C. ~0.7 mM 
sample was prepared in 50 mM Tris[D11], 50 mM NaCl with 10% D2O at pH 7.4.  
 
To obtain information on the peptide folding, 2-D TOCSY and NOESY 
were employed. These experiments give information about through-bond 
and through-space 1H-1H interactions, respectively. An overlay of the 
TOCSY (blue) and NOESY (red) spectra are shown in Figure 5.11 A. The 
distribution of backbone amide proton peaks spans the range 6.9-8.9 
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ppm which indicates a lack of conventional protein folding and secondary 
structure.  For the apo-form of HRGP330, partial assignment was 
achieved at pH 6.20 and 5°C (Figure 5.11 A). Full details of chemical 
shifts are provided in Table A4 (Appendix). Approximately 27 NH-CH(α) 
crosspeaks can be detected in the fingerprint region of the TOCSY  
whereas 30 would be expected therefore it is clear some residues are not 
observed. A significant number of crosspeaks are observed in the 
NOESY which indicates that the structure is not completely random coil. 
The nomenclature used for the imidazole protons of His (Hε1 and Hδ2) is 
shown in Figure 5.11 B and these can be clearly observed in the TOCSY 
spectrum. The His Hδ2 protons are observed at 7.0 ppm and the Hε1 
protons centred around 8.0 ppm at 5 °C. On closer inspection the His 
residues are resolved in the NH direction and approximately 11 can be 
distinguished although they cannot be assigned unambiguously (Figure 
5.11 C).  Three that could be identified are His3, His7 and His30 which 
are highlighted.  
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Figure 5.11 Fingerprint region of [
1
H,
1
H] TOCSY and NOESY spectra of HRGP330 
obtained at 700 MHz. A) Full fingerprint region showing assigned peaks. B) Chemical 
structure of His showing nomenclature of resonances. C) Identification of approximately 
11 His residues from their Hisβ-Hisδ2 crosspeaks, each distinguished with a dashed line.   
Sample concentration was ~0.4 mM in 50 mM Tris[D11], 50 mM NaCl with 10% D2O. The 
pH was 6.20 and the spectra were obtained at 5 °C. The TOCSY spectrum (blue) is 
overlaid onto the NOESY spectrum (red).  
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5.4.2 1-D and 2-D NMR spectroscopy of Zn2+-HRGP330 
A Zn2+ titration was carried out by addition of microlitre aliquots of ZnCl2 
to HRGP330 followed by the recording of 1-D 1H spectra which are 
shown in Figure 5.12. Upon addition of 1 mol. equiv. Zn2+ the His residues 
in the aromatic region broadened considerably which indicates they are 
participating in metal binding. When 2 mol. equiv. were added, the peaks 
had broadened significantly into the baseline and no further change was 
seen at 3 mol. equiv. Zn2+. Some of the peaks, however, remain relatively 
sharp for example Gln12, Gln32 and Arg31 which are annotated in the 
spectrum. Asp1 and Leu2 are also still visible in the presence of 3 mol. 
equiv. Zn2+ although are much broader.  These amino acids are not 
thought to be involved in metal binding although some broadening could 
be due to their close proximity to Zn2+ binding residues.  
 
It must also be noted that broadening of residues other than His may 
mean Zn2+ is promoting the formation of oligomers. With greater than 3 
mol. equiv. ZnCl2, aggregation of the peptide was visible as white 
precipitate in the NMR tube. This could be due to high peptide 
concentrations used for NMR spectroscopy as only a small amount of 
dimer was observed in ESI-MS and only in the presence of metal ions. As 
shown in Figure A7 (Appendix), this was a minor species and the relative 
abundance compared to the HRGP330 monomer was 1.5-2% relative 
intensity in the samples.  
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Figure 5.12 Stacked plot of 700 MHz 1-D 
1
H-NMR spectra showing fingerprint 
region of HRGP330 in the presence of varying mol. equiv. ZnCl2. Sample was 
prepared in 50 mM Tris[D11], 50 mM NaCl with 10% D2O at pH 7.4 and 278 K. The His 
protons are annotated but significant overlapping meant they could not be assigned 
unambiguously. f denotes formate. 
 
Intriguingly, this oligomerisation of HRGP330 in the presence of Zn2+ may 
have physiological relevance as Jones et al. (2004) hypothesised that 
Zn2+ may be able to crosslink the HRR regions of HRG molecules. This 
would form a functional oligomeric complex that would have an enhanced 
binding affinity towards cell surfaces. From the NMR data it can be 
suggested that a number of Zn2+-bound complexes were present which 
are in intermediate exchange with each other. It cannot be said 
conclusively from the NMR data that Zn2+ alters the peptide structure, 
however, TWIM-MS did suggest a more compact conformation was 
formed upon Zn2+ binding. Furthermore, both NMR data and the 
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broadness of the ATDs support that fact that there are a number of 
complexes present once Zn2+ is bound. 
 
Figure 5.13 shows an overlay of the TOCSY spectra obtained for 
HRGP330 in the absence and presence of Zn2+. Upon Zn2+ binding, most 
of the residues disappear completely which is clearly seen by the overall 
lack of orange peaks (with Zn2+) compared to the blue peaks (no Zn2+). 
Interestingly, some spin systems remain unaffected as highlighted in 
Figure 5.13 A.  Peaks for the amino acids Asp1 and Leu2 are still 
relatively strong which indicates they have similar behaviour in the 
presence of Zn2+. In this case, the amino group at the N-terminus has 
been modified to an amide group which lowers its exchange rate with 
water and allows it to be observed. The Arg31Hδ-Hε crosspeak is also 
still prominent which could indicate residues at both ends of the peptide 
are generally less affected by Zn2+ binding. This is further supported by 
the observation that Gln32 can be seen in the aromatic region of the 
spectrum even when the His crosspeaks are significantly broadened 
(Figure 5.13 B).  
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Figure 5.13 Effect of Zn
2+
 on TOCSY spectrum of HRGP330 at 700 MHz. A) 
Fingerprint region B) Aromatic region. The TOCSY spectrum of Zn-HRGP330 (orange) 
is overlaid onto the TOCSY spectrum of apo-HRGP330 (blue). ~0.5 mM samples were 
prepared in 50 mM Tris[D11], 50 mM NaCl with 10% D2O at pH 6.20 and 278 K. The 
peaks that remain upon Zn
2+
 binding are annotated. The His crosspeaks are labelled to 
show that they are no longer observed when Zn
2+
 is bound.  
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5.5 Tandem mass spectrometry  
5.5.1 An overview of MS/MS 
Tandem mass spectrometry (MS/MS) involves at least two steps of mass 
analysis and is a valuable tool for gaining structural information about 
biomolecules. Typically, an ion of interest is isolated using a first mass 
analyser (known as the precursor or parent ion) and then fragmented to 
yield ions of smaller masses which are detected by a second mass 
analyser. Fragmentation of a protein provides information about the 
amino acid sequence and depending on the MS/MS technique used, 
different types of ions can be formed. Assignment of these product ions is 
carried out using the Biemann nomenclature which is summarised in 
Figure 5.14 (Biemann, 1982; Roepstorff and Fohlmann, 1984; Johnson et 
al., 1988). If the charge on the ion is retained on the N-terminal fragment 
then the ion is denoted a, b or c and if it is on the C-terminal fragment the 
assignment is x, y and z. 
 
 
Figure 5.14 Schematic showing the nomenclature of peptide ions formed from 
tandem MS/MS experiments. This notation is based on the Biemann method (Biemann, 
1982; Roepstorff and Fohlmann, 1984; Johnson et al., 1988). The numbers in subscript 
next to the letters represent the number of residues in the fragment ion.  
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5.5.2 Collision-induced dissociation (CID) 
Collision-induced dissociation (CID1) was first introduced by Jennings and 
McLafferty and carried out on small organic molecules (Jennings, 1968; 
McLafferty et al., 1973). During CID the ion of interest is subjected to high 
energy collisions with inert gas molecules (Ar, N2, He etc.) in a collision 
cell and the internal energy within the molecule increases until 
fragmentation occurs. With the advent of new mass spectrometry 
techniques to study biomolecules, CID was soon applied to peptides and 
proteins and was able to provide valuable information about post 
translational modifications (Hunt et al., 1986). As a result of CID, 
cleavage occurs at the amide bond and predominantly b and y ions are 
formed. CID experiments are dependent on the size of the biological 
molecule as with large proteins the efficiency of energy transfer is 
considerably reduced which results in individual collisions being less 
effective.  
 
5.5.3 Electron Capture Dissociation and Electron Transfer 
Dissociation 
Other more recently developed techniques include electron capture 
dissociation (ECD) and electron transfer dissociation (ETD) and in both 
cases fragmentation is driven by free radicals.  Zubarev was first to apply 
ECD to proteins in 1998 and the technique involves electrons being 
captured by ions which induces fragmentation (Zubarev et al., 1998). 
More efficient fragmentation is achieved and a predictable series of c and 
                                                 
1
 Also known as collisonally activation dissociation (CAD) 
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z ions is produced following cleavage of the N-Cα bond. Other ions such 
as y can be generated from secondary reactions but these are less 
abundant. One disadvantage of ECD is that it can only be used with 
highly expensive FT-ICR instrumentation which is not readily available. 
This drove the development of the analogous technique ETD for lower 
resolution ion-trap instruments (Syka et al., 2004). 
 
During ETD protein ions that are positively charged are allowed to react 
with radical anions (e.g. fluoranthene). This can be followed by Proton 
transfer reaction (PTR) which reduces the charge on the resulting 
fragments and simplifies the spectra to allow easier interpretation of the 
data (Coon et al., 2005). The mechanisms by which ECD and ETD occur 
are not fully understood but they do have some advantages over CID. 
Firstly, these techniques are more site-specific and labile modifications or 
“weak linkages” are able to be retained (e.g phosphorylation) which may 
not be the case during CID (Zubarev, 2004; Zhou et al., 2011). Secondly, 
they are independent of the size of the peptide/protein and so are suited 
to the analysis of larger biomolecules (Coon et al., 2005).  
 
The majority of examples in the literature on non-covalent protein 
complexes utilise ECD and not ETD which is due to the accuracy and 
high resolution that FT-ICR instruments afford. A study on non-covalently 
bonded peptide-antibiotic complexes using ECD showed that the 
interactions were preserved (Haselmann et al., 2002) and binding site 
information has also been obtained from ECD of larger protein-ligand 
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complexes (Xie et al., 2006; Clarke et al., 2011; Breuker and McLafferty, 
2003) . This is a good indication that ECD and ETD could be used to 
study metalloproteins as the metal-protein interactions occur through non-
covalent bonds. Although it is not entirely clear what effect the positively 
charged metal ion may have on these processes.  
 
5.5.4 MS/MS of non-covalent protein complexes: metalloproteins 
It is of much interest to develop the application of different fragmentation 
techniques that allow identification of metal ions on peptide fragments 
and which could be a good indication of high affinity binding sites. It is 
challenging to maintain metal binding during fragmentation and carry out 
experiments under non-denaturing conditions which will preserve any 
non-covalent interactions, however, a limited number of studies have 
been able to achieve this. Loo et al. (1994) investigated the interaction of 
Zn2+ ions with an angiotensin peptide of 8 residues in size and were able 
to gain evidence of how the metal ion was coordinating to the peptide. A 
year later Hu and Loo extended this work by comparing the fragmentation 
chemistry of angiotensin peptides in the presence of Zn2+, Co2+ and Ni2+ 
(Hu and Loo, 1995). More recently, the Zn2+ binding site of a 23-residue 
histidine-rich peptide, H5WYG, was investigated using CID and it was 
shown that the metal ion was associated with three out of the five 
histidine residues (Buré et al., 2009a), even though conclusive evidence 
required the generation of mutant peptides (Buré et al., 2009b). A similar 
experiment was used to map the site of Cu2+ binding on CP12, a protein 
originating from Chlamydomonas reinhardtii that is involved in the Calvin 
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cycle (Erales et al., 2009). The largest metalloprotein to be studied by 
tandem MS in a native state is carbonic anhydrase (29 kDa) although this 
utilised supercharging with m-nitrobenzyl alcohol.   Yin and Loo (2011) 
did not obtain good sequence coverage but were able to identify some 
Zn2+--bound fragments. One recent example utilised ETD/PTR to study a 
bacterial metallothionein and showed that folded dimeric Zn4SmtB2  
yielded  few fragments while the monomeric form did produce some Zn2+-
bound fragments which contained residues thought to be Zn2+ ligands 
within the intact protein (Kondrat et al., 2012). 
 
5.5.5 MS/MS of HRGP330 
The 5+ charge state was selected for study as this showed the greatest 
intensity (Figure A8, Appendix) and so the 867 m/z ion was isolated and 
fragmented using CID and ETD. ETD was followed by PTR which allowed 
the isotopic pattern of many of the ions to be clearly observed and 
facilitates easier identification of metal-containing fragments. As shown in 
Figures 5.15 A and 5.16 A, good sequence coverage was achieved for 
apo-HRGP330 in both experiments: 82.9% achieved in the ETD 
fragmentation compared to a slightly lower value of 74.6% for CID. The 
Biemann nomenclature was used to annotate the fragments and 
fragmentation schemes in Figure 5.15 B and 5.16 B summarise the 
cleavages that occurred in each experiment. CID tends to give lower 
sequence coverage than ETD because while ETD produces a defined ion 
series that is independent of the protein size, CID induces more random 
fragmentation along the backbone.  
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Figure 5.15 CID spectrum of apo-HRGP330. A) CID spectrum of 867 m/z B) 
Fragmentation scheme showing the b and y ions produced. The b-18 and y-17 ions 
correspond to the loss of water and ammonia respectively. Analysis was carried out 
using Biotools v3.2 and Sequence Editor v3.2.  Sequence coverage of 74.6% was 
obtained.  
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Figure 5.16 ETD spectrum of apo-HRGP330. A) ETD spectrum of 867 m/z B) 
Fragmentation scheme showing the c and z ions produced. Analysis was carried out 
using Biotools v3.2 and Sequence Editor v3.2. Sequence coverage of 82.9% was 
obtained.  
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Full sequence coverage was still not expected for ETD because 
HRGP330 contains 5 Pro residues and cleavage of the N-Cα bond in the 
N-terminal direction cannot occur due to its cyclic structure. This 
precludes the observation of c3, c13, c18 c23, c33, z2, z12, z17, z22 and z32.  In 
addition to c and z ions, a number of y ions were also detected in the 
ETD spectra which can be produced from secondary reactions. An 
important feature of the ETD spectrum is the charge-reduced states of 
the parent ion (4+, 3+ and even 2+) which are visible at high intensity and 
are labelled on Figure 5.16 A. 
 
5.5.6 MS/MS of Zn2+-bound HRGP330 
The intact spectrum prior to isolation and fragmentation is provided in 
Figure A8 (Appendix). Comparison of the CID spectra for fragmentation 
of 867 m/z (apo-HRGP330) and 880 m/z (Zn1-HRGP330) showed that a 
significant number of peaks were produced in each case. This is evident 
from the spectra shown in Figures 5.15 A and 5.17 A. In fact, there also 
appeared to be more fragmentation once the Zn2+ was bound (Figure 
5.17 A) which suggested that additional fragment peaks with Zn2+ ions 
bound were likely. Immediately a number of possible Zn2+ binding 
fragments could be identified from the isotopic distribution. A summary of 
the fragments that were Zn2+-adducts is given in the fragmentation 
scheme in Figure 5.17 B (A table of the mass list with comparison to 
theoretical values is provided in Table A5, Appendix).  
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Figure 5.17 CID spectrum of Zn-HRGP330. A) CID spectrum of 880 m/z B) 
Fragmentation scheme showing the b and y ions produced and those that were 
identified to be Zn
2+
-adducts. Analysis was carried out using Biotools v3.2 and 
Sequence Editor v3.2. 
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In some cases these were observed as a mixture of the Zn2+-free and 
Zn2+-bound fragments. Many of them identified were large fragments 
which did not provide useful information about the specific interactions 
that are occurring. In order to confirm that the new peaks were observed 
as a result of Zn2+ binding, the 893 m/z (+2 Zn2+ ions) peak was 
fragmented as this was also observed in the intact spectrum (Figure A8, 
Appendix). A comparison of the mass range 540-740 m/z from the CID 
spectra of 867 m/z, 880 m/z and 893 m/z is shown in Figure 5.18. This 
showed that in the CID spectrum of 893 m/z the same peaks were 
present as in that for 880 m/z, however, the intensity was increased. 
 
 
Figure 5.18 Comparison of the MS/MS spectra of apo-HRGP330 (867 m/z), Zn1-
HRGP330 (880 m/z) and Zn2-HRGP330 (893 m/z). The highlighted regions indicate the 
new peaks that appear in the Zn
2+
-bound samples. Those that could be assigned are 
labelled and those that were not conclusive are marked with a ? 
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These peaks were clearly not observed in the CID spectrum of apo-
HRGP330, 867 m/z. The blue regions highlight the new Zn2+-bound 
peaks that appear and illustrate how they increase in intensity at a higher 
concentration of Zn2+. Two of the small fragments identified to bind Zn2+ 
were y8 and y10 which are highlighted in Figure 5.18.  The y10 fragment 
had a mass loss of 17 Da indicating that ammonia had been lost. In the 
case of the y8 ion these data suggest that the metal ion is interacting with 
His35, His33, and His27. This is in good agreement with the proposal that 
three His residues are involved in Zn2+ ion ligation. Additionally His25 
could also be involved in the case of the y10 ion. The Zn
2+-bound ions 
were characterised by their distinctive isotopic distribution. The isotopic 
patterns for the y12
1+ ion and y10-NH3
2+ ion are shown in Figure 5.19 A 
and C respectively.  
 
 
Figure 5.19 Comparison of experimental and theoretical isotopic patterns for the 
Zn
2+
 adducts of y12 and y10 generated from CID. A) Experimental isotopic distribution 
of the y12 
1+ 
ion with Zn
2+
 bound B) Theoretical isotopic distribution of the y12 
1+ 
ion with 
Zn
2+ 
bound. C) Experimental isotopic distribution of the y10 
2+ 
ion with a loss of NH3 and 
Zn
2+
 bound D) Theoretical isotopic distribution of the y10 
2+ 
ion with a loss of NH3 and 
Zn
2+
 bound.  The peaks marked with * are contaminating peaks.  
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The experimental isotopic distributions are in agreement with the 
theoretical simulations (Figure 5.19 B and D) which is evidence that the 
Zn2+ was bound in this location in the full-length HRGP330. Furthermore, 
the doubly charged ion for the y12 fragment with Zn
2+ bound was also 
identified which provides further confirmation. Although the masses of the 
ions identified to be Zn2+-adducts proved that a metal ion was bound, the 
intensities for some of the peaks in the isotopic distribution did not exactly 
match those of the simulation which could be because there is 
considerable overlap in the complex spectra.   
 
As shown in the fragmentation scheme in Figure 5.17 B, fragments from 
the N-terminal end of the molecule were also observed to be interacting 
with Zn2+. The smallest fragment was b11 which indicates that any of the 
five His residues in the sequence DLHPHKHHSHE could be coordinating 
to a Zn2+ ion. Interestingly, compared to the CID of apo-HRGP330, Zn-
HRGP330 showed a considerable lack of fragmentation around the 
GHHPH pentapeptide unit. This could be due to a conformational change 
upon Zn2+ binding which means the central residues of the peptide are 
less predisposed to collisions with the gas molecules. 
 
In contrast to CID, the ETD spectrum of Zn2+-HRGP330 showed 
considerably less fragment ions as illustrated by Figure 5.20. Overall, the 
spectrum in Figure 5.20 A is noisier and the peaks throughout are less 
well resolved. The fragmentation scheme in Figure 5.20 B shows 
predominantly low mass c and z ion which suggests that only the two  
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Figure 5.20 ETD spectrum of Zn-HRGP330. A) ETD spectrum of 880 m/z B) 
Fragmentation scheme showing the c and z ions produced and those that were 
identified to be Zn
2+
 adducts. Analysis was carried out using Biotools v3.2 and 
Sequence Editor v3.2. The spectrum does not show many peaks compared to the 
fragmentation scheme because most of the peaks were of too low intensity to be 
recognised by the software. Therefore, the raw data was manually interrogated to 
produce the fragmentation scheme. 
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ends of the peptide can be fragmented by ETD when Zn2+ is attached. 
Intriguingly, fragments around the GHHPH pentapeptide are noticeably 
absent as was the case for the CID spectrum. There is a significant 
increase in the intensity of the y7 ion (911.61m/z) once Zn
2+ is present as 
shown in Figure 5.21. A concomitant decrease in the intensity of the c7 
ion (924.66 m/z) is also observed which could indicate a conformational 
change upon Zn2+ binding that has an impact on the way the molecule 
fragments.  
 
 
Figure 5.21 Zn
2+ 
binding to HRGP330 has an effect on the intensity of different 
ions produced by ETD. A) c7 ion observed in the ETD spectrum of 867 m/z B) y7 ion 
observed in the ETD spectrum of 880 m/z. The y ion is produced from a secondary 
reaction.  
 
It appeared as though a number of Zn2+-bound peaks appeared in the 
ETD spectrum of 880 m/z although the complex spectrum did not allow all 
of these to be assigned. Those that were distinguishable with the most 
certainty are described in Table A6 (Appendix). The smallest ion 
identified to have a Zn2+ ion bound was Z13*, although this was of low 
intensity, which would suggest that any of the six His residues could be 
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involved in binding: His35, His33, His30, His27, His25 or His23 (Figure 
5.22 B). This correlates well with the observation that the y12 ion detected 
in CID also associated with Zn2+. Figure 5.22 C illustrates the well 
resolved peaks for ETD of 867 m/z compared to that for 880 m/z in D.  
 
 
 
 
Figure 5.22 Identification of Zn
2+
-adducts in the ETD spectrum of Zn1-HRGP330. A) 
ETD spectrum of apo-HRGP330 showing z13* B) Observation of a Zn
2+
 ion bound to z13* 
C) ETD spectrum of apo-HRGP330 shows a number of clearly resolved peaks between 
1500-2100 m/z D) ETD spectrum of Zn1-HRGP330 shows a number of peaks identified 
to be Zn
2+
-adducts although the spectrum is much noisier. Those peaks that appear to 
coordinate Zn
2+
 but not assigned are marked with a ? 
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There appears to be many Zn2+ adducts but these cannot all be fully 
assigned with confidence. The lack of fragments for the ETD spectrum of 
the Zn1-HRGP330 compared to those produced in the absence of Zn
2+, 
could indicate that the molecule undergoes a conformational change to 
form a less flexible structure that is less susceptible to fragmentation. 
ETD has in principle the advantage of leaving more labile interactions 
intact so it is possible that the ETD mechanism cannot fragment Zn2+-
HRGP330 as efficiently whereas CID is a higher energy fragmentation 
and can overcome the structural changes to some extent to still produce 
b and y ions effectively.  This is supported by the IM data which indicated 
that the HRGP330 structure becomes more compact when Zn2+ binding 
occurs. The contribution of the Zn2+ ion to the electron transfer process, 
however, can also not be ignored as two earlier studies reported that the 
cation may act as an electron sink. Zubarev et al. (2000) demonstrated 
through ECD of cytochrome c that the region around the heme, with 
bound Fe3+, was resistant to backbone cleavage. Similarly, ECD of an 
angiotensin peptide produced fewer fragments in its Zn2+-bound form 
(Zubarev et al., 2002). This would rationalise the lack of fragmentation 
around the GHHPH region if Zn2+ was indeed bound there, however, the 
observation of Zn2+ adducts not containing this pentapeptide would point 
towards the partial occupation of different sites. 
 
Taking into account the findings of the MS/MS data it would appear that 
there is not a single preferred binding site for Zn2+ to HRGP330 as 
fragments from both N-terminal and C-terminal ends of the molecule were 
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observed in a Zn2+-bound form. This would suggest that several of the His 
residues, and the binding sites they may form, have a similar affinity for 
Zn2+ ions and that at sub-stoichiometric Zn2+:HRGP330 ratios they are 
likely to be partially occupied. However, it was noticed that in the 
presence of Zn2+ the least fragmentation occurred around the GHHPH 
unit. Further work is needed to rationalise this observation fully which 
could involve fragmentation of other metal ion-HRGP330 complexes and 
a comparison of the data.  
 
5.6 Conclusion 
The biologically-active peptide from the HRR of HRG was shown to bind 
up to 5 Zn2+ ions by native ESI-MS. Broadening of the proton signals and 
aggregation of the peptide did not allow any significant information to be 
gained from 1H-NMR spectroscopy although the large number of NOESY 
cross peaks suggested it was not completely random coil structure. 
TWIM-MS showed that a number of complexes were present in the Zn2+-
bound forms which could not be resolved. Interestingly, the collisional 
cross sections that were estimated showed that the peptide complexes 
with Zn2+ had a more compact structure. Furthermore, CD spectroscopy 
showed evidence of a polyproline II helix and a substantial change upon 
addition of Zn2+. These results give an insight into how active multimeric 
HRG complexes could form and it would appear significant changes 
occur in the HRR in order to facilitate this.  
 
Top down MS/MS was utilised to map the sites for Zn2+ binding. 
HRGP330 was able to be sequenced by CID and ETD with high levels of 
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sequence coverage, most likely due to its extended conformation which 
allowed it to fragment easily. When Zn2+ was bound to HRGP330, less 
sequence coverage was achieved, indicating that a conformational 
change may have taken place. Zn2+ binding fragments were identified in 
both CID and ETD data and it was found that the metal ion was primarily 
associating with y fragments from the C terminus although some Zn2+-
binding fragments from the N-terminus were also identified. ETD was not 
able to efficiently fragment the Zn2+-bound HRGP330 to the same extent 
as CID indicating that a conformational change had occurred that ETD 
was not able to overcome. Overall, the observation of Zn2+-peptides has 
important implications for the field of top-down MS/MS of metalloproteins 
as few studies have attempted this.    
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Chapter 6 
Investigating metal ion 
distribution between HSA 
and HRGP330 
 
6.1 Introduction 
The hypothesis being investigated in this chapter is that the fatty acid 
“switch” mechanism could have implications for other Zn2+ binding 
proteins in plasma. If the balance of fatty acids in plasma were perturbed, 
during a disease for example, then other proteins may play a role in 
protecting the cells from toxic concentrations of Zn2+. This chapter 
investigates if Zn2+ can transfer between HSA and HRGP330. 
Furthermore, the effect of fatty acid is investigated to establish if this 
could facilitate Zn2+ binding to HRG. It also explores if HRGP330 could 
acquire Cu2+ from the N-terminal site on HSA as Cu2+ may also have an 
effect on the antiangiogenic activity of HRG.   
 
6.2 Results and discussion 
6.2.1 Zn2+ transfer occurs between HSA and HRGP330 
Reports addressing interactions between HSA and HRG are lacking apart 
from two examples where Zn2+ distribution between rabbit HRG and HSA 
was investigated using equilibrium dialysis (Guthans and Morgan, 1982) 
and also the effect of HRG on heme binding to HSA was probed (Morgan, 
1981). It has been demonstrated that small molecules such as histidine 
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can affect Zn2+ distribution between the two proteins (Guthans and 
Morgan, 1982), therefore, this work sought to address if fatty acids can 
also have an effect. First, Zn2+ transfer from HSA to HRGP330 at a 1:1 
ration and in the absence of fatty acids was probed. Separation of HSA 
and HRGP330 was achieved using a molecular weight cut-off filter, 
retaining the HSA on the membrane but allowing the HRGP330 to pass 
through. Analysis of the HRGP330 fraction by ESI-MS showed that 
compared to the control sample, HRGP330 had obtained Zn2+ from HSA 
(Figure 6.1 A).  
 
B 
Sample Zn
2+
:HSA stoichiometry 
Zn-HSA 0.96 
Zn-HSA following incubation with 
HRGP330 
0.12 
 
Figure 6.1 ESI-MS of HRGP330 and ICP-OES of HSA as evidence for Zn
2+
 transfer 
having occurred. A) Mass spectra of HRGP330 before and after incubation with Zn-
HSA B) ICP-OES analysis of the HSA fraction confirms a significant loss of Zn
2+ 
in the 
presence of HRGP330. Analysis was carried out on a maXis-UHR-TOF in 10 mM 
ammonium acetate (pH 7.4). HSA samples were diluted in 0.1 M HNO3 and analysed on 
a Perkin Elmer Optima 7500 DV.  
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The fact that the majority of Zn2+ is removed from HSA is an indicator that 
HRG has a higher binding affinity for Zn2+ than any site on HSA under the 
conditions employed. Furthermore, high resolution ESI-MS allowed the 
metal ion to be unambiguously assigned as Zn2+ as opposed to Cu2+. In 
order to confirm that the source of Zn2+ was HSA, the protein fraction 
retained on the membrane was diluted and subjected to ICP-OES 
analysis. Figure 6.1 B shows that the Zn2+ bound to HSA had reduced by 
87% from 0.96 to 0.12 Zn2+ ions per HSA molecule. Analysis of the buffer 
also failed to detect any Zn2+; giving strong evidence that Zn2+ transfer 
occurred between HSA and HRGP330. Additionally, the preparation of 
Zn-HSA involved passing the sample through a PD-10 column prior to 
incubation with HRGP330 to ensure no unbound metal ions were present 
in the solution. 
 
6.2.2 Does Zn2+ transfer occur from HRGP330 to HSA? 
To confirm the findings of the previous experiment, the reverse Zn2+ 
transfer reaction was carried out. HRGP330 was incubated with 5 
equivalents of Zn(CH3COO)2.2H2O and then excess metal ions were 
removed. Four different species were observed (apo-HRGP330, Zn1-
HRGP330, Zn2-HRGP330 and Zn3-HRGP330) as shown in Figure 6.2. 
This sample was combined with dialysed HSA in a 1:1 molar ratio and 
infused into the mass spectrometer. The conditions were optimised to 
favour observation of HRGP330 over HSA. Following incubation with 
dialysed HSA the distribution of metallated species in HRGP330 did not 
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change perceptibly. This demonstrates that at a 1:1 molar ratio, the Zn2+ 
ions have a higher affinity for HRGP330 rather than for HSA.  
 
 
  
Figure 6.2 Direct infusion of a 1:1 mixture of dialysed HSA and Zn-HRGP330. Mass 
spectrometry was carried out on a maXis-UHR-TOF in 10 mM ammonium acetate (pH 
7.4) with conditions optimised for HRGP330.  
 
 
The experiments suggested that HRGP330 has a higher affinity for Zn2+ 
than HSA and this is not in agreement with the hypothesis that HRG 
could only obtain Zn2+ if it was displaced from HSA. The next step was to 
ascertain if fatty acid had any further effect on the Zn2+ distribution.  
 
 
6.2.3 Effect of fatty acid on Zn2+ distribution  
Although it appeared that HRGP330 was able to readily obtain Zn2+ from 
HSA under the conditions used for ESI-MS, the effect of myristate was 
investigated to try and identify any perceptible differences. One of the 
samples was supplemented with 5 mol. equiv. myristate and the other 
with no fatty acid. The instrumental parameters were optimised in order to 
observe HRGP330 as a probe for Zn2+ binding. A charge state distribution 
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for HRGP330 was observed including the +5 and +4 which were of the 
highest intensity (Figure 6.3 A).  A charge state distribution for native 
HSA could be observed but this was of low intensity and the peaks were 
extremely broad. Compared to the starting HRGP330 sample that was 
analysed (Figure 6.3 A), two new peaks for Zn1-HRGP330 and Zn2-
HRGP330 became present as shown in the deconvoluted spectrum in 
Figure 6.3 B. A Zn2-HRGP330 species was also formed before the apo-
HRGP330 was saturated with one metal ion. This is the same result 
described in section 6.2.2 which confirms reproducibility. 
 
 
 
Figure 6.3 Direct infusion of a 1:1 mixture of Zn-HSA and HRGP330 in the absence 
and presence of myristate. A) HRGP330 control sample B) HRGP330 incubated with 
Zn-HSA at a 1:1 ratio C) HRGP330 incubated with Zn-HSA at a 1:1 ratio with 5 mol. 
equiv. myristate. The spectra on the left show the charge states and the spectra on the 
right are the deconvolution of the HRGP330 peaks.  Mass spectrometry was carried out 
on a maXis-UHR-TOF in 10 mM ammonium acetate (pH 7.4) with conditions optimised 
for HRGP330. Native HSA peaks can be observed but at low intensity. 
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The sample analysed with addition of myristate is shown in Figure 6.3 C. 
The same amount of Zn2+ was bound to HRGP330 in both cases as 
evidence by similar intensity peaks in the mass spectrum corresponding 
to the Zn1-HRGP330 and Zn2-HRGP330 complexes. This indicates that 
the myristate had no effect on the distribution of Zn2+ between HSA and 
HRGP330 in this case because HRGP330 was already an effective 
competitor for the metal ion.   
 
To corroborate the findings of the previous section and investigate the 
ternary system in more detail, HSA was incubated with the various 
ligands followed by separation from HRGP330. A summary of the ICP-
OES measurements is provided in Figure 6.4.   
 
Figure 6.4 HSA:Zn
2+
 stoichiometry in the presence of 1 mol. equiv. HRGP330 (± 
myristate). Samples were prepared in 10 mM ammonium acetate at pH 7.4. Following 
incubation with the ligands HSA was separated from HRGP330. HSA fractions were 
diluted in 0.1 M HNO3 and analysed on a Perkin Elmer Optima 7500 DV.  
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The control sample of only HSA showed less than the expected 1 Zn2+ 
bound, likely due to some loss during gel filtration. In the presence of 
myristate no change in the Zn2+ bound to HSA was observed which is 
consistent with the findings in Chapter 3. With the addition of HRGP330, 
a substantial loss of Zn2+ occurred (82%) and the same effect was also 
observed for the sample with myristate where 81% of the HSA-bound 
Zn2+ is transferred to HRGP330. There is only a small difference in Zn2+ 
content between the samples with and without myristate, therefore it can 
be concluded that the myristate appears to have no effect on whether the 
Zn2+ is bound to HSA or HRGP330. 
 
6.2.4 Effect of excess HSA on Zn2+ distribution 
To determine if the presence of HRGP330 had an impact on Zn2+ binding 
when HSA was in significant excess, as in blood plasma, the Zn2+ 
distribution between 600 µM HSA and 20 µM HRGP330 was investigated. 
This was used because the concentration of HRGP330 in blood plasma is 
~2.5 µM, however, the effective concentration could be 10 times higher 
due to the proposed HRG: metal stoichiometry of 1:10. Additionally, a 
higher concentration had to be used in these experiments in order to 
obtain sufficient signal for ESI-MS following separation from HSA. 
Although good quality spectra of HRGP330 were obtained from 5 µM 
samples, it was found that a small proportion of contaminating HSA, 
following the separation of the proteins, supressed the ionisation of the 
HRGP330 signals when lower concentrations were used (Appendix, 
Figure A9).  
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Following incubation with 600 µM Zn-HSA (± myristate) an increase in the 
relative intensity of the Zn1-HRGP330 was observed as shown in Figure 
6.5. The control HRGP330 sample (Figure 6.5 A) showed a slight amount 
of Zn2+ contamination (34%) most likely from the purification procedure. 
Following incubation with Zn-HSA the relative intensity of this peak 
increased by 7% compared to the control sample indicating that some 
Zn2+ had been obtained from HSA. This supports the data in the previous 
section of HRGP330 being a good competitor for Zn2+ even without fatty 
acid-induced Zn2+ release. In the presence of myristate there was a 
further increase of 4% in the relative intensity of the peak. Overall, this 
may indicate that slightly more Zn2+ was transferred from HSA to 
HRGP330 in the presence of fatty acids, but this could not be confirmed 
by ICP-OES analysis (see below).  
 
Figure 6.5 Relative intensity of Zn1-HRGP330 following incubation with Zn-HSA (± 
myristate). A) HRGP330 control sample B) 20 µM HRGP330 incubated with 600 µM Zn-
HSA C) 20 µM HRGP330 incubated with 600 µM Zn-HSA with 5 mol. equiv. myristate.  
Mass spectrometry was carried out on a maXis-UHR-TOF in 10 mM ammonium acetate 
(pH 7.4) 
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Elemental analysis was carried out on the HSA fractions. The results in 
Figure 6.6 showed a greater amount of Zn2+ associating with HSA in the 
presence of myristate: 0.74 Zn2+ ions per HSA compared to 0.66 Zn2+ 
determined for the control sample. With the addition of HRGP330 there 
was a decrease of the Zn2+ interacting with HSA which is consistent with 
an increased amount bound to HRGP330 as demonstrated by ESI-MS 
(Figure 6.5 B).  
 
Figure 6.6 HSA:Zn
2+
 stoichiometry (600 µM) in the presence of  20 µM HRGP330 (± 
myristate). Samples were prepared in 10 mM ammonium acetate at pH 7.4. Following 
incubation with the ligands HSA was separated from HRGP330, diluted in 0.1 M HNO3 
and analysed on a Perkin Elmer Optima 7500 DV.  
 
The quaternary system, with the addition of myristate, showed slightly 
more Zn2+ bound to HSA than only with HRGP330: 0.60 Zn2+ per HSA 
with myristate compared to 0.50 Zn2+ with no myristate. Importantly, both 
HSA samples allowed to react with HRGP330 had less Zn2+ bound than 
those without HRGP330 which is good agreement with the increases in 
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Zn2+-bound HRGP330 shown in Figure 6.5 B and C. Overall, this would 
indicate that even when HSA is in significant excess, as in plasma, a 
small proportion of Zn2+ becomes bound to HRG.  
 
ESI-MS and ICP-OES results indicate that HRGP330 can readily 
compete for Zn2+ under these conditions. This is in good agreement with 
the work by Guthans and Morgan (1982). Based on the original 
hypothesis it was expected that Zn2+ transfer would only occur between 
HSA and HRGP330 in the presence of fatty acids. Therefore, the 
question to address is would HRG carry Zn2+ endogenously or would it 
only come into play if Zn2+ was displaced from another protein i.e. through 
elevated fatty acids? Overall this work is in agreement with the former 
conclusion. Although HRG is present at relatively low abundance in 
comparison to other proteins thought to be major Zn2+ transporters, it 
could be able to compete with these because of its high number of 
potential metal binding sites. If it is assumed that HRG binds 10 metal 
ions and is 2 µM in human plasma (Morgan et al., 1978) then the effective 
binding site concentration is as high as 20 µM. This could be an 
explanation as to why HRGP330 binds preferentially to Zn2+ in the 
presence of HSA  in vitro although it is unclear as to if this is something 
that could occur in vivo. It is important to note that these experiments 
were carried out at low ionic strength due to the low tolerance of ESI-MS 
to salts, however, changes in ionic strength could affect the stability of the 
metal:protein complexes.  
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6.2.5 Investigation of metal binding between HSA and HRGP330 at 
plasma Zn2+ concentrations 
Experiments were carried out with physiologically relevant Zn2+ 
concentrations using a combination of size exclusion chromatography 
(SEC) and inductively coupled plasma mass spectrometry (ICP-MS). 
These techniques are also more amenable to high concentrations of salt 
and so the effect of this can be probed. Calibration of the column was 
achieved using HSA (66.5 kDa) and insulin B chain (3.5 kDa) as shown in 
Figure 6.7. The two proteins eluted at 7 ml and 9 ml respectively.  
 
 
Figure 6.7 Elution of HSA and insulin B chain on a BioSep-SEC-2000 column. HSA 
eluted at 7 ml (blue) which is 66 kDa. Insulin B chain which is 3.5 kDa eluted at 9-10 ml 
(red) which indicates HRGP330 (4.3 kDa) should elute in similar fractions. The buffer 
was 10 mM HEPES, 50 mM NaCl (pH 7.4).  
 
Insulin B-chain has a similar size to HRGP330, therefore they would be 
expected to elute around the same volume. Surprisingly, when a 
concentrated HRGP330 sample was loaded onto the column, an increase 
in absorbance at 220 nm at an elution volume of 11-12 ml was observed 
(blue trace of Figure 6.8 A). The fact that this fraction has absorbance at 
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220 nm but not 280 nm also suggests that this is HRGP330 as it has a 
lack of aromatic residues (inset of Figure 6.8 A). Some residual HSA from 
a previous run was also observed at a lower intensity in the HRGP330 
sample (sharp peak in blue trace at 7.40 ml). Therefore it would appear 
that HRGP330 elutes ~1 ml later than expected.  
 
To investigate plasma concentrations of Zn2+ with respect to HSA and 
HRGP330, samples of HSA (600 µM) and HRGP330 (20 µM) were 
incubated at 37 °C with 25 µM ZnCl2 and one sample included the 
addition of 5 mol. equiv. myristate. The proteins were applied to a 
BioSep- SEC-2000 gel filtration column and the fractions were analysed 
for Zn2+ content (ICP-MS) and protein content (BCA assay). As can be 
seen in Figure 6.8 B the Zn2+ detected at ppb levels eluted with the HSA 
across the fractions labelled 7 and 8. This is consistent with 
chromatographic separation of both human and rabbit plasma which has 
shown that the majority of Zn2+ elutes with HSA (Muñiz et al., 2001; 
Manley et al., 2009). The HRGP330 could not be observed in the UV 
chromatogram due to the lower concentration used in these samples. 
Interestingly, in the presence of myristate, the concentration of Zn2+ 
eluting with HSA was considerably reduced to 300 ppb (Figure 6.8 C) 
compared to 600 ppb without myristate. This is one piece of evidence that 
myristate could shift the Zn2+ distribution from HSA at physiologically 
relevant Zn2+ levels. One reason for this result could be the presence of 
salt in the buffer, as ionic strength may affect the stability of the   
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Figure 6.8 Elution of HSA and HRGP330 from a BioSep-SEC-2000 column.. A) 
Chromatograms for HSA (green), HRGP330 at 220 nm (blue) and HRGP330 at 280 nm 
(red). The inset shows an increase in absorbance at 220 nm at 11.50 ml which could 
correspond to elution of HRGP330. B) Zn
2+
 concentration (black) and corresponding 
protein concentration (grey, dashed line) of fractions when a sample of 600 µM HSA, 20 
µM HRGP330 and 25 µM ZnCl2 was applied to the column C) 600 µM HSA, 20 µM 
HRGP330 and 25 µM ZnCl2 with 5 mol. equiv. myristate. The buffer was 10 mM HEPES, 
50 mM NaCl (pH 7.4).  
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metal:protein complex, although this is a further avenue that needs 
exploring. On analysis of the Zn2+ content of fractions eluting at 11-12 ml 
there does appear to be a small peak in Zn2+ concentration at 11-12 ml, 
however, no significant difference was observed between the samples 
with or without myristate. One possibility is that free Zn2+ that had been 
shifted from HSA may elute in another fraction although this could not be 
concluded from this experiment.  It would appear that under these 
conditions, myristate was able to perturb metal binding although other 
work has provided non-conclusive evidence for this. 
 
6.2.6 Estimation of the apparent binding constant for Zn-HRGP330 
Zincon was used in a competition assay to determine an apparent binding 
constant (Kapp) for HRGP330. Complexation of Zincon with Zn
2+ produces 
a 1:1 complex with a blue colour and a characteristic absorbance at 620 
nm. This absorbance can be exploited to assess the binding of Zn2+ to 
peptides and proteins (Shaw et al., 1990; Mekmouche et al., 2005; Armas 
et al., 2006; Talmard et al., 2007).   
 
Titrating increasing amounts of HRGP330 into the Zn2+-Zincon complex 
produced a decrease in the absorbance at 620 nm (Figure 6.9). 
Approximately 4.8 µM HRGP330 was required to reduce the absorbance 
at 620 nm by 50% which indicates that half of the Zn2+ originally bound to 
Zincon had been transferred to HRGP330. A plateau in the absorbance is 
reached relatively quickly which demonstrates that Zn2+ exchange 
between HRGP330 and Zincon is rapid.  The results indicate that the 
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binding constants are globally similar but HRGP330 is a slightly stronger 
Zn2+ binder than Zincon. The Kapp for Zincon has previously been 
determined to be 7.9 x 104 M-1 at pH 7.4 (Shaw et al., 1990) and more 
recently a slightly different value of 8.5 x 104 M-1 was found by 
Mekmouche et al. (2006) under 50 mM HEPES, 100 mM NaCl at pH 7.4. 
Using this value, Equation 3 in the experimental methods can be used 
which results in a Kapp for HRGP330 of 2.7 x 10
5 M-1   
 
 
Figure 6.9 Estimation of the apparent binding constant of Zn
2+
 and HRGP330 
using competition with Zincon. HRGP330 was titrated into a solution of 10 µM Zincon 
and 5 µM ZnCl2 in 50 mM HEPES, 100 mM NaCl, pH 7.4. 100% relative absorbance 
corresponds to the maximum absorbance observed at 620 nm at t=0 and t=∞. The inset 
shows the structure of Zincon. 
 
 
As HRGP330 is able to obtain Zn2+ from the 1:1 Zn2+-Zincon complex this 
would suggest it is also able to rapidly acquire Zn2+ from other available 
donors, including HSA under appropriate conditions. This result yields an 
apparent logK of 5.43 which is in the same range as the values published 
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for full length HRG (Table 1.4) therefore it would appear that HRGP330 
has a similar binding affinity to the intact protein. Differences will be due 
to the different buffer conditions and ionic strengths used. Recently, our 
laboratory has determined an apparent logK of 5.67 for  Zn2+ binding to 
BSA in 50 mM Tris, 50 mM NaCl at pH 7.2 (Lu et al., 2012b). Therefore, 
although BSA or HSA would bind Zn2+ with greater affinity than HRG, the 
high number of potential binding sites may mean the binding capacity of 
HRG is underestimated. It would be invaluable to assess the binding 
affinity of HSA and human HRG under the same conditions by a method 
such as ITC although there may be difficulties in comparing a cooperative 
binder (HRG) to a non-cooperative binder (HSA).  
 
6.2.7 Cu2+ transfer between Gly-Gly-His and HRGP330  
The major Cu2+ binding site on HSA is the N-terminal ATCUN-motif. Gly-
Gly-His is a peptide mimic of this site that has been previously studied as 
a model for the N-terminal site (Figure 6.10). The apparent stability 
constant for the Cu2+-peptide complex has been shown to be logK = 16 
compared to 16.2 for Cu2+-HSA (Lau et al., 1974). Although most of the 
ligands that interact with HRG are thought to be mediated by Zn2+ binding 
to the HRR, these associations could also be influenced by the 
concentration of Cu2+. Borza and Morgan (1998) confirmed that the only 
other transition metal apart from Zn2+ to be effective at promoting heparin 
binding to HRG at physiological pH was Cu2+. Binding of Cu2+ to rabbit 
HRG has also been shown to be stronger than Zn2+ (Morgan, 1981). In 
fact, analysis of serum indicates that while the concentration of Zn2+ is 
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reduced in human cancers (Kuo et al., 2002), plasma Cu2+ levels are 
actually increased (Coates et al., 1989). Therefore, it must be 
acknowledged that Cu2+ could potentially be biologically relevant for HRG 
although the question still remains as to whether it contributes 
significantly to anti-angiogenic activity.  
 
ESI-MS experiments of Gly-Gly-His showed binding of 1 equivalent of 
Cu2+ which is consistent with the literature. Cu2+ distribution between Gly-
Gly-His and HRGP330 was also studied using this technique. First the 
Cu2+-Gly-Gly-His complex was formed which can be observed at 331 m/z 
in spectra A and C in Figure 6.11. 
 
 
Figure 6.10 Structure of Gly-Gly-His. The peptide mimic for the N terminus of HSA. 
 
This was reacted with 1 or 0.2 mol. equiv. of HRGP330, shown in Figure 
6.11 B and D respectively. With addition of 1 mol. equiv. of HRGP330, 
the intensity of ESI-MS peaks corresponding to the Cu2+-Gly-Gly-His 
species reduced considerably to 10% relative intensity from 69% and the 
peak at 270 m/z, corresponding to Gly-Gly-His without a metal ion, 
became the most abundant species (Figure 6.11 B). This showed that  
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Figure 6.11 Effect of HRGP330 on Cu
2+
 binding to Gly-Gly-His. Cu
2+
 was allowed to 
react with Gly-Gly-His producing the spectra in A and C.  HRGP330 was added at 
concentrations of 1 mol. equiv. (B) and 0.2 mol. equiv. (D). Samples were prepared in 10 
mM ammonium acetate at pH 7.4 and analysed on a maXis-UHR-TOFinstrument. 
 
Cu2+ transfer had occurred to HRGP330. A similar approach was to add 1 
mol. equiv. of Cu2+ to a 1:1 HRGP330:Gly-Gly-His: the same result was 
achieved as the metal ion preferentially bound to HRGP330 over Gly-Gly-
His. As HRGP330 was clearly shown to be able to bind up to 5 metal ions 
in Chapter 5, this reaction was repeated with 0.2 mol. equiv. HRGP330. 
This means that the potential binding sites between the two peptides are 
approximately equal. At this concentration there was a significant 
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increase in the 270 m/z peak to the point where a 50:50 ratio of Gly-Gly-
His and Cu2+-Gly-Gly-His was observed. This experiment indicated that 
not all of the Cu2+ had been transferred to HRGP330. At this point it can 
be assumed that globally the binding affinities are roughly similar as 
approximately half of Cu2+ is bound to each peptide. This result is 
surprising  as Gly-Gly-His binds to Cu2+ with a much stronger affinity than 
proposed for HRG: logK = 16 for Cu2+-Gly-Gly-His (Lau et al., 1974) 
compared to ~6.70 for Cu2+-HRG (Morgan, 1981). Therefore, it may be 
that case that the large number of potential binding sites makes Cu2+ 
binding to HRGP330 more favourable. These results indicate that one 
route through which HRG may obtain Cu2+ in plasma could be through 
transfer from HSA. Furthermore, as Cu2+ binds to HRG more strongly 
than Zn2+ then it would be feasible that Cu2+ would sufficiently block metal 
binding sites and this might have consequences for the Zn2+-dependent 
activities of HRG.  
 
6.2.8 Implications of Zn2+ transfer to HRG: effect of Zn2+ on HRGP330 
binding to heparin 
The results described in this chapter have suggested that, using 
HRGP330 as a mimic, Zn2+ would transfer from HSA even without 
elevated fatty acid levels to displace Zn2+ from HSA under the conditions 
used. One consequence of Zn2+ being transferred to HRG would be an 
increase in its biological activities as evidence has suggested that its 
interactions with other biomolecules are enhanced by Zn2+. Native HRG 
has a pI of 6.45 so will be negatively charged at physiological pH. 
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However, through interactions with metal ions it can acquire positive 
charges which facilitate complex formation with other ligands such as 
heparin. It has been demonstrated that HRG is the only plasma protein 
that can compete with antithrombin for heparin which gives an insight into 
the importance of this interaction. This is likely because the dissociation 
constant of heparin binding to human HRG has been reported to be 7 nM 
(Lijnen et al., 1983).  To investigate one biological implication of HRG 
obtaining Zn2+ from HSA, the interaction of HRGP330 with a heparin 
dodecasaccharide (Figure 6.12) was investigated by ESI-MS. Previous 
data have shown that this gives maximal binding to a related peptide, 
HRGP335 (Vanwildemeersch et al., 2006). 
 
Figure 6.12 Chemical structure of the heparin dodecasaccharide (dp12) used in 
this work. 
 
There are examples of work where ESI-MS has be used to observe 
complexes of heparin with a fibroblast growth factor (Harmer et al., 2004; 
Harmer et al., 2006) and a chemokine (Przybylski et al., 2010). The 
average mass of the heparin dodecasaccharide (dp12) was 3550 Da. 
Following incubation of dp12 with HRGP330 at a 1:1 mol. ratio, a new 
group of peaks became visible that were centred around 1550 and 1950 
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m/z (Figure 6.13 A). These corresponded to the 5+ and 4+ charge states 
of a 1:1 HRGP330:dp12 complex which has a theoretical mass of 7883 
Da.  Low intensity peaks for unbound dp12 were also observed between 
these charge states. Although some complex formation was detected 
between the peptide and the heparin, in the presence of 1 mol. equiv. 
Zn2+, the intensity of the complex was increased more than two-fold : 18% 
relative intensity of the complex compared  to 7% without Zn2+ (Figure 
6.13 B).  
  
Figure 6.13 ESI-MS shows increased HRGP330:dp12 complex in the presence of 
Zn
2+
. A) HRGP330 was incubated with 1 mol. equiv. of heparin dodecasaccharide B) 
HRGP330 was incubated with Zn
2+
 prior to addition of dp12. A greater amount of the 
complex was formed with Zn
2+
 as judged by the relative intensities of the peaks. 
 
This is the first ESI-MS evidence of heparin binding to a HRG-derived 
peptide. Currently, there are no examples of His-rich peptides binding to 
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heparin in the gas phase, therefore, this result indicates that the 
complexes are strong enough to be detected. Furthermore, this adds 
support to the argument that heparin binding occurs at the HRR. There 
has been much debate over this in recent years with one study 
demonstrating that the N-terminal domain bound to immobilised heparin 
and cell-surface heparan sulphate while no interaction was observed with 
HRR-derived peptides (Jones et al., 2004). It is surprising that such a 
large fragment of heparin can bind to a relatively small peptide, however, 
longer fragments may have multiple sites that can interact with the 
peptide and stabilise the association.  The fact that the formation of the 
complex appears to be enhanced by the presence of Zn2+ is in good 
agreement with the literature. The complex spectra contained many 
overlapping peaks although a close-up view of the 5+ charge state 
provides evidence for the fact that Zn2+ is bound to the complex (Figure 
6.14). Two sets of abundant peaks (marked with * and †) are visible in 
Figure 6.14 A and the difference between them is an SO3 group (80 Da). 
The other peaks are attributed to ammonia and sodium adduction. In the 
presence of Zn2+ these peaks are clearly shifted by 63 Da (Figure 6.14 B) 
therefore it is indeed possible that a ternary complex of HRGP330-Zn2+-
dp12 exists in the gas phase. This observation is consistent with the 
suggested mechanism that the interaction is mediated by metal ions 
bound to HRG and the addition of EDTA completely abolishes complex 
formation (Lijnen et al., 1983). 
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Figure 6.14 Close-up view of the 5+ charge state of HRGP330:heparin complex. A)  
HRGP330 incubated with 1 mol. equiv. of heparin dodecasaccharide shows two sets of 
abundant peaks marked with * and †. The difference between them is 80 Da which 
corresponds to loss of an SO3 group. B) The complex with addition of Zn
2+
 shows that 
these peaks are still most abundant and shifted by the mass of 63 Da i.e. addition of a 
Zn
2+ 
ion. 
 
6.9 Conclusion 
ESI-MS has demonstrated that Zn2+ transfer can occur from HSA to 
HRGP330 even in the absence of fatty acids. Even with HSA in 
significant excess, as would be in plasma, an increase in Zn2+ bound to 
HRGP330 was still detected.  This indicates that the affinities of HSA and 
HRG are very close to each other, however, this could depend on the 
solution conditions. At low ionic strength, HRG displays higher affinity, 
whilst the data presented in section 6.2.5 suggest that at higher ionic 
strength, HSA retains bound Zn2+. Therefore, the question remains: is 
HRG carrying Zn2+ endogenously or would it only obtain Zn2+ if there was 
a change in the plasma conditions? This work provides support for the 
former conclusion. The apparent dissociation constant determined 
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appeared to be in good agreement with these experimental observations 
although further work, such as ITC, is warranted to make direct 
comparisons with full length HRG. HRGP330 is also able to compete for 
HSA-bound Cu2+ which could have implications for the activities of HRG 
as this metal ion has been shown to mediate some HRG-ligand 
interactions.  
 
SEC revealed that at physiologically relevant Zn2+ concentrations, the 
metal ion eluted with HSA and no increase in Zn2+ was observed in the 
fractions corresponding to HRGP330. This SEC approach could be 
utilised to analyse whole plasma samples and detect less abundant Zn2+ 
binding plasma proteins although a higher resolution separation method 
may be desirable to separate HSA and HRG which are close in size (66 
kDa compared to 75 kDa). With regards to biological consequences of 
Zn2+ transfer to HRG, experiments with heparin as a model ligand 
showed a larger amount of HRGP330:heparin complex formation with 
Zn2+ as assessed by ESI-MS. This is the first ESI-MS evidence of a 
heparin complex with a peptide derived from HRG. 
 
 
 
 
Chapter Seven 
173 
 
Chapter 7 
Conclusion  
 
7.1 Summary of observations  
7.1.1 Native ESI-MS of HSA-ligand complexes 
In Chapter 3, methods were developed to study HSA in its native form 
using ESI-MS. This proved challenging as the gentle conditions allowed 
buffer and salt adducts to remain bound to the protein. However, once 
these could be effectively removed, single metal ion binding to HSA was 
detected. The addition of fatty acids to HSA did not yield any significant 
mass increase, therefore, it was concluded that the interactions with 
these must be broken on entering the gas phase. Evidence to support 
this was obtained by observing a protonated myristic acid molecule in the 
low mass range while infusing HSA-myristate complexes into the mass 
spectrometer.  
 
In contrast, a perfluorinated derivative of octanoic acid was found to 
remain bound in the gas phase and also a ternary HSA-PFOA-Zn2+ 
complex was detected. This is in agreement with molecular modelling that 
indicates the binding of octanoate does not induce a conformational 
change great enough to abolish metal binding at Site A (Lu et al., 2012b). 
Recently, a perfluorinated derivative of myristic acid has become 
commercially available and so this could be tested in the future. It would 
appear that these molecules are good fatty acid mimics and the 
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hydrophilic nature of fluorine can be exploited to preserve the binding of 
these molecules in the gas phase.  
 
TWIM-MS was also used as a novel technique to study the conformation 
of HSA and its complexes in Chapter 4. The estimated collisional cross 
section for apo-HSA was in good agreement with that calculated from the 
X-ray crystal structure (1AO6). No change in conformation was seen in 
the presence of Zn2+ or Cd2+ although the collisional cross section was 
slightly larger upon Cd2+ binding. Increasing the cone voltage provided 
sufficient energy for HSA to begin to unfold although with the addition of 
Zn2+, less of these extended conformations were detected which is 
evidence that occupation of Site A confers some stability onto the domain 
I/domain II interface. Although the fatty acids appeared to dissociate from 
HSA in the gas phase, the myristate-bound sample showed an increased 
collisional cross section compared to that to fatty acid-free HSA. This 
could indicate that a conformational change takes place within the protein 
upon fatty acid binding but that the protein doesn’t revert back to its 
normal fatty acid-free conformation during the timescale of the IM 
experiment.  
 
7.1.2 Metal binding properties of HRGP330 
In the work reported in Chapter 5, a peptide derived from the HRR of 
HRG was studied by various techniques. Complexes with Zn2+, Cd2+ and 
Cu2+ were able to be observed in the gas phase and CD spectroscopy 
suggested a conformational change occurs upon Zn2+ binding. A dimeric 
Chapter Seven 
175 
 
form of HRGP330 was identified only in the presence of Zn2+ which could 
give an important insight as to how multimeric complexes of HRG form in 
plasma. To obtain further information on residues involved in metal 
binding, NMR analysis was carried out in the absence and presence of 
Zn2+. The addition of the metal ion ligand significantly broadened the 
signals suggesting that the binding to the peptide is dynamic. This 
precluded gaining any structural information from NMR spectroscopy 
although using sub-stoichiometric quantities may allow this to a greater 
extent. 
 
TWIM-MS confirmed that a change occurred to the peptide upon Zn2+ 
binding as the estimated cross sectional area of the Zn2+-bound 
complexes were observed to be significantly more compact than apo-
HRGP330. Top-down ESI-MS was then utilised to map the Zn2+ binding 
sites within the peptide. High sequence coverage was obtained from both 
CID and ETD/PTR of HRGP330 which could be due to a lack of 
conventional secondary structure which allows it to fragment easily. Zn2+-
bound fragments from both N- and C- terminal ends of the molecule were 
detected which implies several His residues have a similar affinity for the 
metal ion.  During the ETD/PTR experiment the sequence coverage was 
dramatically reduced and fewer fragments were identified. Intriguingly, 
the most pronounced loss of fragments was observed around the 
GHHPH pentapeptide although further studies are required to completely 
rationalise this.  
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Overall the data suggest that a conformational change within the peptide 
could have occurred upon Zn2+ binding that was unable to be overcome 
by the ETD mechanism which can maintain weaker linkages. This work 
could have implications for the study of His-rich proteins by mass 
spectrometry as interestingly one of the other studies to retain Zn2+ 
binding during MS/MS also concerns a His-rich protein (Buré et al, 2009a 
and 2009b). There has also been little research into how metal cations 
may affect the processes involved in the ECD or ETD mechanisms 
although it has been suggested that they may act as an electron sink 
(Zubarev et al., 2002). This could be another explanation for the 
significant decrease in fragmentation upon Zn2+ binding, although further 
investigation is needed.  
 
7.1.3 Metal ion distribution between HSA and HRGP330 
Competition experiments between HSA and HRGP330 showed that the 
majority of Zn2+ was transferred to HRGP330. The presence of fatty acids 
had no further effect on this distribution, which indicates that HRG could 
be an important competitor for Zn2+ in normal plasma. However, this is in 
agreement with Chapter 3 which showed no loss of Zn2+ in the presence 
of myristate under the conditions used.  Competition with Zincon 
suggested the apparent binding constant for Zn-HRGP330 was similar to 
that for full-length HRG which validated the potential biological 
significance of the observations in Chapter 6. The exact role of HRG is 
uncertain although it would appear from these results that it would be 
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found in a Zn2+-bound state endogenously even with high concentrations 
of HSA.  
 
It is also important to note that other factors may trigger an increase in 
Zn2+ concentration in plasma which could affect the activities of HRG, for 
example at sites of injury degranulating platelets can release high 
concentrations of Zn2+ that are 30-60 times higher than plasma levels with 
the metal ion distributed between the cytoplasm and α-granules 
(Gorodetsky et al., 1993; Marx et al., 1993). Taken together with the 
information that HRG is also released from human platelets (Leung et al., 
1983) then this could clearly be another route through which the Zn2+-
dependent activities of HRG are modulated. More recent evidence has 
indicated that activated platelets contained the antiangiogenic fragment of 
the HRR with one possibility being that the large increase in Zn2+ 
concentration could stimulate proteolysis to release this active domain. In 
the tissue of cancer patients, this peptide was also found to associate 
with the vessel wall but no binding was observed in healthy patients 
(Thulin et al., 2009).   
 
Additionally HRG could become activated through low pH to the extent 
that Borza and Morgan (1998) suggested an important role as a plasma 
pH sensor. During hypoxia or ischemia an onset of acidosis can occur 
which could be extremely detrimental to tissues (Levine, 1993). This 
would cause the His sidechains to become protonated and would 
enhance the interaction with negatively charged glycosaminoglycans on 
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the cell surface. Apart from HMWK, HRG appears to be the only plasma 
protein that can be regulated in this way. Some parallels can be drawn 
between HMWK, a cofactor in blood coagulation, and HRG as numerous 
reports have found that binding of HMWK to endothelial cells is Zn2+-
dependent (van Iwaarden et al., 1988; Schmaier et al., 1988; Joseph et 
al., 1996). Although, HMWK may not act as a pH sensor to the same 
extent as HRG as the His-rich region contains a greater number of Arg 
and Lys which are permanently protonated at physiological pH. As a 
whole, this evidence points toward HRG being a unique protein whose 
multi-domain structure and polycationic nature are extremely important 
for the formation of functional complexes in plasma.   
 
More recently it has been acknowledged that Cu2+ could be biologically 
relevant for HRG, although given the fact that only 5-10% of 
exchangeable serum Cu2+ is bound to HSA it is questionable whether a 
proportion would be bound to HRG. The competition experiments with the 
N-terminal peptide mimic of HSA in Chapter 6 showed that HRG is able 
to compete with the N-terminus even though Gly-Gly-His has a higher 
binding affinity for Cu2+ than HRG. This could be due to the large number 
of possible binding sites as Cu2+ can deprotonate backbone amides and 
may only require two additional imidazole side chains for stable binding. 
This could have important consequences for Cu2+ homeostasis, because 
if the levels of Cu2+ are increased in tumours then the expression of Cu2+-
carrying proteins may be upregulated (Lowndes and Harris, 2005). There 
is ongoing work to use Cu2+-chelators as a therapeutic strategy to combat 
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tumour angiogenesis, one example being Tetrathiomolybdate (TM) which 
significantly reduced Cu2+ levels in clinical trials (Redman et al., 2003).  
  
7.2 Future directions 
1. Native mass spectrometry of full-length HRG 
No detailed structural information is available on HRG and suggestions 
have only been made based on analysis of the fragments obtained from 
proteolysis. Analysis of HRGP330 by TWIM-MS highlighted a possible 
conformational change upon Zn2+ binding therefore this could be verified 
by gas-phase studies of full-length HRG. Most of the observations in the 
literature have been made using in vitro model peptides although many of 
these show the same biological activity of HRG therefore it could be 
argued that in this case these studies are relevant.  
 
2. Investigate the binding of other fatty acid molecules to HSA using 
TWIM-MS 
As TWIM-MS was able to identify an increased collisional cross section 
for myristate-HSA, it would be of interest to study the conformational 
changes induced by fatty acids of different chain lengths. Furthermore, a 
titration could be carried out with varying fatty acid concentrations to 
follow the changes that occur to the protein structure.  
 
3. Zn2+ distribution between HSA and HRG 
This work has utilised a peptide derived from the His-rich region as there 
are challenges associated with isolating sufficient amounts of human 
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HRG from plasma. Further investigations are warranted using a direct 
comparison between human HSA and HRG which would have more 
relevance than the studies using rabbit HRG. The influence of different 
buffers and ionic strengths also needs to be explored as this may impact 
upon binding affinities.  
 
4. A metalloproteomics approach to characterising Zn2+ binding 
proteins in plasma: does Zn2+ associate with HRG endogenously? 
It would be of great interest to develop protocols in order to isolate HRG 
from human plasma and determine the amount of Zn2+ associated with it. 
This is associated with difficulties as HSA is so abundant. Previous 
strategies to identifying less abundant proteins have involved targeted 
depletion of highly concentrated plasma proteins with antibody columns. 
A metallopoteomics approach to fractionating metal binding proteins in 
the marine cyanobacterium Synechococcus sp. WH8102 has recently 
been developed in our laboratory which could be applied to plasma 
samples (Barnett et al., 2012). It is important to note that due to its large 
number of binding partners in serum it is possible that HRG could be 
isolated in a complex with another biomolecule. It would also be 
interesting to achieve this from the point of view of Cu2+ to establish 
whether any Cu2+ is associated with HRG in vivo, considering it might be 
a stronger binder.  Plasma samples could then be supplemented with 
fatty acids of varying chain lengths to see what effect this has on the 
metal ion distribution.  
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5. Analysis of clinical samples: can a correlation between fatty acids 
and Zn2+ be observed in vivo? 
An important future direction would be to study clinical samples from 
patients with conditions known to be associated with elevated fatty acid 
levels.  There is a growing body of evidence that indicates serum Zn2+ 
levels are reduced during diseases such as diabetes (Kinlaw et al., 1983; 
Chausmer, 1998) and cardiovascular disease (Shokrzadeh et al., 2009; 
Little et al., 2010). The fact that elevated fatty acids are also associated 
with diabetes, obesity (Boden and Shulman, 2002) and cardiovascular 
disease (Bhagavan et al., 2009) makes it even more pertinent that the 
relationship between these two nutrients is addressed. The allosteric 
binding of fatty/acid Zn2+ to HSA may go some way to explaining shifts in 
Zn2+ distribution observed during disease. Although many studies have 
analysed plasma levels of Zn2+ or fatty acid, testing needs to be carried 
out for both to assess if there is any correlation between them.  
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Appendix 
 
Thesis reference: Chapter 2, page 37 
 
Figure A1 Expression of recombinant albumin in Saccharomyces 
cerevisiae. A 2 µM plasmid for expression of recombinant HSA in yeast 
which is a safe and alternative product to albumin extracted form blood 
plasma. The HSA gene (green/black/red) is incorporated between the 
STB and the origin of replication (Evans et al., 2010). 
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Thesis reference: Chapter 3, page 66  
 
Table A1 Comparison of the experimental and theoretical masses 
observed for HSA. Values are expressed as average masses in Da. 
Errors in the mass become larger at lower charge states due to peak 
broadening. 
 
Charge state Experimental m/z Theoretical m/z ∆mass (Da) 
16+ 4152.96 4153.34 -0.38 
17+ 3908.68 3909.08 -0.40 
18+ 3691.60 3691.97 -0.37 
19+ 3497.36 3497.71 -0.35 
20+ 3322.93 3322.87 +0.06 
21+ 3164.60 3164.69 -0.09 
22+ 3020.91 3020.89 +0.02 
23+ 2889.74 2889.59 +0.15 
24+ 2769.39 2769.23 +0.16 
25+ 2658.53 2658.50 +0.03 
26+ 2556.33 2556.29 +0.04 
27+ 2461.59 2461.65 -0.03 
28+ 2373.77 2373.77 0.00 
29+ 2292.04 2291.95 +0.09 
30+ 2215.63 2215.58 +0.05 
31+ 2144.15 2144.15 0.00 
32+ 2077.30 2077.17 +0.13 
33+ 2014.32 2014.26 +0.06 
34+ 1955.04 1955.05 -0.01 
35+ 1899.19 1899.22 -0.03 
36+ 1846.50 1846.49 +0.01 
37+ 1796.58 1796.61 -0.03 
38+ 1749.34 1749.36 -0.02 
39+ 1704.55 1704.53 +0.02 
40+ 1662.00 1661.94 +0.06 
41+ 1621.39 1621.43 -0.04 
42+ 1582.86 1582.85 +0.01 
43+ 1546.03 1546.06 +0.03 
44+ 1510.92 1510.94 +0.02 
45+ 1477.41 1477.39 +0.02 
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Figure A2 HSA reacted with 40 mol. equiv. DTNB and analysed by 
ESI-MS. The observed mass was 66,635.63 Da. From the relative 
intensity of the peaks, it was estimated that 68% of the free thiol was 
available to react with DTNB. This is in agreement with the thiol assay by 
UV-Vis spectroscopy. The protocol for reaction with DTNB has previously 
been described (Stewart et al., 2005). The fact that the other species 
remaining corresponds to HSA + 2O atoms suggests that the oxidation 
has occurred at Cys34.  
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Figure A3  Effect of PFOA binding to HSA on His residues and metal 
binding. A)  1 mM samples were prepared in 50 mM Tris [D11]-Cl, 50 mM NaCl 
in 100% D2O (pH 7.10). Spectra were acquired at 37 °C on a Bruker Avance 
Ultrashield spectrometer operating at 700 MHz. f = sodium formate at 8.48 ppm 
which was added as a chemical shift reference. B) 1 mM samples were 
prepared in 50 mM Tris-Cl, 50 mM NaCl in 10% D2O (pH 7.4). Spectra were 
acquired at 37 °C on a Bruker DRX-500 spectrometer operating at 106 MHz for 
111Cd. Peaks A and B correspond to Site A and Site B respectively.  
 
A 
B 
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Figure A4.  Comparison of spectra obtained for HSA complexes prior to 
ion mobility experiments. A) HSA with 2. mol. equiv. Zn2+ added (purple) 
compared to apo-HSA (green). B) HSA with 2. mol. equiv. Cd2+ (blue). The inset 
shows a close-up view of the 15+ charge state showing the mass shift observed. 
Samples were in 200 mM ammonium acetate (pH 7.4). Spectra were obtained 
on a Synapt HDMS G2 instrument (Waters).  
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Table A2 Comparison of the experimental and theoretical masses of 
charge states observed for HRGP330. Values are expressed as 
monisotopic masses.  
 
Charge state Experimental 
m/z 
Theoretical m/z ∆mass (Da) 
3+ 1445.00 1445.00 0.00 
4+ 1083.99 1084.00 0.01 
5+ 867.39 867.40 0.01 
6+ 722.99 723.00 0.01 
7+ 619.85 619.86 0.01 
8+ 542.49 542.50 0.01 
 
 
 
Table A3 Comparison of the experimental and theoretical masses of 
metalloforms observed for HRGP330. Values are expressed as 
monoisotopic neutral masses in Da. The italicised numbers are the 
theoretical values. 
 
 
 
Metal 
ion 
Number of metal ions 
0 1 2 3 4 5 
Zn
2+ 
 4331.98 4393.89 4455.80 4517.71 4579.63 4641.54 
Zn
2+  
 
4331.88 4393.89 4455.79 4517.78 4579.70 4641.64 
Cd
2+
 4331.98 4443.86 4555.75 4667.64 4779.53 N/A 
Cd
2+
  4331.88 4443.81 4555.75 4667.63 4779.54 N/A 
Cu
2+
 4331.98 4392.89 4453.80 4514.72 4575.63 4636.54 
Cu
2+
  4331.88 4392.96 4453.71 4514.68 4575.60 4636.61 
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Figure A5 Comparison of products from RP-HPLC of crude 
HRGP330. A) Peptide that eluted at 9.2 min shows a mass that matches 
that expected for HRGP330. B) Peptide that eluted at 9.6 min had a mass 
4390.0 Da, a mass increase of 56 Da compared to that expected for 
HRGP330. It is likely that the second peptide still has a protecting group 
attached as t-butyl has a mass of 56 Da. 
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Experimental mass Theoretical mass 
Δmass 
(Da) 
Assignment 
477.197 477.165 -0.032 (R)CPEE(F) 
477.197 477.219 0.022 (F)IEDT(E) 
477.197 477.230 0.033 (A)NTKD(S) 
477.197 477.249 0.051 (G)QCKV(I) 
477.197 477.303 0.106 (C)KTTK(P) 
499.178 499.255 0.077 (D)GYLF(Q) 
521.160 521.220 0.060 (F)GTNET(H) 
521.160 521.224 0.064 (C)PEEF(N) 
543.142 543.234 0.092 (H)QHAMG(P) 
543.142 543.245 0.102 (Y)YVDF(S) 
543.142 543.277 0.135 (P)LPEAN(F) 
737.273 737.299 0.025 (I)EDTEPF(R) 
737.273 737.340 0.066 (H)QHAMGPP(P) 
737.273 737.358 0.084 (V)DFSVRN(C) 
737.273 737.358 0.084 (G)PQDLHQ(H) 
737.273 737.387 0.113 (S)PVLFDF(I) 
759.255 759.298 0.042 (D)FNCTTSS(V) 
759.255 759.425 0.169 (P)LAEKALD(L) 
759.255 759.425 0.169 (L)AEKALDL(I) 
759.255 759.425 0.169 (K)TTKPLAE(K) 
759.255 759.425 0.169 (N)TKDSPVL(F) 
759.255 759.437 0.182 (I)NKWRR(D) 
781.237 781.336 0.099 (S)FDVEASN(L) 
781.237 781.340 0.102 (D)VKETDCS(V) 
781.237 781.340 0.102 (V)KETDCSV(L) 
781.237 781.366 0.129 (F)GFCRADL(S) 
803.218 803.379 0.161 (T)NETHRF(P) 
 
Figure A6 ESI-MS of full-length rabbit HRG. A) Low intensity signals 
are observed for HRG along with peptides visible in the low mass range B) 
Identification of peptides using FindPept (ExPasy) yields a number of 
matches that are within 0.2 Da. 
 
A 
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Table A4 1H resonance assignments of HRGP330 recorded at 700 
MHz. The spectra were measured at pH 6.20 and 5 °C in 50 mM Tris-D11 
and 50 mM NaCl. 
 
 
 
Residue NH Hα Hβ Others 
D1 8.38 4.51 2.65, 2.51 - 
L2 8.43 4.24 1.54 Hδ1 0.81; Hδ2 0.89; γCH 1.403 
H3 8.58 4.60 3.06 (Q) Hδ2 7.04 
K6 8.34 4.25 1.69 (Q) γCH2 1.29 (Q); εCH2 2.94 (Q) 
H7 8.64 - 3.20, 3.12 Hδ2 7.13 
S9 8.45 - 3.94, 3.85 - 
Q12 8.53 4.23 - γCH2 2.27 (Q); Hε21 6.94; Hε22 7.60 
E26 8.37 4.20 1.93 (Q) γCH2 2.14 (Q) 
H27 8.63 4.65 - - 
D28 8.40 4.66 2.74, 2.65 - 
T29 8.31 4.23 - γCH3 1.16 
H30 8.53 4.61 3.21, 3.14 Hδ2 7.16 
R31 8.19 4.38 1.80, 1.71 δCH2 3.17 (Q); γCH2 1.54; Hε 7.27 
Q32 8.51 4.25 - γCH2 2.32 (Q); Hε21 6.97; Hε22 7.62 
Hs† 8.81 4.64 3.19, 3.13 Hδ2 7.10 
Ht† 8.76 4.64 3.20, 3.15 - 
Hu† 8.73 4.62 3.15, 3.08 - 
Hv† 8.71 4.64 3.11 (Q) - 
 
 
† These four His residues (labelled s, t, u and v) are all thought to be after 
Pro based on strong crosspeaks observed. Therefore they could be His5, 
His15, His20, His25 or His35.  
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Figure A7 Identification of a Zn2+-bound HRGP330 dimer. The sample 
was 10 µM HRGP330 in 10 mM ammonium acetate (pH 7.4) that had 
been incubated with 5 mol. equiv. Zn(CH3COO)2.2H2O. The inset shows 
the +7 charge states of a low intensity Zn2+-bound dimer. The peaks 
between those labelled in the inset correspond to sequential addition of a 
Zn2+ ion.  
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Figure A8 Intact spectrum of HRGP330 prior to top-down MS/MS. A) 
ESI-MS spectrum of apo-HRGP330 B) ESI-MS spectrum showing Zn1-
HRGP330 and Zn2-HRGP330. In each case the 5+ charge state was 
isolated with a width of 4 m/z and fragmented by CID and ETD/PTR on 
an amaZon speed ETD instrument. 
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Table A5 Summary of Zn2+-bound peptides identified from CID.  
 
 
Assignment 
of fragment 
Experimental 
[M+H]
1+
 
Theoretical 
[M+H]
1+
 
∆mass 
(Da) 
Experimental  
+ Zn 
[M+H]
1+
 
Theoretical  
+ Zn 
[M+H]
1+
 
∆mass 
(Da) 
y8 1026.68 1026.49 +0.19 1087.54 1087.40 +0.14 
y10-NH3 1275.70 1275.57 +0.13 1337.74 1337.50 +0.24 
b11 1397.70 1397.64 +0.06 1459.65 1459.55 +0.10 
y12  1526.96 1526.71 +0.25 1588.86 1588.62 +0.24 
y17 2106.34 2105.97 -0.37 2168.20 2167.89 -0.31 
b18 2290.08  2289.93 +0.15 2290.08  2289.93 +0.15 
y22 2671.30 2671.22 +0.08 2733.24  2733.14 +0.10 
b23  2807.32 2807.28 +0.04 2869.24  2869.19 +0.05 
b28 3422.68 3422.52 +0.16 3484.54  3484.43 +0.11 
y29 3563.74 3563.60 +0.14 3625.63  3625.51 +0.12 
y32 3926.15  3925.80 +0.35 3988.15 3987.71 +0.44 
y32 –H2O 3908.12 3907.79 +0.33 3970.00 3969.71 +0.29 
y33 4125.12 4124.77 +0.35 4125.12 4124.77 +0.35 
b33 4082.02 4081.84 +0.18 4144.04 4143.76 +0.28 
y34  4176.65 4175.94 +0.71 4238.30 4237.86 +0.44 
y34-NH3 4158.60 4158.92 -0.32 4220.65 4220.85 -0.20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
219 
 
Thesis reference: Chapter 5, page 144 
 
 
 
 
Table A6 Summary of Zn2+-bound peptides identified from ETD. 
 
 
Assignment 
of fragment 
Experimental 
[M+H]
1+
 
Theoretical 
[M+H]
1+
 
∆mass 
(Da) 
Experimental 
+ Zn 
[M+H]
1+
 
Theoretical 
+Zn 
[M+H]
1+
 
∆mass 
(Da) 
z13* 1648.06 1647.75 +0.31 1711.06 1711.56 -0.5 
c20 2479.50 2479.15 +0.35 2542.50 2542.65 -0.15 
c26 3187.68 3187.46 +0.22 3250.62 3250.96 -0.34 
c27 3324.82 3324.52 +0.30 3388.68 3388.02 +0.66 
c28 3439.82 3439.54 +0.28 3502.76 3503.04 -0.28 
z28* 3410.76 3410.52 +0.24 3473.76 3474.02 -0.26 
z29* 3547.82 3548.58 -0.76 3611.62 3612.08 -0.46 
z30* 3676.76 3676.68 +0.08 3739.62 3740.18 -0.56 
z31* 3812.76 3812.74 +0.02 3876.82 3876.24 +0.58 
c31 3833.76 3833.75 +0.01 3986.82 3897.25 +0.57 
z33* 4047.94 4047.85 +0.09 4110.82 4111.35 -0.47 
z34* 4160.94 4160.94 0.00 4223.82 4224.44 +0.62 
c34 4195.94 4195.92 +0.02 4258.94 4259.42 -0.48 
 
*denotes (z+1) and (z+2) ions 
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Figure A9 ESI-MS of HRGP330 following incubation with HSA and 
then separation for analysis. A) 5 µM HRGP330 B) 5 µM HRGP330 
following separation from HSA. The HRGP330 can clearly be identified, 
however, the presence of a small proportion of HSA supressed the 
HRGP330 charge states considerably. Samples were in 10 mM 
ammonium acetate (pH 7.4) and spectra were acquired on a maXis-UHR-
TOF instrument. 
 
 
 
 
 
